<SEC-DOCUMENT>0001654954-25-005066.txt : 20250505
<SEC-HEADER>0001654954-25-005066.hdr.sgml : 20250505
<ACCEPTANCE-DATETIME>20250502175436
ACCESSION NUMBER:		0001654954-25-005066
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		14
FILED AS OF DATE:		20250505
DATE AS OF CHANGE:		20250502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PALATIN TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0000911216
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				954078884
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286280
		FILM NUMBER:		25910291

	BUSINESS ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		609-495-2200

	MAIL ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERFILM INC
		DATE OF NAME CHANGE:	19930825
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>ptn_s1a.htm
<DESCRIPTION>FORM S-1/A
<TEXT>
<html><head><title>ptn_s1a.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As filed with the Securities and Exchange Commission on May 2, 2025.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Registration No. 333-286280 </strong></p> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> Amendment No.1 </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> To </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">FORM S-1/A </font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">Palatin Technologies, Inc.</font></strong></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Delaware</strong></p></td> <td style="width:5%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2834</strong></p></td> <td style="width:5%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>95-4078884</strong></p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction of</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">incorporation or organization)</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Primary Standard Industrial</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Classification Code Number)</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(I.R.S. Employer</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Identification No.)</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>4B Cedar Brook Drive</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cranbury, New Jersey 08512</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Phone: (609) 495-2200</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stephen T. Wills</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Executive Vice President, Chief Financial Officer</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Chief Operating Officer</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>4B Cedar Brook Drive</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cranbury, New Jersey 08512</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Phone: (609) 495-2200</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><em>Copies to:</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Faith L. Charles, Esq.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Thompson Hine LLP</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>300 Madison Avenue, 27th Floor</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>New York, New York 10017</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Phone: (212) 344-5680</strong></p></td> <td style="width:5%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:30%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stephen A. Slusher, Esq.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Chief Legal Officer</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>4B Cedar Brook Drive</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cranbury, New Jersey 08512</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Phone: (609) 495-2200</strong></p></td> <td style="width:5%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:30%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ron Ben-Bassat, Esq.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Eric Victorson, Esq.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Sullivan &amp; Worcester LLP</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>1251 Avenue of the Americas</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>New York, New York 10020</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Phone: (212) 660-3000</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. &#9746;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Large accelerated filer</p></td> <td style="width:20%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td> <td style="width:30%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated filer</p></td> <td style="width:20%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Non-accelerated filer</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller reporting company</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><font style="color:red">The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="color:red"><strong>PRELIMINARY PROSPECTUS</strong>&nbsp;</font></p></td> <td style="width:50%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong><font style="color:red">SUBJECT TO COMPLETION, DATED MAY 2, 2025</font></strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ptn_s1img1.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Shares of Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Series F Common Warrants to Purchase Up to 57,339,449 Shares of Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Series G Common Warrants to purchase up to 57,339,449 Shares of Common Stock </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Series H Common Warrants to purchase up to 57,339,449 Shares of Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Pre-Funded Warrants to Purchase Up 57,339,449 Shares of Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Shares of Common Stock Underlying the Series F Common Warrants</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> <strong>Up to 57,339,449 Shares of Common Stock Underlying the Series G Common Warrants</strong> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> Up to 57,339,449 Shares of Common Stock Underlying the Series H Common Warrants </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Shares of Common Stock Underlying the Pre-Funded Warrants</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are offering on a reasonable best efforts basis up to 57,339,449 shares of our common stock, par value $0.01 (the &#8220;Common Stock&#8221;), together with Series F common stock purchase warrants (the &#8220;Series F Common Warrants&#8221;) to purchase up to 57,339,449 shares of our Common Stock and Series G common stock purchase warrants (the &#8220;Series G Common Warrants&#8221; and together with the Series F Common Warrants, the &#8220;Common Warrants&#8221;) to purchase up to 57,339,449 shares of our Common Stock. Each share of Common Stock, or a pre-funded warrant in lieu thereof, is being sold together with a Series F Common Warrant to purchase one share of Common Stock and a Series G Warrant to purchase one share of Common Stock. The shares of Common Stock and Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. The assumed combined public offering price for each share of Common Stock and accompanying Common Warrants is $0.218, which was the closing price of our Common Stock on the NYSE American LLC (&#8220;NYSE American&#8221;) on May 1, 2025. Each Series F Common Warrant will have an exercise price per share equal to 200% of the combined public offering price per share of the Common Stock and accompanying Common Warrants, and will be immediately exercisable. Each Series G Common Warrant will have an exercise price per share equal to 100% of the combined public offering price per share of the Common Stock and accompanying Common Warrants, and will be immediately exercisable. The Series F Common Warrants will expire on the five-year anniversary of the original issuance date, however, if a holder&#8217;s Series G Common Warrants are not exercised in full within 30 days after the Food and Drug Administration (&#8220;FDA&#8221;) acceptance of the Company&#8217;s Investigational New Drug (&#8220;IND&#8221;) for an in-house obesity treatment compound (long-acting peptide or oral small molecule) (the &#8220;FDA Exercise Period&#8221;), such holder&#8217;s Series F Common Warrants will terminate automatically upon the expiration of the FDA Exercise Period and prior to the five-year anniversary of the issuance of the Series F Common Warrant. The Series G Common Warrants will expire on the earlier of (i) the 24 month anniversary of the original issuance date or (ii) the expiration of the FDA Exercise. Additionally, in the event a holder of the Series G Common Warrant exercises their Series G Common Warrant, they will receive a Series H Common Warrant (the &#8220;Series H Common Warrants&#8221;). Each Series H Common Warrant will have an exercise price equal to 150% of the combined public offering price per share of Common Stock and accompanying Common Warrants and will expire on the 24 month anniversary of the original issuance date. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are also offering to certain purchasers whose purchase of shares of Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;), in lieu of shares of Common Stock that would otherwise result in such purchaser&#8217;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock. The public offering price of each Pre-Funded Warrant and accompanying Common Warrants will be equal to the price at which one share of Common Stock and accompanying Common Warrants are sold to the public in this offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant will be $0.0001 per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants and Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. For each Pre-Funded Warrant we sell, the number of shares of Common Stock we are offering will be decreased on a one-for-one basis.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have engaged A.G.P./Alliance Global Partners (&#8220;A.G.P.&#8221;) and Laidlaw &amp; Company (UK) Ltd. (&#8220;Laidlaw&#8221; and together with A.G.P., the &#8220;Placement Agents&#8221;), to act as our Placement Agents, whereby A.G.P. is serving as lead placement agent and Laidlaw as co-placement agent in connection with this offering. The Placement Agents have agreed to use their reasonable best efforts to arrange for the sale of the securities offered in this offering. The Placement Agents are not purchasing or selling any of the securities we are offering, and the Placement Agents are not required to arrange the purchase or sale of any specific number of securities or dollar amount. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The offering will terminate on May 30, 2025, unless (i) the closing occurs prior thereto or (ii) we decide to terminate the offering prior thereto (which we may do at any time in our discretion); however, the shares of our common stock underlying the Common Warrants and Pre-Funded Warrants will be offered on a continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). We expect to enter into a securities purchase agreement relating to the offering with those investors that choose to enter into such an agreement on the day that the registration statement of which this prospectus forms a part is declared effective and that the closing of the offering will end one trading day after we first enter into a securities purchase agreement relating to the offering.&nbsp;The offering will settle delivery versus payment (&#8220;DVP&#8221;)/receipt versus payment (&#8220;RVP&#8221;). That is, on the closing date, we will issue the shares of Common Stock directly to the account(s) at the Placement Agents identified by each purchaser; upon receipt of such shares, the Placement Agents shall promptly electronically deliver such shares to the applicable purchaser, and payment therefor shall be made by the Placement Agents (or their clearing firm) by wire transfer to us.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since we will deliver the securities to be issued in this offering upon our receipt of investor funds, we and the Placement Agents have not made any arrangements to place investor funds in an escrow, trust or similar account. Because this is a best-efforts offering, the Placement Agents do not have an obligation to purchase any securities, and, as a result, there is a possibility that we may not be able to sell the securities. There is no minimum offering requirement as a condition of closing of this offering. Because there is no minimum offering amount required as a condition to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue our business goals described in this prospectus. In addition, because there is no escrow account and no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to fulfill all of our contemplated objectives due to a lack of interest in this offering. Further, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. See the section of this prospectus entitled &#8220;Risk Factors&#8221; for more information.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Common Stock is listed on the NYSE American under the symbol &#8220;PTN.&#8221; On May 1, 2025, the last reported sale price of our Common Stock on the NYSE American was $0.218 per share. The actual public offering price per share of Common Stock and accompanying Common Warrants, and per Pre-Funded Warrant and accompanying Common Warrants, will be determined between us, the Placement Agents, and the investors in this offering at the time of pricing, and may be at a discount to the current market price for the Common Stock. Therefore, the assumed offering price per share of Common Stock and accompanying Common Warrants may not be indicative of the final offering price. There is no established public trading market for the Common Warrants and the Pre-Funded Warrants, and we do not expect such a market to develop. Without an active trading market, the liquidity of the Common Warrants and the Pre-Funded Warrants will be limited. In addition, we do not intend to list the Common Warrants and the Pre-Funded Warrants on the NYSE American, any other national securities exchange, or any other trading system.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"> Our Chief Executive Officer and Chief Financial Officer/Chief Operating Officer and certain directors have indicated interest in participating in this offering at the public offering price and on the same terms as the other purchasers in this offering. However, because&nbsp;indications&nbsp;of&nbsp;interest&nbsp;are not binding, we cannot guarantee if any&nbsp;officer&nbsp;or director will participate in this offering. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>INVESTING IN OUR SECURITIES INVOLVES RISKS. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE 7 OF THIS PROSPECTUS AND UNDER SIMILAR HEADINGS IN THE OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Per Share of </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accompanying</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> Warrants </strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Per Pre-Funded </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrant and</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accompanying</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> Warrants </strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Public offering price<sup style="vertical-align:super">(1)</sup></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td> <td style="width:9%;"></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td> <td style="width:9%;"></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td> <td style="width:9%;"></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Placement agent fees<sup style="vertical-align:super">(2)</sup></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds to us, before expenses<sup style="vertical-align:super">(3)</sup></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(1) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The assumed combined public offering price is $0.218 per share of Common Stock and accompanying Common Warrants and $0.2179 per Pre-Funded Warrant and accompanying Common Warrants. </p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Represents a cash fee equal to 7.0% of the aggregate purchase price paid by investors in this offering. We have also agreed to reimburse certain expenses of the Placement Agents in connection with the offering. See &#8220;Plan of Distribution&#8221; for additional disclosure regarding compensation payable to the Placement Agents.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(3)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Does not include proceeds from the exercise of the Common Warrants and/or Pre-Funded Warrants in cash, if any.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Delivery of the securities is expected to be made on or about __________, 2025, subject to customary closing conditions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>Lead Placement Agent</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">A.G.P.</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>Co- Placement Agent</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>LAIDLAW &amp; COMPANY (UK) LTD.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>The date of this prospectus is __________, 2025</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="TOC">TABLE OF CONTENTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Page</strong></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#CAUTIONARYNOTE">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">ii<a href="#a_001"></a>&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#ABOUTTHISPROSPECTUS">ABOUT THIS PROSPECTUS&nbsp;</a></p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#SUMMARY">SUMMARY</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#THEOFFERING">THE OFFERING</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#RISKFACTORS">RISK FACTORS</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#USEOFPROCEEDS">USE OF PROCEEDS</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">14</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#DILUTION">DILUTION</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">15</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#DIVIDENDPOLICY">DIVIDEND POLICY</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">17</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#DESCRIPTIONOFSECURITIESOFFERED">DESCRIPTION OF SECURITIES OFFERED</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">18</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#PLANOFDISTRIBUTION">PLAN OF DISTRIBUTION</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">24</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#LEGALMATTERS">LEGAL MATTERS</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">27</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#EXPERTS">EXPERTS</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">27</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#WHEREYOUCANFINDMOREINFORMATION">WHERE YOU CAN FIND MORE INFORMATION</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">28</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#INFORMATIONWEINCORPORATE">INFORMATION WE INCORPORATE BY REFERENCE</a></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">29</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">i</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="CAUTIONARYNOTE">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus, including the documents incorporated by reference, contains, and any prospectus supplement may contain, &#8220;forward-looking statements&#8221; as defined in the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our significant operating losses since our inception and our need to obtain additional financing has caused management to determine there is substantial doubt regarding our ability to continue as a going concern;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays in receiving funds as a result of economic disruptions;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our expectation that we will incur losses for the foreseeable future and may never achieve or maintain profitability;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our business, financial condition, and results of operations may be adversely affected by increases in costs of and delays in conducting human clinical trials and the performance of our contractors and suppliers, reduction in our productivity or the productivity of our contractors and suppliers, supply chain constraints, and labor shortages;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">whether Cosette Pharmaceuticals, Inc. (&#8220;Cosette&#8221;), which acquired our product Vyleesi&#174; (the trade name for bremelanotide for treatment of hyperactive sexual desire disorder in premenopausal women) in December 2023, will have sufficient sales to generate significant milestone payments under our purchase agreement with Cosette;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the results of clinical trials with our late-stage products, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024 with topline results announced in March 2025, in which co-administration demonstrated an increased weight loss over tirzepatide alone; PL9643, an ophthalmic peptide solution for dry eye disease (&#8220;DED&#8221;), which completed a first Phase 3 clinical trials with top line results announced from the Phase 3 clinical trial in the first quarter of calendar year 2024 and which has concluded a positive Type C meeting with the FDA and can, depending on financial resources and product development priority, commence patient enrollment as early as the first half of calendar year 2025; and PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials in the third quarter of calendar year 2022 and announced topline results in March 2025, with one-third of patients dosed with PL8177 achieving clinical remission while the placebo group saw no clinical remission; </p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">estimates of our expenses, future revenue and capital requirements;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our ability to achieve profitability;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our ability to advance product candidates into, and successfully complete, clinical trials;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the timing or likelihood of regulatory filings and approvals;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our expectations regarding the clinical efficacy and utility of our melanocortin agonist product candidates for treatment of inflammatory and autoimmune related diseases and disorders, including ocular indications;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our ability to compete with other products and technologies treating the same or similar indications as our product candidates;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">ii</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the ability of our third-party collaborators to timely carry out their duties under their agreements with us;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our ability to recognize the potential value of our licensing arrangements with third parties;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the potential to achieve revenues from the sale of our product candidates;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our ability to obtain adequate reimbursement from private insurers and other healthcare payers;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our ability to maintain product liability insurance at a reasonable cost or in sufficient amounts, if at all;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the performance and retention of our management team, senior staff professionals, other employees, and third-party contractors and consultants;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology in the United States and throughout the world;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our compliance with federal and state laws and regulations;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the timing and costs associated with obtaining regulatory approval for our product candidates;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the impact of fluctuations in foreign exchange rates;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the impact of any geopolitical instability, economic uncertainty, financial markets volatility, or capital markets disruption resulting from the ongoing Russia-Ukraine and Israel-Hamas military conflicts, and any resulting effects on our revenue, financial condition, or results of operations;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the impact of legislative or regulatory healthcare reforms in the United States;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our ability to adapt to changes in global economic conditions as well as competing products and technologies; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our ability to remain listed on the NYSE American stock exchange.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In some cases, you can identify these statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this prospectus and are subject to risks and uncertainties. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">You should carefully read this prospectus, any related free writing prospectus, the documents that we incorporate by reference into this prospectus, and the documents we reference in this prospectus and have filed as exhibits to the registration statement, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">iii</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="ABOUTTHISPROSPECTUS">ABOUT THIS PROSPECTUS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus is part of a registration statement that we have filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). You should read this prospectus, and any applicable prospectus supplement, together with the information incorporated herein by reference as described under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Information We Incorporate by Reference.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">You should rely only on the information that we have provided or incorporated by reference in this prospectus, which may be amended, supplemented, or superseded from time to time by other reports that we subsequently file with the SEC. We have not authorized, nor have the Placement Agents authorized, any dealer, salesperson, or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus. You should not rely upon any information or representation not contained or incorporated by reference in this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered or securities are sold on a later date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">References in this prospectus to the terms &#8220;<em>we</em>,&#8221; &#8220;<em>us</em>,&#8221; or the &#8220;<em>Company</em>&#8221; or other similar terms mean Palatin Technologies, Inc. and its subsidiary, unless we state otherwise or the context indicates otherwise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;border-top:#000000 1px solid;border-right:#000000 1px solid;border-bottom:#000000 1px solid;text-align:justify;border-left:#000000 1px solid;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="SUMMARY">SUMMARY</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>This summary highlights certain information appearing elsewhere in this prospectus and in the documents we incorporate by reference into this prospectus. The summary is not complete and does not contain all of the information that you should consider before investing in our common stock. After you read this summary, you should read and carefully consider the entire prospectus and the more detailed information and financial statements and related notes that are incorporated by reference into this prospectus.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Overview</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Melanocortin Receptor System</em>. The MCr system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects. We believe that our MC1r agonist peptides have broad anti-inflammatory effects and utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. We are also developing peptides that are active at more than one melanocortin receptor and small molecule MCr agonists.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our new product development activities focus on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity, which has completed Phase 2 in the fourth quarter of calendar year 2024, with topline results&nbsp; announced in March 2025, in which co-administration demonstrated an increased weight loss over tirzepatide alone; and secondarily on ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (&#8220;DED&#8221;), which completed Phase 3 clinical trials and announced top line results from the first Phase 3 clinical trial in the first quarter of calendar year 2024; ulcerative colitis, including PL8177, an oral peptide formulation, which entered Phase 2 ulcerative colitis clinical trials in the third quarter of calendar year 2022 and announced topline results in March 2025, with one-third of patients dosed with PL8177 achieving clinical remission while the placebo group saw no clinical remission. We are actively engaged in discussions with potential partners and licensees that have the financial and operational resources to progress our products for ocular conditions through development, approval and commercialization. &nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our FDA approved melanocortin receptor agonist, Vyleesi, an &#8220;as needed&#8221; therapy used in anticipation of sexual activity and self-administered in the thigh or abdomen via a single-use subcutaneous auto-injector by premenopausal women with hypoactive sexual desire disorder (&#8220;HSDD&#8221;), was acquired by Cosette in December 2023. Vyleesi is the first FDA-approved melanocortin agent and the first and only FDA-approved as-needed treatment for premenopausal women with HSDD.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Our Business Strategy</em>. Key elements of our business strategy include:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="width:72%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Maintaining a team to create, develop and commercialize MCr products addressing unmet medical needs;</p></td></tr> <tr style="height:15px"> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:72%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="width:72%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Entering into strategic alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale, and distribution of product candidates that we are developing;</p></td></tr> <tr style="height:15px"> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:72%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="width:72%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Partially funding our product development programs with the cash flow generated from the sale of Vyleesi to Cosette and existing license agreements, as well as any future research, collaboration, or license agreements; and</p></td></tr> <tr style="height:15px"> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:72%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="width:72%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Completing development and seeking regulatory approval of certain of our other product candidates.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;border-top:#000000 1px solid;border-right:#000000 1px solid;border-bottom:#000000 1px solid;text-align:left;border-left:#000000 1px solid;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following chart illustrates the status of our drug development programs.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ptn_s1aimg4.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Implications of Being a Smaller Reporting Company</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because our annual revenue was less than $100.0 million during the most recently completed fiscal year, and the market value of our voting and non-voting common stock held by non-affiliates was less than $560.0 million on the last business day of our most recently completed second fiscal quarter, we qualify as a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Accordingly, we may provide less public disclosure than larger public companies, including the inclusion of only two years of audited financial statements and only two years of related selected financial data and management&#8217;s discussion and analysis of financial condition and results of operations disclosure. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NYSE Listing Compliance</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 10, 2023, we received written notification from the NYSE American that we are not in compliance with Section 1003(a)(i) and (ii) of the NYSE American Company Guide. Section 1003(a)(i) requires a listed company to have stockholders&#8217; equity of $2 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, and Section 1003(a)(ii) requires a listed company to have stockholders&#8217; equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Company submitted a plan to regain compliance (the &#8220;Plan&#8221;) to the NYSE American on November 9, 2023, addressing how the Company intends to regain compliance with these requirements by April 10, 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 13, 2023, the Company received notice from the NYSE American that it had accepted the Company's Plan and granted a plan period through April 10, 2025 to regain compliance with the continued listing standards. If the Company is not in compliance with the continued listing standards by that date or if the Company does not make progress consistent with the Plan during the plan period, the NYSE American may commence delisting procedures.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 4, 2024, we received written notification from the NYSE American that we are not in compliance with Section 1003(a)(iii) of the NYSE American Company Guide, which requires a listed company to have stockholders&#8217; equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Plan now includes continued listing standards under Section 1003(a)(iii).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> On April 10, 2025, the Company received written notification from the NYSE American stating that the NYSE Regulation determined to commence proceedings to delist the Company&#8217;s Common Stock from NYSE American. NYSE Regulation has determined the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the &#8220;Company Guide&#8221;) as the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide by the end of the maximum 18-month compliance plan period, which expired on April 10, 2025. On April 14, 2025, the Company appealed the NYSE Regulation&#8217;s decision and on April 15, 2025, the Company requested a hearing with the office of the General Counsel of the NYSE American. On April 28, 2025, the Company received notice that their hearing will be on June 12, 2025.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> The Company has been advised that the Common Stock will continue to be listed and traded on NYSE American during the pendency of the Company&#8217;s appeal, which we expect to last between sixty to ninety days, subject to NYSE American's discretion to suspend trading if it believes suspension to be in the public interest. Following the appeal, the decision of the committee of the Board of Directors of the NYSE American hearing the appeal will be announced by NYSE Regulation regarding either proceeding with suspension and delisting or continued trading in the Common Stock. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"> There can be no assurance we will cure the deficiency or win on appeal.&nbsp;In the event we fail to raise $15 million in this offering, we do not expect to cure the deficiency and expect that our Common Stock will be delisted from the NYSE American. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;border-top:#000000 1px solid;border-right:#000000 1px solid;border-bottom:#000000 1px solid;text-align:left;border-left:#000000 1px solid;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recent Developments</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>February 2025 Sales Agreement with A.G.P./Alliance Global Partners</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 11, 2025, we entered into a certain sales agreement with A.G.P. (the &#8220;Sales Agreement&#8221;), pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $6,000,000 from time to time through A.G.P., acting as our sales agent or principal. A.G.P. will be entitled to compensation under the terms of the Sales Agreement at a fixed commission rate of up to 3.0% of the gross sales price per share sold, in addition to reimbursement of certain expenses. As of the date of this prospectus, we have sold 11,011,896 shares of our common stock under such Sales Agreement. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>February 2025 Registered Direct Offering and Concurrent Private Placement</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 6, 2025, we entered into a securities purchase agreement with an institutional investor to sell in a registered offering (the &#8220;February 2025 RD Offering&#8221;) an aggregate of 2,550,000 shares of common stock (the &#8220;February 2025 RD Shares&#8221;) of the Company and pre-funded warrants (the &#8220;February 2025 RD Pre-Funded Warrants&#8221;) to purchase up to 2,138,000 shares of our common stock. The securities purchase agreement also provided that the Company issue to the same investor in the February 2025 RD Offering unregistered Series E common stock purchase warrants to purchase up to 4,688,000 shares of our common stock in a concurrent private placement. The February 2025 RD Shares were offered at an offering price of $1.00 per February 2025 RD Share and the February 2025 RD Pre-Funded Warrants were offered at an offering price of $0.9999 per February 2025 RD Pre-Funded Warrant to purchase one share of our common stock. The Series E common stock purchase warrants were offered concurrently with the February 2025 RD Shares and February 2025 RD Pre-Funded Warrants. The gross proceeds from the February 2025 RD Offering and concurrent private placement, before deducting the placement agent fees and offering expenses, were approximately $4.7 million.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 6, 2025, we entered into a placement agency agreement A.G.P., as lead placement agent, and Laidlaw, as co-placement agent, pursuant to which we engaged A.G.P. and Laidlaw as the exclusive placement agents in connection with the February 2025 RD Offering and concurrent private placement. We agreed to pay the Placement Agents a fee in cash equal to 7.00% of the gross proceeds from the sale of the February 2025 RD Shares, February 2025 RD Pre-Funded Warrants, and Series E common stock purchase warrants to the investor. We also agreed to reimburse the Placement Agents for out-of-pocket expenses, including the reasonable fees of legal counsel not to exceed $50,000.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Litigation</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 13, 2025, a complaint was filed in the Supreme Court of the State of New York, County of New York, captioned <em>H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) v. Palatin Technologies, Inc.</em>, Case No: 650878/2025. The complaint names the Company as defendant, asserting three causes of action for breach of contract and seeking monetary damages and the award of warrants allegedly due under the parties&#8217; agreement. The breach of contract claims each relate to the engagement agreement entered into by the Company and Wainwright on or about January 29, 2024. On March 20, 2025, the Company filed its answer in response to the complaint, in which it denied all liability and asserted several affirmative defenses.&nbsp;The Company plans to vigorously defend against the lawsuit and the action will proceed next to the discovery stage and for further proceedings.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Corporate Information</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We were incorporated under the laws of the State of Delaware on November 21, 1986, and commenced operations in the biopharmaceutical area in 1996. Our corporate offices are located at 4B Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, New Jersey 08512, and our telephone number is (609) 495-2200. We maintain a website at http://www.palatin.com, where, among other things, we make available free of charge our Forms 3, 4 and 5, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) and Section 16 of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our website and the information contained in it or connected to it are not incorporated into this prospectus and should not be considered to be part of this prospectus. Our website address is included in this prospectus as an inactive textual reference only.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC <em>(www.sec.gov</em>).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Palatin Technologies&#174; is a registered trademark of the Company, and Palatin&#8482; and the Palatin logo are trademarks of the Company. Other trademarks referred to in this prospectus are the property of their respective owners.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;border-top:#000000 1px solid;border-right:#000000 1px solid;border-bottom:#000000 1px solid;text-align:justify;border-left:#000000 1px solid;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="THEOFFERING">THE OFFERING</a></strong></p></td></tr> <tr style="height:15px"> <td style="width:15%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Securities Offered by Us: </strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Up to 57,339,449 shares of Common Stock and accompanying Series F Common Warrants to purchase up to 57,339,449 shares of Common Stock and Series G Common Warrants to purchase up to 57,339,449 shares of Common Stock, or up to 57,339,449 Pre-Funded Warrants to purchase shares of Common Stock and accompanying Series F Common Warrants to purchase up to 57,339,449 shares of Common Stock and Series G Common Warrants to purchase up to 57,339,449 shares of Common Stock on a reasonable &#8220;best efforts&#8221; basis. The shares of Common Stock or the Pre-Funded Warrants, and accompanying Common Warrants are immediately separable and will be issued separately in this offering, but must initially be purchased together in this offering. Each Series&nbsp; F Common Warrant will have an exercise price per share equal to 200% of the combined public offering price per share of the Common Stock and accompanying Common Warrants, and will be immediately exercisable. Each Series G Common Warrant will have an exercise price per share equal to 100% of the combined public offering price per share of the Common Stock and accompanying Common Warrants, and will be immediately exercisable. The Series F Common Warrants will expire on the five-year anniversary of the original issuance date, however, if a holder&#8217;s Series G Common Warrants are not exercised in full within the FDA Exercise Period, such holder&#8217;s Series F Common Warrants will terminate automatically upon the expiration of the FDA Exercise Period and prior to the five-year anniversary of the issuance of the Series F Common Warrant. The Series G Common Warrants will expire on the earlier of (i) the 24 month anniversary of the original issuance date or (ii) the expiration of the FDA Exercise Period. Additionally, in the event a holder of the Series G Common Warrant exercises their Series G Common Warrant, they will receive a Series H Common Warrant. Each Series H Common Warrant will have an exercise price equal to 150% of the combined public offering price per share of Common Stock and accompanying Common Warrants and will expire on the 24 month anniversary of the original issuance date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">This prospectus also relates to the offering of the shares of Common Stock issuable upon exercise of the Common Warrants and Pre-Funded Warrants. For more information regarding the Common Warrants and Pre-Funded Warrants, you should carefully read the section titled &#8220;Description of Securities Offered&#8221; in this prospectus</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Pre-Funded Warrants Offered By Us:</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">We are also offering to each purchaser whose purchase of shares of Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following the consummation of this offering, the opportunity to purchase, if the purchaser so chooses, Pre-Funded Warrants (each Pre-Funded Warrant to purchase one share of our Common Stock) in lieu of shares that would otherwise result in the purchaser&#8217;s beneficial ownership exceeding 4.99% of our outstanding Common Stock (or, at the election of the purchaser, 9.99%). The purchase price of each Pre-Funded Warrant and accompanying Common Warrants will equal the price at which one share of Common Stock and accompanying Common Warrants are being sold to the public in this offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant will be $0.0001 per share. The Pre-Funded Warrants will be exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. For each Pre-Funded Warrant we sell, the number of shares of Common Stock we are offering will be decreased on a one-for-one basis.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Reasonable Best Efforts Offering:</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">We have agreed to issue and sell the securities offered hereby to the purchasers through the Placement Agents. The Placement Agents are not required to buy or sell any specific number or dollar amount of the securities offered hereby, but will use their reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. See the &#8220;Plan of Distribution&#8221; section of this prospectus.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Use of Proceeds:</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Assuming all of the securities we are offering under this prospectus are sold at an assumed combined public offering price of $0.218 per share of Common Stock and accompanying Common Warrants and assuming no sale of any Pre-Funded Warrants, we estimate that we will receive approximately $11.5 million in net proceeds from this offering, after deducting the estimated placement agent fees and estimated offering expenses. However, this is a reasonable best efforts offering with no minimum number of securities or amount of proceeds as a condition to closing, and we may not sell all or any of the securities offered pursuant to this prospectus; as a result, we may receive significantly less in net proceeds.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">We currently intend to use the net proceeds from this offering primarily for working capital and general corporate purposes, including for development work on our combination of bremelanotide, or another melanocortin-4 agonist, and tirzepatide, a GLP-1 agonist. See &#8220;Use of Proceeds&#8221; for additional information. </p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong> Insider Participation: </strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> Our Chief Executive Officer and Chief Financial Officer/Chief Operating Officer and certain directors have indicated interest in participating in this offering at the public offering price and on the same terms as the other purchasers in this offering. However, because&nbsp;indications&nbsp;of&nbsp;interest&nbsp;are not binding, we cannot guarantee if any&nbsp;officer&nbsp;or director will participate in this offering. </p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Lock-Up:</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Our directors and officers have agreed with the Placement Agents, subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of the Common Stock or securities convertible into or exercisable or exchangeable for the Common Stock for a period of 60 days after the completion of this offering.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Standstill and Variable Rate Transaction Prohibition:</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">We have agreed, subject to certain exceptions, not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of Common Stock (or securities convertible into or exercisable for Common Stock) or, subject to certain exceptions, file any registration statement, including any amendments or supplements thereto (other than the registration statement or amendment to the registration statement relating to the securities offered hereunder and a registration statement on Form S-8), until 45 days after the completion of this offering.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">We have also agreed not to enter into or issuance any shares pursuant to a variable rate transaction (as defined in the securities purchase agreement) for&nbsp; four months after the completion of this offering.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">See &#8220;Plan of Distribution&#8221; for more information.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Risk Factors:</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">You should carefully read and consider the information set forth under &#8220;Risk Factors,&#8221; together with all of the other information set forth in this prospectus and the documents incorporated by reference into this prospectus, before deciding to invest in our securities.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>NYSE American Symbol:</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">PTN</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;border-top:#000000 1px solid;border-right:#000000 1px solid;border-bottom:#000000 1px solid;text-align:justify;font:10pt times new roman;border-left:#000000 1px solid;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Unless otherwise indicated, all information in this prospectus related to the number of shares of our common stock to be outstanding immediately after this offering is based on 39,155,742 shares of our common stock outstanding as of May 2, 2025. The number of shares outstanding as of May 2, 2025, excludes:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">6,672 shares issuable on the conversion of our immediately convertible Series A Preferred Stock, subject to adjustment, for no further consideration;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">2,249,102 shares issuable upon the exercise of stock options with a weighted-average exercise price of $6.12 per share;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">859,613 shares issuable under restricted stock units which will vest on dates between June 22, 2025 and June 4, 2028, subject to the fulfillment of service or performance conditions;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">279,700 shares of common stock which have vested under restricted stock unit agreements, but are subject to provisions to delay delivery;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">66,666 shares of common stock issuable upon exercise of warrants at an exercise price of $12.50 per share, and expire on May 11, 2026;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">1,885,632 shares of common stock issuable upon exercise of Series B warrants at an exercise price of $1.88 per share, 261,431of which expire on June 24, 2029, and 1,624,201 may not be exercised until stockholder approval and will expire on the five-year anniversary from the date of such stockholder approval;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">3,907,679 shares of common stock issuable upon exercise of Series C warrants at an exercise price of $0.875 per share and with an expiration date of December 17, 2029;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">1,953,839 shares of common stock issuable upon exercise of Series D warrants at an exercise price of $0.875 per share, which warrants may not be exercised until stockholder approval and will expire on the five-year anniversary from the date of such stockholder approval;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">1,831,503 shares of common stock issuable upon exercise of common warrants at an exercise price of $5.46 per share, and that expire on February 1, 2028;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">90,909 shares of common stock issuable upon exercise of the placement agent warrants issued to the placement agent or its designees as compensation in connection with the Company&#8217;s October 2022 offering, with an exercise price of $6.875 per share, and an expiration date of October 31, 2027;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">91,575 shares of common stock issuable upon exercise of outstanding placement agent warrants issued as part of the placement agent&#8217;s compensation in connection with the registered direct offering that the Company completed on February 1, 2024, with an exercise price of $6.825 per share, and an expiration date of February 1, 2028;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">117,925 shares of common stock issuable upon exercise of the placement agent warrants issued to the placement agent or its designees as compensation in connection with the October 2023 Offering, with an exercise price of $2.65 per share, and an expiration date of October 20, 2028;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">4,688,000 shares of common stock issuable upon exercise of the Series E common stock purchase warrants issued in connection with the February 2025 RD Offering, with an exercise price of $1.00 per share, and an expiration date of August 11, 2030; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">223,538 shares of common stock available for future issuance under our 2011 Stock Incentive Plan.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="RISKFACTORS">RISK FACTORS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Investing in our securities involves risk. Prior to making a decision about investing in our securities, you should carefully consider the risk factors below as well as those discussed under the heading &#8220;Risk Factors&#8221; in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are incorporated herein by reference and may be amended, supplemented, or superseded from time to time by other reports we have filed with the SEC or will file with the SEC in the future. If any of these risks actually occurs, our business, results of operations, and financial condition could suffer. In that case, the trading price of our common stock could decline, and you could lose all or a part of your investment.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risks Related to Our Financial Results and Need for Financing</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We have a history of substantial net losses, including a net loss of $29.7 million for the year ended June 30, 2024. We expect to incur substantial net losses over the next few years, and we may never achieve or maintain profitability.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2024, we had an accumulated deficit of $452.0 million. We had $29.7 million in net loss for the year ended June 30, 2024, compared to $24.0 million in net loss for the year ended June 30, 2023. We may not achieve or sustain profitability in future years, depending on numerous factors, including whether and when development and product commercialization milestones are met, whether and when we enter into license agreements for any of our products under development, regulatory actions by the FDA and other regulatory bodies, the performance of our licensees, and market acceptance of our products.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We expect to incur significant expenses as we continue our development of MC1r and MCr products. These expenses, among other things, have had and will continue to have an adverse effect on our stockholders&#8217; equity, total assets and working capital.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We sold our Vyleesi product to Cosette in December 2023 and have the potential to receive milestone payments based on sales of Vyleesi by Cosette. However, we do not anticipate receiving significant milestone payments for the next 12 to 24 months and may never receive significant milestone payments. For the foreseeable future, we will have to fund our operations and capital expenditures from license, royalty and contract revenue under license agreements, existing cash balances and outside sources of financing, which may not be available on acceptable terms, if at all. We will not have product revenue from our products in development unless and until we receive approval from the FDA or other equivalent regulatory authorities outside the United States. We have devoted substantially all of our efforts to research and development, including preclinical and clinical trials. Because of the numerous risks associated with developing drugs, we are unable to predict the extent of future losses, whether or when any of our product candidates will become commercially available, or when we will become profitable, if at all.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We will need additional funding, including funding to complete clinical trials for our product candidates other than Vyleesi, which may not be available on acceptable terms, if at all.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We intend to focus future efforts on our bremelanotide combination products, MC1r product candidates, primarily for ocular indications. As of December 31, 2024, we had cash, cash equivalents and marketable securities of $3.4 million, with current liabilities of $9.6 million. Based on our available cash, cash equivalents and marketable securities, we have concluded that substantial doubt exists about our ability to continue as a going concern for one year after the date our consolidated financial statements contained in our Quarterly Report on Form 10-Q filed with the SEC on February 13, 2025 were issued, and we are seeking additional funding to complete development activities and required clinical trials for our MCr product candidates and, if those clinical trials are successful (which we cannot predict), to complete submission of required regulatory applications to the FDA.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will need to raise additional capital, even if we raise the maximum amount offered in this offering, to fund our operations. We may raise additional funds through public or private equity or debt financings, collaborative arrangements on our product candidates, or other sources. However, such financing arrangements may not be available on acceptable terms, or at all. To obtain additional funding, we may need to enter into arrangements that require us to develop only certain of our product candidates or relinquish rights to certain technologies, product candidates and/or potential markets.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we are unable to raise sufficient additional funds when needed, we may be required to curtail operations significantly, cease clinical trials, and decrease staffing levels. We may seek to license, sell or otherwise dispose of our product candidates, technologies and contractual rights on the best possible terms available. Even if we are able to license, sell or otherwise dispose of our product candidates, technologies and contractual rights, it is likely to be on unfavorable terms and for less value than if we had the financial resources to develop or otherwise advance our product candidates, technologies and contractual rights ourselves.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our future capital requirements depend on many factors, including:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the expense and timing of obtaining regulatory approvals for our other product candidates;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the number and characteristics of any additional product candidates we develop or acquire;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the scope, progress, results and costs of researching and developing our future product candidates, and conducting preclinical and clinical trials;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the cost of commercialization activities if any future product candidates are approved for sale, including marketing, sales and distribution costs;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the cost of manufacturing any future product candidates and any products we successfully commercialize;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the terms and timing of such arrangements;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the degree and rate of market acceptance of any future approved products;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products or treatments;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">any product liability or other lawsuits related to our products;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the expenses needed to attract and retain skilled personnel;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the timing, receipt and amount of sales of, or royalties on, future approved products, if any.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 20, 2025, President Trump signed an executive order creating an advisory commission, the &#8220;Department of Government Efficiency,&#8221; to reform federal government processes and reduce expenditures. Pressures on and uncertainty surrounding the U.S. federal government&#8217;s budget, and potential changes in budgetary priorities and spending levels, could adversely affect staffing levels and the funding for the FDA. Disruptions at the FDA and other agencies due to these policies may slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the past decade, the U.S. government has shut down, at least partially, several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC, and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We are currently not in compliance with the continued listing standards of the NYSE American. Our failure to resume compliance with the continued listing standards or make continued progress toward compliance consistent with a plan of compliance that we submitted to NYSE Regulation may result in the delisting of our common stock.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our common stock is listed on the NYSE American, a national securities exchange, under the symbol &#8220;PTN&#8221;. As a result, we are subject to NYSE American&#8217;s listing standards, which generally mandate that we meet certain requirements relating to stockholders&#8217; equity, market capitalization, aggregate market value of publicly held shares and distribution requirements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 4, 2024, the Company received a letter from the staff of NYSE American stating that the Company&#8217;s stockholders&#8217; equity as reported in its Annual Report on Form 10-K for the year ended June 30, 2024 was not in compliance with the NYSE American&#8217;s continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide. Section 1003(a)(iii) requires a listed company to have stockholders&#8217; equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 10, 2023, the Company received a notice from the staff of NYSE American that the Company was not in compliance with the NYSE American&#8217;s continued listing standards under Section 1003(a)(i) and (ii) of the NYSE American Company Guide. Section 1003(a)(i) requires a listed company to have stockholders&#8217; equity $2 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, and Section 1003(a)(ii) requires a listed company to have stockholders&#8217; equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Company remains subject to the procedures and requirements of Section 1009 of the Company Guide, and previously submitted a plan (the &#8220;Plan&#8221;) of actions it has taken or will take to regain compliance with the continued listing standards by April 10, 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The NYSE American accepted the Plan and granted a Plan period through April 10, 2025 to regain compliance with the continued listing standards, which now includes continued listing standards under Section 1003(a)(iii). The Company will be able to continue its listing during the Plan period and will be subject to periodic reviews including quarterly monitoring for compliance with the Plan until it has regained compliance. If the Company is not in compliance with the continued listing standards by that date or if the Company does not make progress consistent with the Plan during the plan period, the Exchange may commence delisting procedures.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">On April 10, 2025, the Company received written notification from the NYSE American stating that the NYSE Regulation determined to commence proceedings to delist the Company&#8217;s Common Stock from NYSE American. NYSE Regulation has determined the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the &#8220;Company Guide&#8221;) as the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide by the end of the maximum 18-month compliance plan period, which expired on April 10, 2025. On April 14, 2025, the Company appealed the NYSE Regulation&#8217;s decision and on April 15, 2025, the Company requested a hearing with the office of the General Counsel of the NYSE American. On April 28, 2025, the Company received notice that their hearing will be held on June 12, 2025. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has been advised that the Common Stock will continue to be listed and traded on NYSE American during the pendency of the Company&#8217;s appeal, which we expect to last between sixty to ninety days, subject to NYSE American's discretion to suspend trading if it believes suspension to be in the public interest. Following the appeal, the decision of the committee of the Board of Directors of the NYSE American hearing the appeal will be announced by NYSE Regulation regarding either proceeding with suspension and delisting or continued trading in the Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">There can be no assurance we will cure the deficiency or win on appeal.&nbsp;In the event we fail to raise $15 million in this offering, we do not expect to cure the deficiency and expect that our Common Stock will be delisted from the NYSE American. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we fail to regain compliance with the continued listing requirements of the NYSE American, the NYSE American may take steps to de-list our common stock. If the NYSE American de-lists our securities for trading on its exchange, we could face significant material adverse consequences, including:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a limited availability of market quotations for our securities</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">reduced liquidity with respect to our securities;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a determination that our shares of common stock are &#8220;penny stock&#8221; which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a limited amount of news and analyst coverage for our Company; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a decreased ability to issue additional securities or obtain additional financing in the future.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Such a de-listing would likely have a negative effect on the price of our common stock and would impair our investors&#8217; ability to sell or purchase our common stock when investors wish to do so.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Shares of our common stock are considered to be covered securities because they are listed on the NYSE American. Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. Further, if we were no longer listed on the NYSE American, our common stock would not be deemed covered securities and we would be subject to regulation in each state in which we offer our securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risks Related to this Offering</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>You will experience immediate and substantial dilution.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because the offering price per share in this offering exceeds the net tangible book value per share of our Common Stock outstanding prior to this offering you will incur an immediate and substantial dilution in the net tangible book value of the shares of Common Stock you purchase in this offering. After giving effect to the Pro Forma Events (as defined in the &#8220;Dilution&#8221; section of this prospectus) and to the sale by us of 57,339,449 shares of our Common Stock at the assumed offering price of $0.218 per share of Common Stock and accompanying Common Warrants, and after deducting Placement Agent fees and estimated offering expenses payable by us, you will experience immediate dilution of approximately $0.05 per share, representing the difference between the assumed offering price per share and our pro forma as adjusted net tangible book value per share as of December 31, 2024, after giving effect to this offering and the Pro Forma Events.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We cannot assure you that we will be able to sell shares of Common Stock or other securities in any other offering at a price per share that is equal to or greater than the price per share paid in this offering, and investors purchasing shares of Common Stock or other securities in the future could have rights superior to existing stockholders, including investors who purchase shares of Common Stock and other securities in this offering. The price per share at which we sell additional shares of our Common Stock or securities convertible into common stock in future transactions, may be higher or lower than the price per share in this offering. Additionally, the exercise of warrants, exercise of outstanding stock options, conversion of outstanding preferred stock, and vesting of other stock awards may result in further dilution of your investment. See the section entitled &#8220;Dilution&#8221; appearing elsewhere in this prospectus for a more detailed illustration of the dilution you would incur if you participate in this offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of the Common Stock. Our failure to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our shares of Common Stock to decline, and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>The sale of our Common Stock in this offering and any future sales of our Common Stock, or the perception that such sales could occur, may depress our stock price and our ability to raise funds in new stock offerings.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may from time-to-time issue additional shares of Common Stock at a discount from the current trading price of our Common Stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our Common Stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock, or Common Stock. Sales of shares of our Common Stock in this offering may lower the market price of our Common Stock and may make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that our management deems acceptable, or at all.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>This is a reasonable best efforts offering, with no minimum amount of securities required to be sold, and we may sell fewer than all of the securities offered hereby.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Placement Agents have agreed to use their reasonable best efforts to solicit offers to purchase the securities in this offering. The Placement Agents have no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum number of securities that must be sold as a condition to completion of this offering, and there can be no assurance that the offering contemplated hereby will ultimately be consummated. Even if we sell securities offered hereby, because there is no minimum offering amount required as a condition to closing of this offering, the actual offering amount is not presently determinable and may be substantially less than the maximum amount set forth on the cover page of this prospectus. We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise additional funds, which may not be available or available on terms acceptable to us or at all.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Because there is no minimum required for the offering to close, investors in this offering will not receive a refund in the event that we do not sell a number of securities sufficient to pursue the business goals outlined in this prospectus.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have not specified a minimum offering amount nor have or will we establish an escrow account in connection with this offering. Because there is no escrow account and no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to fulfill our objectives due to a lack of interest in this offering. Further, because there is no escrow account in operation and no minimum investment amount, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. Investor funds will not be returned under any circumstances whether during or after the offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>If the price of the Common Stock fluctuates significantly, your investment could lose value.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Although the Common Stock is listed on the NYSE American, we cannot assure you that an active public market will continue for the Common Stock. If an active public market for the Common Stock does not continue, the trading price and liquidity of the Common Stock will be materially and adversely affected. If there is a thin trading market or &#8220;float&#8221; for our stock, the market price for the Common Stock may fluctuate significantly more than the stock market as a whole. Without a large float, the Common Stock would be less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of the Common Stock may be more volatile. In addition, in the absence of an active public trading market, investors may be unable to liquidate their investment in us. Furthermore, the stock market is subject to significant price and volume fluctuations, and the price of the Common Stock could fluctuate widely in response to several factors, including:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our quarterly or annual operating results;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">investment recommendations by securities analysts following our business or our industry;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">additions or departures of key personnel;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our failure to achieve operating results consistent with securities analysts&#8217; projections;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">results of our clinical trials; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">changes in industry, general market, or economic conditions.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The stock market has experienced extreme price and volume fluctuations in recent years that have significantly affected the quoted prices of the securities of many companies, including companies in our industry. The changes often appear to occur without regard to specific operating performance. The price of the Common Stock could fluctuate based upon factors that have little or nothing to do with our Company and these fluctuations could materially reduce our stock price.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Because we do not anticipate paying any cash dividends on our Common Stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We do not anticipate paying any cash dividends in the foreseeable future and intend to retain future earnings, if any, for the development and expansion of our business. Our outstanding Series A convertible preferred stock, consisting of 4,030 shares on May 2, 2025, provides that we may not pay a dividend or make any distribution to holders of any class of stock unless we first pay a special dividend or distribution of $100 per share to the holders of the Series A convertible preferred stock. In addition, the terms of existing or future agreements may limit our ability to pay dividends. As a result, capital appreciation, if any, of our Common Stock will be your sole source of gain for the foreseeable future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>There is no public market for the Common Warrants or Pre-Funded Warrants to purchase shares of the Common Stock being offered by us in this offering.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There is no established public trading market for the Common Warrants or Pre-Funded Warrants to purchase shares of the Common Stock that are being offered as part of this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the Common Warrants or Pre-Funded Warrants on any national securities exchange or other nationally recognized trading system, including the NYSE American. Without an active market, the liquidity of the Common Warrants and Pre-Funded Warrants will be limited.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>The Common Warrants and Pre-Funded Warrants are speculative in nature.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Except as specified therein, the Common Warrants and Pre-Funded Warrants offered hereby do not confer any rights of Common Stock ownership on their holders, such as voting rights, but rather merely represent the right to acquire shares of the Common Stock at a fixed price. Specifically, commencing on the date of issuance, holders of the Common Warrants and Pre-Funded Warrants may exercise their right to acquire the shares of the Common Stock upon the payment of the exercise price per share of the Common Warrants and the Pre-Funded Warrants. Moreover, following this offering, the market value of the Common Warrants and Pre-Funded Warrants is uncertain and there can be no assurance that the market value of the Common Warrants will equal or exceed their imputed public offering prices. Furthermore, (i) each Series F Common Warrant will expire five years from the original issuance date, however, if a holder&#8217;s Series G Common Warrants are not exercised in full within the FDA Exercise Period, such holder&#8217;s Series F Common Warrants will terminate automatically upon expiration of the FDA Exercise Period and prior to the five-year anniversary of the issuance of the Series F Common Warrant, (ii) each Series G Common Warrant will expire on the earlier of 24 months from the original issuance date or the expiration of the FDA Exercise Period, and (iii) each Pre-Funded Warrant will not expire until it has been exercised in full. In the event the price of the Common Stock does not exceed the exercise price of the Common Warrants during the period when such Common Warrants are exercisable, the Common Warrants may not have any value. There is no established public trading market for the Common Warrants and Pre-Funded Warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the Common Warrants or Pre-Funded Warrants on any securities exchange or nationally recognized trading system, including NYSE American. Without an active market, the liquidity of the Common Warrants and Pre-Funded Warrants will be limited.&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Except as specified therein, holders of the Common Warrants and Pre-Funded Warrants will have no rights as a common stockholder until they acquire shares of the Common Stock.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Except as specified therein, the Common Warrants and Pre-Funded Warrants in this offering do not confer any rights of share ownership on their holders, but rather merely represent the right to acquire shares of the Common Stock at a fixed price. Until holders of the Common Warrants and Pre-Funded Warrants acquire shares of the Common Stock upon exercise of the Common Warrants and Pre-Funded Warrants, as applicable, holders of Common Warrants and Pre-Funded Warrants will have no rights with respect to our shares of Common Stock underlying such Common Warrants and Pre-Funded Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Provisions of the Common Warrants and Pre-Funded Warrants offered by this prospectus could discourage an acquisition of us by a third party.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition to the provisions of our restated certificate of incorporation, as amended, and our amended and restated bylaws, certain provisions of the Common Warrants and Pre-Funded Warrants offered by this prospectus could make it more difficult or expensive for a third party to acquire us. The Common Warrants and Pre-Funded Warrants prohibit us from engaging in certain transactions constituting &#8220;fundamental transactions&#8221; unless, among other things, the surviving entity assumes our obligations under the Common Warrants or Pre-Funded Warrants, as applicable. These and other provisions of the Common Warrants and Pre-Funded Warrants offered by this prospectus could prevent or deter a third party from acquiring us even where the acquisition could be beneficial to you.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We may not receive any additional funds upon the exercise of the Common Warrants or Pre-Funded Warrants.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each Common Warrant and each Pre-Funded Warrant may be exercised by way of a cashless exercise under certain circumstances, meaning that the holder may not pay a cash purchase price upon exercise, but instead would receive upon such exercise the net number of shares of Common Stock determined according to the formula set forth in the Common Warrants or Pre-Funded Warrant, respectively. Accordingly, we may not receive any additional funds upon the exercise of the Common Warrants or Pre-Funded Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>If we sell Common Stock or preferred stock in the future, stockholders may experience immediate dilution and, as a result, our stock price may decline.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may from time-to-time issue additional shares of Common Stock or preferred stock at a discount from the current trading price of the Common Stock, including potentially under the Sales Agreement that we entered into a with A.G.P. on February 11, 2025. As a result, our stockholders could experience immediate dilution upon the purchase of any shares sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, Common Stock, or preferred stock. If we issue additional Common Stock or additional securities convertible into Common Stock, the holders of the Common Stock could experience additional dilution and, as a result, our stock price may decline. In addition, to the extent that any Common Warrants, Pre-Funded Warrants, other warrants, or options are exercised, new options or restricted stock units are issued under our equity incentive plans, or we otherwise issue additional shares of Common Stock in the future, at a price less than the public offering price, our stockholders could experience dilution.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement including, but not limited to: (i) timely delivery of securities; and (ii) indemnification for breach of contract.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="USEOFPROCEEDS">USE OF PROCEEDS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We currently intend to use the net proceeds from this offering for working capital purposes. We may also use a portion of the net proceeds to invest in or acquire businesses that we believe are complementary to our own, although we have no current plans, commitments, or agreements with respect to any acquisitions. The amounts and timing of our use of the net proceeds from this offering will depend on a number of factors, such as the timing, scope, progress, and results of our development efforts and the timing and progress of any collaboration efforts. As of the date of this prospectus, we cannot specify with certainty all of the particular uses of the proceeds from the sale of securities under this prospectus. Accordingly, we will retain broad discretion over the use of such proceeds. Pending the use of the net proceeds from the sale of securities under this prospectus as described above, we intend to invest the net proceeds in investment-grade, interest-bearing instruments.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The amounts and timing of any expenditures will vary depending on the amount of cash generated by our operations, and the rate of growth, if any, of our business, and our plans and business conditions. The foregoing represents our intentions as of the date of this prospectus based upon our current plans and business conditions to use and allocate the net proceeds of the offering. However, our management will have significant flexibility and discretion in the timing and application of the net proceeds of the offering. Unforeseen events or changed business conditions may result in application of the proceeds of the offering in a manner other than as described in this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We estimate that we will receive net proceeds from this offering of approximately $11.5 million (assuming the sale of the maximum number of securities offered hereby), based upon an assumed combined public offering price of $0.218 per share of Common Stock and accompanying Common Warrants (which is the last reported sale price of the Common Stock on the NYSE American on May 1, 2025), after deducting the estimated Placement Agent fees and estimated offering expenses payable by us and assuming no sale of any Pre-Funded Warrants and no exercise of the Common Warrants. However, because this is a reasonable best efforts offering with no minimum number of securities or amount of proceeds as a condition to closing, the actual offering amount, Placement Agent fees, and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus, and we may not sell all or any of the securities we are offering. As a result, we may receive significantly less in net proceeds. We estimate that our net proceeds from the sale of 75%, 50%, and 25% of the maximum number of securities offered in this offering would be approximately $8.6 million, $5.7 million, and $2.8 million, respectively, after deducting the estimated Placement Agent fees and estimated offering expenses payable by us, and assuming no sale of any Pre-Funded Warrants and assuming no exercise of the Common Warrants. We will only receive additional proceeds from the exercise of the Common Warrants we are selling in this offering if the Common Warrants are exercised for cash. We cannot predict when or if these Common Warrants will be exercised. It is possible that these Common Warrants may expire and may never be exercised.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each $0.10 increase (decrease) in the assumed combined public offering price of $0.218 per share of Common Stock and accompanying Common Warrants (which is the last reported sale price of the Common Stock on the NYSE American on May 1, 2025) would increase (decrease) the net proceeds to us from this offering by approximately $5.3 million, assuming the number of securities offered, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated offering expenses payable by us and assuming no sale of any Pre-Funded Warrants and assuming no exercise of the Common Warrants. Each one million share increase (decrease) in the number of securities offered by us in this offering would increase (decrease) the net proceeds to us from this offering by approximately $0.2 million, assuming that the price per share of Common Stock and accompanying Common Warrants for the offering remains at $0.218 (which is the last reported sale price of the Common Stock on the NYSE American on May 1, 2025), and after deducting the estimated offering expenses payable by us and assuming no sale of any Pre-Funded Warrants and assuming no exercise of the Common Warrants included in the securities in the offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">These estimates exclude the proceeds, if any, from the exercise of Common Warrants offered hereby. If all of the Common Warrants offered hereby were to be exercised in cash at the assumed exercise price of $0.218 per share, we would receive additional proceeds of approximately $56.2 million. We cannot predict when or if these Common Warrants will be exercised. It is possible that these Common Warrants may expire and may never be exercised. Additionally, these Common Warrants contain a cashless exercise provision that permit exercise of such Common Warrants on a cashless basis at any time when there is no effective registration statement under the Securities Act covering the issuance of the underlying shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="DILUTION">DILUTION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the offering price per share of our Common Stock in this offering and the pro forma as adjusted net tangible book value per share of our Common Stock immediately after this offering. The net tangible book value (deficit) of our Common Stock as of December 31, 2024 was approximately $(6.4) million, or approximately $(0.27) per share of Common Stock based upon 23,455,846 shares outstanding. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of shares of Common Stock outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">After giving effect, on a pro forma basis, to (i) the issuance of an aggregate of 2,550,000 shares of common stock and pre-funded warrants to purchase up to 2,138,000 shares of common stock pursuant to the February 2025 RD Offering; (ii) the issuance of an aggregate of Series E common stock purchase warrants to purchase up to 4,688,000 shares of common stock in a private placement concurrent with the February 2025 RD Offering, and giving effect to the subsequent exercise in full of such Series E common stock purchase warrants and pre-funded warrants, and (iii) the sale of 11,011,896 shares of common stock at prices ranging from $1.00 to $0.1888 per share pursuant to our Sales Agreement with A.G.P., (collectively, the &#8220;Pro Forma Events&#8221;), the pro forma net tangible book value of our Common Stock as of December 31, 2024 was approximately $5.1 million, or approximately $0.12 per share of Common Stock based upon 43,843,742 shares outstanding.&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">After giving further effect to the sale of 57,339,449 shares of our Common Stock in this offering at an assumed offering price of $0.218 per share and accompanying Common Warrants, and after deducting Placement Agent fees and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of December 31, 2024 would have been approximately $16.6 million, or $0.164 per share of Common Stock. This represents an immediate increase in net tangible book value of $0.047 per share to existing stockholders and immediate dilution of $0.054 per share to investors purchasing our Common Stock in this offering at the offering price. The following table illustrates this dilution on a per share basis:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Assumed public offering price per share of Common Stock</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> $ </p></td> <td style="width:9%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> 0.218 </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt">Historical net tangible book value per share as of December 31, 2024</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> $ </p></td> <td style="width:9%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> (0.272 </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> ) </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt">Increase in net tangible value attributable to the Pro Forma Events</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> $ </p></td> <td style="width:9%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> 0.389 </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt">Pro forma net tangible book value per share as of December 31, 2024 </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> $ </p></td> <td style="width:9%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> 0.117 </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.5pt">Increase in pro forma net tangible book value per share attributable to this offering</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> $ </p></td> <td style="width:9%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> 0.047 </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Pro forma as adjusted net tangible book value per share after giving effect to this offering</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> $ </p></td> <td style="width:9%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> 0.164 </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Dilution in net tangible book value per share to investors participating in this offering</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> $ </p></td> <td style="width:9%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> (0.054) </p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A $0.10 increase or decrease in the assumed public offering price of $0.218 per share of Common Stock and accompanying Common Warrants (which is the closing price of our Common Stock on the NYSE American on May 1, 2025) and assuming no sale of Pre-Funded Warrants or exercise of any Common Warrants, would decrease or increase our pro forma as adjusted net tangible book value per share by approximately $0.05 and decrease or increase the dilution per share to new investors by approximately $0.05, assuming that the number of shares of Common Stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the Placement Agent fees and estimated offering expenses payable by us and assuming no sale of Pre-Funded Warrants or exercise of any Common Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">An increase or decrease of 10,000,000 shares in the number of shares of Common Stock and Common Warrants offered by us, as set forth on the cover page of this prospectus, and assuming no sale of Pre-Funded Warrants or exercise of any Common Warrants, would decrease or increase our as adjusted net tangible book value per share by approximately $0.004 and increase or decrease the dilution per share to new investors by approximately $0.004, assuming no change in the assumed public offering price per share of Common Stock and Common Warrants and after deducting the Placement Agent fees and estimated offering expenses payable by us and assuming no sale of Pre-Funded Warrants or exercise of any Common Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">An increase or decrease of 5,000,000 shares in the number of shares of Common Stock and Common Warrants offered by us, as set forth on the cover page of this prospectus, and assuming no sale of Pre-Funded Warrants or exercise of any Common Warrants, would decrease or increase our as adjusted net tangible book value per share by approximately $0.002 and increase or decrease the dilution per share to new investors by approximately $0.002, assuming no change in the assumed public offering price per share of Common Stock and Common Warrants and after deducting the Placement Agent fees and estimated offering expenses payable by us and assuming no sale of Pre-Funded Warrants or exercise of any Common Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The discussion and table above assume (i) no exercise of the Common Warrants to be issued in this offering and (ii) no sale of any Pre-Funded Warrants, which, if sold, would reduce the number of shares of Common Stock that we are offering on a one-for-one basis.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The above discussion and table are based on 23,455,846 shares of our common stock outstanding as of December 31, 2024, and exclude:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6,672 shares issuable on the conversion of our immediately convertible Series A Preferred Stock, subject to adjustment, for no further consideration;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2,249,102 shares issuable upon exercise of stock options with a weighted-average exercise price of $6.12 per share;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">859,613 shares issuable under restricted stock units which vested or will vest on dates between June 16, 2024 and June 20, 2027, subject to the fulfillment of service or performance conditions;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">279,700 shares of common stock which have vested under restricted stock unit agreements, but are subject to provisions to delay delivery;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">66,666 shares of common stock issuable upon the exercise of warrants at an exercise price of $12.50 per share, and expire on May 11, 2026;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1,831,503 shares of common stock issuable upon exercise of common warrants at an exercise price of $5.46 per share, and expire on February 1, 2028;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1,885,632 shares of common stock issuable upon the exercise of Series B warrants at an exercise price of $1.88 per share, 261,431 of which warrants expire on June 24, 2029, and 1,624,201, may not be exercised until stockholder approval and will expire on the five-year anniversary from the date of such stockholder approval;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3,907,679 shares of common stock issuable upon exercise of Series C warrants at an exercise price of $0.875 per share and with an expiration date of December 17, 2029;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1,953,839 shares of common stock issuable upon exercise of Series D warrants at an exercise price of $0.875 per share, which warrants may not be exercised until stockholder approval and will expire on the five-year anniversary from the date of such stockholder approval;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">117,925 shares of common stock issuable upon exercise of the placement agent warrants issued to the placement agent or its designees as compensation in connection with the October 2023 Offering, with an exercise price of $2.65 per share, and an expiration date of October 20, 2028;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">91,575 shares of common stock issuable upon exercise of outstanding placement agent warrants issued as part of the placement agent&#8217;s compensation in connection with the registered direct offering that the Company completed on February 1, 2024, with an exercise price of $6.825 per share and an expiration date of February 1, 2028;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">90,909 shares of common stock issuable upon exercise of the placement agent warrants issued to the placement agent in connection with the October 2022 offering, with an exercise price of $6.875 per share, and an expiration date of October 31, 2027;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">223,538 shares of common stock available for future issuance under our 2011 Stock Incentive Plan.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To the extent that outstanding options as of December 31, 2024 have been or may be exercised, unvested restricted stock units or performance-based restricted stock units have settled or other shares issued, investors purchasing our securities in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="DIVIDENDPOLICY">DIVIDEND POLICY</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have never declared or paid any dividends on our Common Stock. Our outstanding Series A convertible preferred stock, consisting of 4,030 shares on May 2, 2025, provides that we may not pay a dividend or make any distribution to holders of any class of stock unless we first pay a special dividend or distribution of $100 per share to the holders of the Series A convertible preferred stock. We currently intend to retain earnings, if any, for use in our business. We do not anticipate paying dividends in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="DESCRIPTIONOFSECURITIESOFFERED">DESCRIPTION OF SECURITIES OFFERED</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are offering up to 57,339,449 shares of Common Stock, or Pre-Funded Warrants in lieu of shares of Common Stock, along with Series F Common Warrants to purchase up to 57,339,449 shares of Common Stock and Series G Common Warrants to purchase up to 57,339,449 shares of Common Stock. For each Pre-Funded Warrant we sell, the number of shares of Common Stock we are offering will be decreased on a one-for-one basis. Each share of Common Stock or Pre-Funded Warrant is being sold together with a Series F Common Warrant to purchase one share of Common Stock and a Series G Common Warrant to purchase one share of Common Stock. The shares of Common Stock or Pre-Funded Warrants and accompanying Common Warrants will be issued separately. We are also registering the shares of Common Stock issuable from time to time upon exercise of the Pre-Funded Warrants offered hereby and the Common Warrants offered hereby, as well as the shares of Common Stock issuable from time to time upon exercise of the Series H Common Warrants offered hereby in the event a holder of the Series G Common Warrant exercises such warrant. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following description of our Common Stock is intended as a summary only and is qualified in its entirety by reference to our restated certificate of incorporation, as amended (the &#8220;Certificate of Incorporation), and our amended and restated bylaws (the &#8220;Bylaws&#8221;), which are filed as exhibits to the registration statement of which this prospectus forms a part. Our authorized capital stock consists of 300,000,000 shares of Common Stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holders of our Common Stock are entitled to one vote per share for the election of directors and on all other matters that require stockholder approval. Holders of shares of Common Stock do not have any cumulative voting rights. Subject to any preferential rights of any outstanding preferred stock, in the event of our liquidation, dissolution or winding up, holders of our Common Stock are entitled to share ratably in the assets remaining after payment of liabilities and the liquidation preferences of any outstanding preferred stock. Our Common Stock does not carry any redemption rights or any preemptive or preferential rights enabling a holder to subscribe for, or receive shares of, any class of our Common Stock or any other securities convertible into shares of any class of our Common Stock. Holders of our Common Stock have the right to participate ratably in dividend distributions. The shares of our Common Stock offered hereby, when issued, will be fully paid and nonassessable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Common Warrants</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following summary of certain terms and provisions of the Common Warrants included with the Common Stock that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Common Warrants, the form of which is filed as an exhibit to our registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the forms of Series F Common Warrant and&nbsp;Series G Common Warrant for a complete description of the terms and conditions of the Common Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Duration and Exercise Price</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Each Common Warrant offered hereby will be a warrant to purchase one share of Common Stock. Each Series F Common Warrant will have an exercise price per share equal to 200% of the combined public offering price per share of the Common Stock and accompanying Common Warrants, and will be immediately exercisable. Each Series G Common warrant will have an exercise price per share equal to 100% of the combined public offering price per share of the Common Stock and accompanying Common Warrants, and will be immediately exercisable. The Series F Common Warrants will expire on the five-year anniversary of the original issuance date, however, if a holder&#8217;s Series G Common Warrants are not exercised in full within the FDA Exercise Period, such holder&#8217;s Series F Common Warrants will terminate automatically upon expiration of the FDA Exercise Period and prior to the five-year anniversary of the issuance of the Series F Common Warrant. The Series G Common Warrants will expire on the earlier of (i) the 24 month anniversary of the original issuance date or (ii) the expiration of the FDA Exercise Period. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of share dividends, share splits, reorganizations or similar events affecting the Common Stock and the exercise price. Subject to the rules and regulations of the applicable trading market, we may at any time during the term of the Common Warrants, subject to the prior written consent of the holders, reduce the then current exercise price to any amount and for any period of time deemed appropriate by our board of directors. The Common Warrants will be issued separately from the shares of Common Stock, or the Pre-Funded Warrants, as the case may be.&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Exercisability</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Common Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the Common Warrant to the extent that the holder would own more than 4.99% of the outstanding shares of our common warrant immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding shares after exercising the holder&#8217;s Common Warrants up to 9.99% of the number of our shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Common Warrants. Purchasers of Common Warrants in this offering may also elect prior to the issuance of the Common Warrants to have the initial exercise limitation set at 9.99% of our outstanding shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Cashless Exercise</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If, at the time a holder exercises its Common Warrants, a registration statement registering the issuance of the shares of Common Stock underlying the Common Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price and subject to the nominal value of the shares being paid up as described below, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares determined according to a formula set forth in the Common Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Fractional Shares</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No fractional shares of Common Stock or scrip representing fractional shares will be issued upon the exercise of the Common Warrants. Rather, the number of shares of Common Stock to be issued will, at our election, either be rounded up to the next whole share or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Transferability</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Subject to applicable laws, a Common Warrant may be transferred at the option of the holder upon surrender of the Common Warrant to us together with the appropriate instruments of transfer and funds sufficient to pay any transfer taxes payable upon such transfer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Trading Market</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There is no trading market available for the Common Warrants on any securities exchange or nationally recognized trading system, and we do not expect a trading market to develop. We do not intend to list the Common Warrants on any securities exchange or nationally recognized trading market. Without a trading market, the liquidity of the Common Warrants will be extremely limited.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Rights as a Stockholder</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Except as otherwise provided in the Common Warrants or by virtue of such holder&#8217;s ownership of Common Stock, the holders of the Common Warrants do not have the rights or privileges of holders of shares of Common Stock, including any voting rights, until they exercise their Common Warrants. The Common Warrants will provide that holders have the right to participate in distributions or dividends paid on Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Fundamental Transaction</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the event of a fundamental transaction, as described in the Common Warrants and generally including (i) our merger or consolidation with or into another person, (ii) the sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of our assets, (iii) any purchase offer, tender offer or exchange offer pursuant to which holders of our Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of our outstanding Common Stock or 50% or more of the voting power of our common equity, (iv) any reclassification, reorganization or recapitalization of our shares of Common Stock or any compulsory share exchange or (v) any stock or share purchase agreement or other business combination with another person or group of persons whereby such other person or group acquires 50% or more of our outstanding shares of Common Stock or 50% or more of the voting power of our common equity, the holders will be entitled to receive the number of shares of the Common Stock for which the Common Warrant is exercisable immediately prior to the occurrence of such fundamental transaction. Notwithstanding the foregoing, in the event of a fundamental transaction, the holders of the Common Warrants have the right to require us or a successor entity to redeem the Common Warrants for cash in the amount of the Black Scholes Value (as defined in each warrant) of the unexercised portion of the Common Warrants concurrently with or within 30 days following the consummation of a fundamental transaction.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">However, in the event of a fundamental transaction which is not in our control, including a fundamental transaction not approved by our board of directors, the holders of the Common Warrants will only be entitled to receive from us or our successor entity, as of the date of consummation of such fundamental transaction the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the Common Warrant that is being offered and paid to the holders of the Common Stock in connection with the fundamental transaction, whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of the Common Stock are given the choice to receive alternative forms of consideration in connection with the fundamental transaction.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Series H Common Warrants </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following summary of certain terms and provisions of the Series H Common Warrants being offered hereby in the event that a holder of the Series G Common warrant exercises their Series G Common Warrant, is not complete and is subject to, and qualified in its entirety by, the provisions of the Series H Common Warrants, the form of which is filed as an exhibit to our registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of Series H Common Warrant for a complete description of the terms and conditions of the Series H Common Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Duration and Exercise Price</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Each Series H Common Warrant offered hereby will be a warrant to purchase one share of Common Stock. Each Series H Common Warrant will have an exercise price equal to 150% of the combined public offering price per share of Common Stock and accompanying Common Warrants and will expire on the 24 month anniversary of the original issuance date. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of share dividends, share splits, reorganizations or similar events affecting the Common Stock and the exercise price. Subject to the rules and regulations of the applicable trading market, we may at any time during the term of the Series H Common Warrant, subject to the prior written consent of the holders, reduce the then current exercise price to any amount and for any period of time deemed appropriate by our board of directors. The Series H Common Warrants will be issued separately from the shares of Common Stock, or the Pre-Funded Warrants, as the case may be.&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Exercisability</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Series H Common Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the Series H Common Warrant to the extent that the holder would own more than 4.99% of the outstanding shares of our common warrant immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding shares after exercising the holder&#8217;s Series H Common Warrants up to 9.99% of the number of our shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Series H Common Warrants. Purchasers of Series H Common Warrants in this offering may also elect prior to the issuance of the Series H Common Warrants to have the initial exercise limitation set at 9.99% of our outstanding shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Cashless Exercise</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">If, at the time a holder exercises its Series H Common Warrants, a registration statement registering the issuance of the shares of Common Stock underlying the Series H Common Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price and subject to the nominal value of the shares being paid up as described below, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares determined according to a formula set forth in the Series H Common Warrants.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Fractional Shares</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">No fractional shares of Common Stock or scrip representing fractional shares will be issued upon the exercise of the Series H Common Warrants. Rather, the number of shares of Common Stock to be issued will, at our election, either be rounded up to the next whole share or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Transferability</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Subject to applicable laws, a Series H Common Warrant may be transferred at the option of the holder upon surrender of the Series H Common Warrant to us together with the appropriate instruments of transfer and funds sufficient to pay any transfer taxes payable upon such transfer.&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Trading Market</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">There is no trading market available for the Series H Common Warrants on any securities exchange or nationally recognized trading system, and we do not expect a trading market to develop. We do not intend to list the Series H Common Warrants on any securities exchange or nationally recognized trading market. Without a trading market, the liquidity of the Series H Common Warrants will be extremely limited.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Rights as a Stockholder</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Except as otherwise provided in the Series H Common Warrants or by virtue of such holder&#8217;s ownership of Common Stock, the holders of the Series H Common Warrants do not have the rights or privileges of holders of shares of Common Stock, including any voting rights, until they exercise their Series H Common Warrants. The Series H Common Warrants will provide that holders have the right to participate in distributions or dividends paid on Common Stock.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Fundamental Transaction</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">In the event of a fundamental transaction, as described in the Series H Common Warrants and generally including (i) our merger or consolidation with or into another person, (ii) the sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of our assets, (iii) any purchase offer, tender offer or exchange offer pursuant to which holders of our Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of our outstanding Common Stock or 50% or more of the voting power of our common equity, (iv) any reclassification, reorganization or recapitalization of our shares of Common Stock or any compulsory share exchange or (v) any stock or share purchase agreement or other business combination with another person or group of persons whereby such other person or group acquires 50% or more of our outstanding shares of Common Stock or 50% or more of the voting power of our common equity, the holders will be entitled to receive the number of shares of the Common Stock for which the Series H Common Warrant is exercisable immediately prior to the occurrence of such fundamental transaction. Notwithstanding the foregoing, in the event of a fundamental transaction, the holders of the Series H Common Warrants have the right to require us or a successor entity to redeem the Series H Common Warrants for cash in the amount of the Black Scholes Value (as defined in each warrant) of the unexercised portion of the Series H Common Warrants concurrently with or within 30 days following the consummation of a fundamental transaction.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">However, in the event of a fundamental transaction which is not in our control, including a fundamental transaction not approved by our board of directors, the holders of the Series H Common Warrants will only be entitled to receive from us or our successor entity, as of the date of consummation of such fundamental transaction the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the Series H Common Warrant that is being offered and paid to the holders of the Common Stock in connection with the fundamental transaction, whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of the Common Stock are given the choice to receive alternative forms of consideration in connection with the fundamental transaction.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Pre-Funded Warrants</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following summary of certain terms and provisions of the Pre-Funded Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Pre-Funded Warrant, the form of which is filed as an exhibit to our registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of Pre-Funded Warrant for a complete description of the terms and conditions of the Pre-Funded Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Duration and Exercise Price</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each Pre-Funded Warrant offered hereby will have an initial exercise price per share equal to $0.0001. The Pre-Funded Warrants will be immediately exercisable and will expire when exercised in full. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of share dividends, share splits, reorganizations or similar events affecting our shares of Common Stock and the exercise price. Subject to the rules and regulations of the applicable trading market, we may at any time during the term of the Pre-Funded Warrant, subject to the prior written consent of the holders, reduce the then current exercise price to any amount and for any period of time deemed appropriate by our board of directors. The Pre-Funded Warrants will be issued separately from the common warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Exercisability</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrant to the extent that the holder would own more than 4.99% of the outstanding shares of the Common Stock immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding shares after exercising the holder&#8217;s Pre-Funded Warrants up to 9.99% of the number of our shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. Purchasers of Pre-Funded Warrants in this offering may also elect prior to the issuance of the Pre-Funded Warrants to have the initial exercise limitation set at 9.99% of our outstanding shares of Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Cashless Exercise</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If, at the time a holder exercises its Pre-Funded Warrants, a registration statement registering the issuance of the shares of Common Stock underlying the Pre-Funded Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Fractional Shares</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No fractional shares of Common Stock or scrip representing fractional shares will be issued upon the exercise of the Pre-Funded Warrants. Rather, the number of shares of Common Stock to be issued will, at our election, either be rounded up to the next whole share or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Transferability</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Subject to applicable laws, a Pre-Funded Warrant may be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments of transfer and funds sufficient to pay any transfer taxes payable upon such transfer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Trading Market</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There is no trading market available for the Pre-Funded Warrants on any securities exchange or nationally recognized trading system, and we do not expect a trading market to develop. We do not intend to list the Pre-Funded Warrants on any securities exchange or nationally recognized trading market. Without a trading market, the liquidity of Pre-Funded Warrants will be extremely limited.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Rights as a Stockholder</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder&#8217;s ownership of Common Stock, the holders of the Pre-Funded Warrants do not have the rights or privileges of holders of the Common Stock, including any voting rights, until they exercise their Pre-Funded Warrants. The Pre-Funded Warrants will provide that holders have the right to participate in distributions or dividends paid on Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Fundamental Transaction</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the event of a fundamental transaction, as described in the Pre-Funded Warrants and generally including (i) our merger or consolidation with or into another person, (ii) the sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of our assets, (iii) any purchase offer, tender offer or exchange offer pursuant to which holders of the Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of our outstanding Common Stock or 50% or more of the voting power of our common equity, (iv) any reclassification, reorganization or recapitalization of our shares of Common Stock or any compulsory share exchange or (v) any stock or share purchase agreement or other business combination with another person or group of persons whereby such other person or group acquires 50% or more of our outstanding shares of Common Stock or 50% or more of the voting power of our common equity, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Penny Stock Regulations</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The SEC has adopted regulations that generally define &#8220;penny stock&#8221; to be an equity security that has a market price of less than $5.00 per share. Our Common Stock may at some point fall within the definition of penny stock and be subject to rules that impose additional sales practice requirements on broker-dealers who sell such securities to persons other than established customers and accredited investors (as defined under the Securities Act).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of such securities and have received the purchaser&#8217;s prior written consent to the transaction. Additionally, for any transaction, other than exempt transactions, involving a penny stock, the rules require the delivery, prior to the transaction, of a risk disclosure document mandated by the SEC relating to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and, if the broker-dealer is the sole market-maker, the broker-dealer must disclose this fact and the broker-dealer&#8217;s presumed control over the market. Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. Consequently, the &#8220;penny stock&#8221; rules, if applicable to the Company, may restrict the ability of broker-dealers to sell our Common Stock and may affect the ability of investors to sell their Common Stock in the secondary market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Anti-Takeover Effects of Provisions of Our Certificate of Incorporation, Our Bylaws and Delaware Law</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain provisions of Delaware law and our Certificate of Incorporation and Bylaws could make more difficult the acquisition of us by means of a tender offer or otherwise, and the removal of incumbent officers and directors. These provisions are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Certificate of Incorporation</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Certificate of Incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, par value $.01 per share, of which 4,030 shares are currently issued and designated as Series A Preferred Stock, 8,100,000 shares are currently issued and designated as Series B Preferred Stock, and 900,000 shares are currently issued and designated as Series C Preferred Stock. The board of directors has the authority, without further approval of the stockholders, to issue and determine the rights and preferences of other series of preferred stock, except as limited by the certificate of designation for the Series A Preferred Stock. The board could issue one or more series of preferred stock with voting, conversion, dividend, liquidation, or other rights which would adversely affect the voting power and ownership interest of holders of common stock. This authority may have the effect of deterring hostile takeovers, delaying or preventing a change in control, and discouraging bids for our common stock at a premium over the market price.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, our Certificate of Incorporation and Bylaws allow the Company&#8217;s board of directors to establish the size of the board and fill vacancies on the board created by an increase in the number of directors and to provide that the Bylaws may be amended by the board of directors without stockholder approval.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Section 203 of the Delaware General Corporation Law</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are subject to Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), which, subject to certain exceptions, prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the time that such stockholder became an interested stockholder, unless:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">prior to such time, the board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested holder;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned (a) by persons who are directors and also officers and (b) by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">at or subsequent to such time, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two thirds of the outstanding voting stock which is not owned by the interested stockholder.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In general, Section 203 defines &#8220;business combination&#8221; to include the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">any merger or consolidation involving the corporation and the interested stockholder;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In general, Section 203 defines &#8220;interested stockholder&#8221; as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Indemnification and Limitation of Liability</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Certificate of Incorporation and Bylaws require us to indemnify our directors, officers, employees and agents against the costs (including fines, judgments and attorney fees) from involvement in legal proceedings arising from their position or service, provided that the person seeking indemnification acted:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">in good faith;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Certificate of Incorporation and Bylaws allow us to buy indemnification insurance for this purpose.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Certificate of Incorporation provides that, to the fullest extent permissible under Delaware law, no director shall be personally liable to the corporation or its stockholders for monetary damages for breach of a fiduciary duty as a director. However, this provision does not eliminate the duty of care, and in appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary relief that will remain available under Delaware law. In addition, each director will continue to be subject to liability for (a) breach of the director&#8217;s duty of loyalty to us or our stockholders, (b) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) violating Section 174 of the DGCL, or (d) any transaction from which the director derived an improper personal benefit. The provision also does not affect a director&#8217;s responsibilities under any other law, such as the federal securities laws or state or federal environmental laws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Transfer Agent and Registrar</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have appointed American Stock Transfer &amp; Trust Company as the transfer agent and registrar for our common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Market Information</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our common stock is traded on the NYSE American under the symbol &#8220;PTN.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="PLANOFDISTRIBUTION">PLAN OF DISTRIBUTION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to a placement agency agreement dated __________, 2025, we have retained A.G.P. and Laidlaw to act as our placement agents, whereby A.G.P. is serving as lead placement agent, and Laidlaw, as co-placement agent in connection with this offering. The Placement Agents are not purchasing or selling any of the securities offered by this prospectus, nor are they required to arrange for the purchase and sale of any specific number or dollar amount of such securities, other than to use their reasonable &#8220;best efforts&#8221; to arrange for the sale of such securities by us. Therefore, we may not sell all of the securities being offered pursuant to this prospectus. The securities will be offered at a fixed price and are expected to be issued in a single closing. We will enter into a securities purchase agreement directly with certain investors, at the investor&#8217;s option, who purchase our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will deliver the securities being issued to the investors upon receipt of investor funds for the purchase of the securities offered pursuant to this prospectus. We expect to deliver the securities being offered pursuant to this prospectus on or about&nbsp;____, 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Fees and Expenses</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have agreed to pay the Placement Agents an aggregate fee equal to 7.0% of the purchase price paid by all purchasers in this offering. In addition, we have agreed to reimburse the Placement Agents for their legal fees in an amount up to $85,000.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We estimate the total expenses of this offering paid or payable by us, exclusive of the placement agent fee and reimbursements, will be approximately $____. After deducting the fees due to the Placement Agents and our estimated expenses in connection with this offering, we expect the net proceeds from this offering will be approximately $11.5 million (based on an assumed combined public offering price per share of Common Stock and accompanying Common Warrants of $0.218, which was the last reported sales price of the Common Stock on the NYSE American on May 1, 2025).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table shows the per share and total cash fees we will pay to the Placement Agents in connection with the sale of the securities pursuant to this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Per Share of</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Common Stock</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>and</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Accompanying</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Common</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> Warrants </strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Per Pre-Funded</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Warrant and</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Accompanying</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Common</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> Warrants </strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Public offering price<sup style="vertical-align:super">(1)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;"></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;"></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;"></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Placement Agent fees</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;"></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;"></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;"></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds before expenses to us<sup style="vertical-align:super">(2)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;"></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;"></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;"></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The assumed combined public offering price is $0.218 per share of Common Stock and accompanying Common Warrants and $0.2179 per Pre-Funded Warrant and accompanying Common Warrants. </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Does not include proceeds from the exercise of the Pre-Funded Warrants or Common Warrants in cash, if any.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Indemnification</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have agreed to indemnify the Placement Agents and specified other persons against specified liabilities, including liabilities under the&nbsp;Securities Act, and to contribute to payments the Placement Agents may be required to make in respect thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Lock-Up Agreements</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our directors and officers have entered into lock-up agreements. Under these agreements, these individuals agreed, subject to specified exceptions, not to sell or transfer any shares of Common Stock or securities convertible into, or exchangeable or exercisable for, Common Stock during a period ending 60 days after the completion of this offering, without first obtaining the written consent of the Placement Agents. Specifically, these individuals agreed, in part, subject to certain exceptions, not to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of Common Stock; or</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any of our securities.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>No Sales of Similar Securities</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have agreed, subject to certain exceptions, not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of Common Stock (or securities convertible into or exercisable for Common Stock) or, subject to certain exceptions, file any registration statement, including any amendments or supplements thereto (other than the registration statement or amendment to the registration statement relating to the securities offered hereunder and a registration statement on Form S-8), until 45 days after the completion of this offering. We have also agreed not to enter into or issue any shares under a variable rate transaction (as defined in the securities purchase agreement) for&nbsp; four months after the completion of this offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong> Insider Participation </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"> Our Chief Executive Officer and Chief Financial Officer/Chief Operating Officer and certain directors have indicated interest in participating in this offering at the public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding, we cannot guarantee if any officer or director will participate in this offering. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Regulation M</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Placement Agents may be deemed to be underwriters within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by them and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As underwriters, the Placement Agents would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of common stock by any of the Placement Agents acting as principal. Under these rules and regulations, each of the Placement Agents:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">may not engage in any stabilization activity in connection with our securities; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Discretionary Accounts</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Placement Agents do not intend to confirm sales of the securities offered hereby to any accounts over which it has discretionary authority.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Other Activities and Relationships</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Placement Agents and certain of its affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The Placement Agents and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For example, on February 11, 2025, we entered into the Sales Agreement with A.G.P., pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $6,000,000 from time to time through A.G.P., acting as our sales agent or principal. A.G.P. will be entitled to compensation under the terms of the Sales Agreement at a fixed commission rate of up to 3.0% of the gross sales price per share sold, in addition to reimbursement of certain expenses. As of the date of this prospectus, we have sold 11,011,896 shares of our common stock under such Sales Agreement. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, on February 6, 2025, we entered into a placement agency agreement with A.G.P., as lead placement agent and Laidlaw, as co-placement agent, pursuant to which we engaged A.G.P. and Laidlaw as the exclusive placement agents in connection with the February 2025 RD Offering and concurrent private placement of Series E common stock purchase warrants. We agreed to pay the Placement Agents a fee in cash equal to 7.00% of the gross proceeds from the sale of the February 2025 RD Shares, February 2025 RD Pre-Funded Warrants, and Series E common stock purchase warrants to the investor. We also agreed to reimburse the Placement Agents for out-of-pocket expenses, including the reasonable fees of legal counsel not to exceed $50,000.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the ordinary course of its various business activities, the Placement Agents and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the Placement Agents or their affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The Placement Agents and their affiliates may hedge such exposure by entering into transactions that consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the Common Stock offered hereby. Any such short positions could adversely affect future trading prices of the Common Stock offered hereby. The Placement Agents and certain of their affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="LEGALMATTERS">LEGAL MATTERS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Thompson Hine LLP, New York, New York will pass upon certain legal matters related to the issuance of the Common Stock, Common Warrants, and Pre-Funded Warrants offered hereby on our behalf. The Placement Agents are being represented by Sullivan &amp; Worcester LLP, New York, New York in connection with this offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="EXPERTS">EXPERTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consolidated financial statements of Palatin Technologies, Inc. as of June 30, 2024 and 2023, and for the years then ended, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The audit report covering the June 30, 2024 consolidated financial statements contains an explanatory paragraph that states that the Company has incurred operating losses and negative cash flows from operations since inception and will need additional funding to complete planned product development efforts that raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="WHEREYOUCANFINDMOREINFORMATION">WHERE YOU CAN FIND MORE INFORMATION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our securities, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other documents are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers, like us, that file electronically with the SEC. The address of that website is http://www.sec.gov.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are subject to the informational reporting requirements of the Exchange Act. We file reports, proxy statements and other information with the SEC. Our SEC filings are available over the Internet at the SEC&#8217;s website at http://www.sec.gov. We make available, free of charge, on our website at http://www.palatin.com, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports and statements as soon as reasonably practicable after they are filed with the SEC. The contents of our website are not part of this prospectus, and the reference to our website does not constitute incorporation by reference into this prospectus of the information contained on or through that site, other than documents we file with the SEC that are specifically incorporated by reference into this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, a copy of the documents incorporated by reference into this prospectus but not delivered with the prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus, at no cost by writing us at the Company address provided below in section titled &#8220;Information We Incorporate by Reference.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="INFORMATIONWEINCORPORATE">INFORMATION WE INCORPORATE BY REFERENCE</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The SEC allows us to &#8220;incorporate by reference&#8221; into this prospectus the information in documents we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in or omitted from this prospectus or any accompanying prospectus supplement, or in any other subsequently filed document, which also is or is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We incorporate by reference the documents listed below and any future documents that we file with the SEC (excluding any portion of such documents that are furnished and not filed with the SEC) under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (1) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to the effectiveness of the registration statement, and (2) on or after the date of this prospectus until the offering of the securities is terminated:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our Annual Report on Form 10-K for the year ended June 30, 2024, as filed with the SEC on September 30, 2024;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the SEC on November 14, 2024;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2024, as filed with the SEC on February 13, 2025;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">our Current Reports on Form 8-K and/or amendments thereto (other than any portions thereof deemed furnished and not filed), as filed with the SEC on September 6, 2024, October 7, 2024, December 16, 2024, February 10, 2025, February 12, 2025, &nbsp; &nbsp; March 31, 2025, and April 10, 2025; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">the description of our Common Stock contained in our Registration Statement on Form 8-A filed with the SEC on December 13, 1999, including all amendments and reports filed for the purpose of updating such description, including the description of our Common Stock contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019, filed with the SEC on September 12, 2019, including any amendment or report for the purpose of updating such description.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will not, however, incorporate by reference in this prospectus any documents or portions thereof that are not deemed &#8220;filed&#8221; with the SEC, including any information furnished pursuant to Item 2.02 or Item 7.01 of our Current Reports on Form 8-K unless, and except to the extent, specified in such Current Reports.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Any statement contained in a previously filed document is deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or in a subsequently filed document incorporated by reference herein modifies or supersedes the statement, and any statement contained in this prospectus is deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in a subsequently filed document incorporated by reference herein modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, a copy of the documents incorporated by reference into this prospectus but not delivered therewith. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus, at no cost by writing or telephoning us at the following address: Stephen T. Wills, Executive Vice President, Chief Financial Officer and Chief Operating Officer, Palatin Technologies, Inc., 4B Cedar Brook Drive, Cranbury, New Jersey 08512, Telephone: (609) 495-2200, Fax: (609) 495-2201.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>You should rely only on information contained in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide you with information that is different. This prospectus may be used only in jurisdictions where offers and sales of these securities are permitted. Offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation. This document may only be used where it is legal to sell these securities. The information in this document may only be accurate on the date of this document.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ptn_s1img3.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Shares of Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Series F Common Warrants to Purchase Up to 57,339,449 Shares of Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> Up to 57,339,449 Series G Common Warrants to Purchase Up to 57,339,449 Shares of Common Stock </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> Up to 57,339,449 Series H Common Warrants to Purchase up to 57,339,449 Shares of Common Stock </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Pre-Funded Warrants to Purchase Up to 57,339,449 Shares of Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Shares of Common Stock Underlying the Series F Warrants</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> Up to 57,339,449 Shares of Common Stock Underlying the Series G Warrants </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> Up to 57,339,449 Shares of Common Stock Underlying the Series H Warrants </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Up to 57,339,449 Shares of Common Stock Underlying the Pre-Funded Warrants</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PRELIMINARY PROSPECTUS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>Lead Placement Agent</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">A.G.P.</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>Co- Placement Agent</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>LAIDLAW &amp; COMPANY (UK) LTD.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">__________<strong>, 2025</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PART II</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>INFORMATION NOT REQUIRED IN PROSPECTUS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 13. Other Expenses of Issuance and Distribution</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table sets forth all costs and expenses payable by us in connection with the sale of the securities being registered. All amounts shown are estimates except for the SEC registration fee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">SEC registration fee</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"> $ </td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> 7,655 </td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Accountant&#8217;s fees and expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Legal fees and expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Miscellaneous fees and expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Total expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"> $ </td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"> 43,655 </td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 14. Indemnification of Directors and Officers</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Certificate of Incorporation and Bylaws require us to indemnify our directors, officers, employees and agents against the costs (including fines, judgments and attorney fees) from involvement in legal proceedings arising from their position or service, provided that the person seeking indemnification acted:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">in good faith;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Certificate of Incorporation and Bylaws allow us to buy indemnification insurance for this purpose.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Certificate of Incorporation provides that, to the fullest extent permissible under Delaware law, no director shall be personally liable to the corporation or its stockholders for monetary damages for breach of a fiduciary duty as a director. However, this provision does not eliminate the duty of care, and in appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary relief that will remain available under Delaware law. In addition, each director will continue to be subject to liability for (a) breach of the director&#8217;s duty of loyalty to us or our stockholders, (b) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) violating Section 174 of the DGCL, or (d) any transaction from which the director derived an improper personal benefit. The provision also does not affect a director&#8217;s responsibilities under any other law, such as the federal securities laws or state or federal environmental laws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">II-1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 15. Recent Sales of Unregistered Securities</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following list sets forth information regarding unregistered securities sold by us within the past three years.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">On February 6, 2025, we entered into a securities purchase agreement with the investor named on the signature page thereto, pursuant to which we issued, in a private placement, Series E common stock purchase warrants to purchase up to 4,688,000 shares of common stock. The warrants and accompanying shares of common stock or pre-funded warrants (which were sold in a concurrent registered direct offering) were offered at a combined offering price of $1.00. A.G.P./Alliance Global Partners acted as lead placement agent and Laidlaw &amp; Company (UK) Ltd., as co-placement agent in connection with such private placement.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">On December 13, 2024, we entered into a letter agreement with a holder of outstanding common stock purchase warrants. To induce the exercise of a portion of such existing warrants by the holder, we agreed to adjust the exercise price of such portion of the existing warrants to $0.875. Pursuant to the letter agreement, the holder agreed to exercise, for cash, the existing warrants to purchase an aggregate of 3,907,679 shares of common stock (which were registered under certain of our registration statements filed with the SEC) at the adjusted exercise price in exchange for our agreement to issue to the holder Series C common stock purchase warrants to purchase 3,907,679 shares of common stock and Series D common stock purchase warrants to purchase 1,953,839 shares of common stock. We received aggregate gross proceeds of approximately $3.4 million from the exercise of the existing warrants by the holder.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">On June 20, 2024, we entered into a letter agreement with a holder of outstanding common stock purchase warrants, pursuant to the holder agreed to exercise, for cash, existing warrants to purchase, in the aggregate, 3,233,277 shares of common stock (which were registered under certain of our registration statements filed with the SEC) in exchange for our agreement to (i) lower the exercise price to $1.88 per share for the 3,233,277 existing warrants being exercised pursuant to the letter agreement and (ii) issue an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock and Series B common stock purchase warrants to purchase 2,122,642 shares of our common stock. We received aggregate gross proceeds of approximately $6.1 million from the exercise of the existing warrants by the holder.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">On January 29, 2024, we entered into a securities purchase agreement with the investors named on the signature page thereto, pursuant to which we issued, in a private placement, common stock purchase warrants exercisable for an aggregate of 1,831,503 shares of common stock. The warrants and accompanying shares of common stock (which were sold in a concurrent registered direct offering) were offered at a combined offering price of $5.46. H.C. Wainwright &amp; Co., LLC acted as exclusive placement agent in connection with such private placement, and we issued to certain designees of H.C. Wainwright &amp; Co., LLC as part of the compensation payable to H.C. Wainwright &amp; Co., LLC warrants exercisable for an aggregate of 91,575 shares of common stock. </p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">On October 20, 2023, we entered into a securities purchase agreement with the investor named on the signature page thereto, pursuant to which we issued, in a private placement, common stock purchase warrants exercisable for an aggregate of 2,358,491 shares of common stock. The warrants and accompanying shares of common stock (which were sold in a concurrent registered direct offering) were offered at a combined offering price of $2.12. H.C. Wainwright &amp; Co., LLC acted as exclusive placement agent in connection with such private placement, and we issued to certain designees of Wainwright as part of the compensation payable to H.C. Wainwright &amp; Co., LLC warrants exercisable for an aggregate of 117,925 shares of common stock.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">On May 12, 2022, we issued and sold 8,100,000 shares of Series B Redeemable Convertible Preferred Stock (&#8220;Series B Preferred Stock&#8221;) and 900,000 shares of Series C Redeemable Convertible Preferred Stock (&#8220;Series C Preferred Stock&#8221;) pursuant to a securities purchase agreement, dated May 11, 2022. Each share of Series B Preferred Stock and Series C Preferred Stock had a purchase price of $1.67. The investors in the Series B Preferred Stock and Series C Preferred Stock also received warrants to purchase up to 66,666 shares of common stock at an exercise price of $12.50 per share, which expire on May 11, 2026. Total gross proceeds from the offering, before expenses, were $15,000,000.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We believe the offers, sales and issuances of the above securities by us were exempt from registration under the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) of the Securities Act as transactions not involving a public offering. All of the investors were accredited investors as such term is defined in Rule 501 under the Securities Act. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates, notes and warrants issued in these transactions, as applicable. All recipients had adequate access, through their relationships with us, to information about our Company. The sales of these securities were made without any general solicitation or advertising.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">II-2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 16. Exhibits and Financial Statement Schedules</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The exhibits listed below are filed as part of this registration statement:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit Number</strong></p></td> <td style="width:1%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td> <td style="width:1%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Filed Herewith</strong></p></td> <td style="width:1%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Form</strong></p></td> <td style="width:1%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:12%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Filing Date</strong></p></td> <td style="width:1%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SEC File No.</strong></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448813005466/ptn_ex301.htm">3.1</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448813005466/ptn_ex301.htm">Restated Certificate of Incorporation, as amended.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">September 27, 2013</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422006963/ptn_ex36.htm">3.2</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422006963/ptn_ex36.htm">Certificate of Decrease of Series A Convertible Preferred Stock.</a> </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">May 16, 2022</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422011989/ptn_ex31.htm">3.3</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422011989/ptn_ex31.htm">Certificate of Amendment of Restated Certificate of Incorporation. </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">August 31, 2022 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495421010197/ptn_ex31.htm">3.4</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495421010197/ptn_ex31.htm">Amended and Restated Bylaws.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">September 17, 2021</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.1</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Reference is made to Exhibits 3.1 through 3.4.</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex42.htm">4.2</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex42.htm">Form of Series F Common Warrant.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> X </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425003691/ptn_ex43.htm">4.3</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425003691/ptn_ex43.htm">Form of Pre-Funded Warrant.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> S-1 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> March 31, 2025 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> 333-286 280 </p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex44.htm"> 4.4 </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex44.htm"> Form of Series G Common Warrant </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> X </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex45.htm"> 4.5 </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex45.htm"> Form of Series H Common Warrant </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> X </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex51.htm">5.1</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex51.htm">Opinion of Thompson Hine LLP.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802009000050/ex10-1.htm">10.1&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802009000050/ex10-1.htm">1996 Stock Option Plan, as amended.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">September 28, 2009</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-1.htm">10.2&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-1.htm">Form of Option Certificate (Incentive Option) Under the 2005 Stock Plan.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">September 21, 2005</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-2.htm">10.3&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-2.htm">Form of Incentive Stock Option Agreement-Standard Under the 2005 Stock Plan.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">September 21, 2005</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-3.htm">10.4&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-3.htm">Form of Option Certificate (Non-Qualified Opinion) Under the 2005 Stock Plan. </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">September 21, 2005 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-4.htm">10.5&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-4.htm">Form of Non-Qualified Stock Option Agreement Under the 2005 Stock Plan. </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">September 21, 2005</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000006/ex10-4.htm">10.6&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000006/ex10-4.htm">2007 Change in Control Severance Plan. </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 8, 2008</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802009000025/ex10-1.htm">10.7&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802009000025/ex10-1.htm">2005 Stock Plan, as amended.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">May 15, 2009</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000022/ex31-1.htm">10.8&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000022/ex31-1.htm">Form of Executive Officer Option Certificate.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">May 14, 2008</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000022/ex10-2.htm">10.9&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000022/ex10-2.htm">Form of Amended Restricted Stock Unit Agreement.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">May 14, 2008</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000022/ex10-1.htm">10.10&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000022/ex10-1.htm">Form of Amended Option Certificate (Incentive Option) Under the 2005 Stock Plan.</a> </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">May 14, 2008</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423012335/ptn_ex1011.htm">10.11&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423012335/ptn_ex1011.htm">2011 Stock Incentive Plan, as amended, restated and adopted by the stockholders on June 20, 2023.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">September 28, 2023</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802011000031/ex10-2.htm">10.12&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802011000031/ex10-2.htm">Form of Restricted Share Unit Agreement Under the 2011 Stock Incentive Plan.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">May 13, 2011</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802011000031/ex10-3.htm">10.13&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802011000031/ex10-3.htm">Form of Nonqualified Stock Option Agreement Under the 2011 Stock Incentive Plan.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">May 13, 2011</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802011000031/ex10-4.htm">10.14&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000108802011000031/ex10-4.htm">Form of Incentive Stock Option Agreement Under the 2011 Stock Incentive Plan.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">May 13, 2011</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448816006209/ptn_ex101.htm">10.15&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448816006209/ptn_ex101.htm">Amended Form of Restricted Share Unit Agreement Under the 2011 Stock Incentive Plan. </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 12, 2016</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448816006209/ptn_ex102.htm">10.16&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448816006209/ptn_ex102.htm">Amended Form of Performance-Based Restricted Share Unit Agreement Under the 2011 Stock Incentive Plan.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 12, 2016</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448816006209/ptn_ex103.htm">10.17&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448816006209/ptn_ex103.htm">Amended Form of Restricted Share Unit Agreement for Non-Employee Directors Under the 2011 Stock Incentive Plan.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 12, 2016</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448815003275/ptn_ex103.htm">10.18</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448815003275/ptn_ex103.htm">Amended and Restated Venture Loan and Security Agreement, dated July 2, 2015, by and between Palatin Technologies, Inc. and Horizon Technology Finance Corporation, Fortress Credit Co LLC, Horizon Credit II LLC and Fortress Credit Opportunities V CLO Limited. </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">July 7, 2015</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">II-3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="width:8%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495417000945/ptn_ex101.htm">10.19&#8224;&#8224;</a></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495417000945/ptn_ex101.htm">License Agreement, dated January 8, 2017, by and between AMAG Pharmaceuticals, Inc. and Palatin Technologies, Inc.</a></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:8%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:12%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 10, 2017</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:8%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.edgarmaster.com/Inet/DocViewServlet?jobNumber=42401&amp;docName=http://www.sec.gov/Archives/edgar/data/911216/000165495417010398/ptn_ex101.htm"> 10.218&#8224;&#8224; </a></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495417010398/ptn_ex101.htm">License Agreement, dated September 6, 2017, by and between Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. and Palatin Technologies, Inc.</a> </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">November 13, 2017</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422008768/ptn_ex101.htm">10.21&#8224;&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422008768/ptn_ex101.htm">Employment Agreement, effective as of July 1, 2022, between Carl Spana and Palatin Technologies, Inc.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">June 24, 2022</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422008768/ptn_ex102.htm">10.22&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422008768/ptn_ex102.htm">Employment Agreement, effective as of July 1, 2022, between Stephen T. Wills and Palatin Technologies, Inc.</a> </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">June 24, 2022</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495420008026/ptn_ex101.htm">10.23&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495420008026/ptn_ex101.htm">Termination Agreement, dated July 24, 2020, between AMAG Pharmaceuticals, Inc. and Palatin Technologies, Inc.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">July 27, 2020</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495420010471/ptn_ex1030.htm">10.24</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495420010471/ptn_ex1030.htm">Manufacturing Services Agreement, dated as of June 1, 2019, by and between Lonza Ltd. and Palatin Technologies, Inc. (as assignee of AMAG Pharmaceuticals, Inc.). </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">September 25, 2020</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495420010471/ptn_ex1031.htm">10.25&#8224;&#8224;&#8224;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495420010471/ptn_ex1031.htm">Supply Agreement, dated as of December 20, 2018, by and between Ypsomed AG and Palatin Technologies, Inc. (as assignee of AMAG Pharmaceuticals, Inc.).</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">September 25, 2020</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423004637/ptn_ex11.htm">10.26</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423004637/ptn_ex11.htm">Equity Distribution Agreement, dated April 12, 2023, between Canaccord Genuity LLC and Palatin Technologies, Inc. </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">April 12, 2023</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423013343/ptn_ex101.htm">10.27</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423013343/ptn_ex101.htm">Form of Securities Purchase Agreement, dated October 20, 2023, between Palatin Technologies, Inc. and the Purchasers named therein.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">October 24, 2023</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423013343/ptn_ex41.htm">10.28</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423013343/ptn_ex41.htm">Form of Pre-Funded Common Stock Purchase Warrant.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">October 24, 2023</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423013343/ptn_ex42.htm">10.29</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423013343/ptn_ex42.htm">Form of Common Stock Purchase Warrant, dated October 24, 2023.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">October 24, 2023</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423013343/ptn_ex43.htm">10.30</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495423013343/ptn_ex43.htm">Form of Placement Agent Common Stock Purchase Warrant, dated October 24, 2023.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">October 24, 2023</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001212/ptn_ex101.htm">10.31</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001212/ptn_ex101.htm">Form of Securities Purchase Agreement, dated January 29, 2024, by and between Palatin Technologies, Inc. and the Purchasers named therein.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 1, 2024</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001212/ptn_ex41.htm">10.32</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001212/ptn_ex41.htm">Form of Common Stock Purchase Warrant, dated February 1, 2024.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 1, 2024</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001212/ptn_ex42.htm">10.33</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001212/ptn_ex42.htm">Form of Placement Agent Common Stock Purchase Warrant, dated February 1, 2024.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 1, 2024</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001789/ptn_ex43.htm">10.34</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001789/ptn_ex43.htm">Form of January 24, 2024 Amendment to the Placement Agent Warrants issued on November 2, 2022 and October 24, 2023.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 14, 2024</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001789/ptn_ex44.htm">10.35</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001789/ptn_ex44.htm">Form of January 24, 2024 Amendment to the Private Warrants issued to the Investor of November 2, 2022 and October 24, 2023.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001789/ptn_ex44.htm">&nbsp;</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 14, 2024</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001789/ptn_ex102.htm">10.36</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424001789/ptn_ex102.htm">Asset Purchase Agreement entered into December 19, 2023, between the Company and Cosette Pharmaceuticals, Inc.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-Q</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 14, 2024</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424008011/ptn_ex101.htm">10.37</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424008011/ptn_ex101.htm">Inducement Letter, dated June 20, 2024.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">June 21, 2024 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424008011/ptn_ex41.htm">10.38</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424008011/ptn_ex41.htm">Form of Series A Common Stock Purchase Warrant, dated June 24, 2024. </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">June 21, 2024 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424008011/ptn_ex42.htm">10.39</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424008011/ptn_ex42.htm">Form of Series B Common Stock Purchase Warrant, dated June 24, 2024. </a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">June 21, 2024 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex101.htm">10.40</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex101.htm">Inducement Letter, dated December 13, 2024.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">December 16, 2024</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex41.htm">10.41</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex41.htm">Form of Series C Common Stock Purchase Warrant, dated December 17, 2024.</a> </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">December 16, 2024</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex42.htm">10.42</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex42.htm">Form of Series D Common Stock Purchase Warrant, dated December 17, 2024.</a> </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">December 16, 2024</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex101.htm">10.43</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex101.htm">Form of Securities Purchase Agreement, dated February 6, 2025, by and between the Company and the Purchasers named therein.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 10, 2025</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex11.htm">10.44</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex11.htm">Placement Agency Agreement, dated February 6, 2025, between the Company, A.G.P./Alliance Global Partners, and Laidlaw &amp; Company (UK) Ltd.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 10, 2025</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex41.htm">10.45</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex41.htm">Form of Pre-Funded Common Stock Purchase Warrant, issued on or about February 10, 2025</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 10, 2025</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex42.htm">10.46</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex42.htm">Form of Series E Common Stock Purchase Warrant, issued on or about February 10, 2025</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 10, 2025</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001362/ptn_ex11.htm">10.47</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001362/ptn_ex11.htm">Common Stock Sales Agreement, dated as of February 11, 2025, by and between the Company and A.G.P./Alliance Global Partners.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">February 12, 2025</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex1048.htm">10.48</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex1048.htm">Form of Securities Purchase Agreement, by and between the Company and the Purchasers named therein.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> X </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425003691/ptn_ex1049.htm">10.49</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425003691/ptn_ex1049.htm">Form of Placement Agency Agreement, between the Company, A.G.P./Alliance Global Partners, and Laidlaw &amp; Company (UK) Ltd.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> S-1 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> March 31, 2025 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> &nbsp; </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> 333-286 280 </p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424012498/ptn_ex21.htm">21</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424012498/ptn_ex21.htm">Subsidiaries of the registrant.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10-K</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">September 30, 2024</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">001-15543</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">23.1</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Consent of Thompson Hine LLP (included in Exhibit 5.1 to this Registration Statement).</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex232.htm">23.2</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex232.htm">Consent of Independent Registered Public Accounting Firm.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#POA">24.1</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#POA">Power of Attorney (included on signature page).</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex107.htm">107</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex107.htm">Filing Fee Table.</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#8224; </p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Management contract or compensatory plan or arrangement. </p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#8224;&#8224; </p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Confidential treatment granted as to certain portions of the exhibit, which portions are omitted and filed separately with the SEC. </p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#8224;&#8224;&#8224; </p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Portions of the exhibit are omitted pursuant to Regulation S-K Item 601(b)(10). The Registrant agrees to furnish to the U.S. Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request. The confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed. </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">II-4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 17. Undertakings</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(a) The undersigned registrant hereby undertakes: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) To include any prospectus required by section 10(a)(3) of the Securities Act; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>provided, however</em>, that the undertakings set forth in paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are incorporated by reference into this registration statement or are contained in a form of prospectus filed pursuant to Rule 424(b) that is part of this registration statement. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">(4) That, for the purpose of determining liability under the Securities Act to any purchaser: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(b) The registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference into the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">II-5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Township of Cranbury, State of New Jersey, on May 2, 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="3" style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Palatin Technologies, Inc.</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Carl Spana</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:45%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:5%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td> <td style="width:35%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Carl Spana, Ph.D.</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title:</p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">President and Chief Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="POA">POWER OF ATTORNEY</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-1 has been signed below by the following persons in the capacities indicated as of May 2, 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Signatures </strong></p></td> <td style="width:2%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Title </strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>/s/ Carl Spana</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">President, Chief Executive Officer and Director (Principal Executive Officer) </p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Carl Spana </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> * </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Executive Vice President, Chief Financial Officer and Chief Operating Officer </p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Stephen T. Wills </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Principal Financial and Accounting Officer) </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em> * </em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">John K.A. Prendergast </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Chairman and Director </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em> * </em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Robert K. deVeer, Jr. </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Director </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em> * </em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">J. Stanley Hull </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Director </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em> * </em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Alan W. Dunton </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Director </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em> * </em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Arlene M. Morris </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Director </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em> * </em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Anthony M. Manning </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Director </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:5%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> * By: </p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"> <em>/s/Carl S</em> <em> pana </em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> Name: </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> Carl Spana </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> Title: </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"> Attorney-in-fact </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">II-6</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ptn_ex42.htm
<DESCRIPTION>FORM OF SERIES F COMMON WARRANT
<TEXT>
<html><head><title>ptn_ex42.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p><!--Document created using EDGARMaster--> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 4.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM OF SERIES F COMMON STOCK PURCHASE WARRANT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">Warrant Shares: [&#8226;]</p></td> <td style="width:50%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">Issue Date: [ &nbsp;], 2025</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">Initial Exercise Date: [ &nbsp;], 2025</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">THIS SERIES F COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, &#9745; or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date above, and on or prior to 5:00 p.m. (New York City time) on the Termination Date (as defined herein) but not thereafter, to subscribe for and purchase from Palatin Technologies, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to&nbsp;[ ]&nbsp;shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one Warrant Share shall be equal to the Exercise Price, as defined in Section 2(b). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 1</u>. <u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Commission</u>&#8221; means the Securities and Exchange Commission. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Termination Date</u>&#8221; means the five (5) year anniversary of the Initial Exercise Date, provided, however, that if&nbsp;&nbsp;the Holder does not exercise its Series G Common Stock Purchase Warrants (as such term is defined in that certain Securities Purchase Agreement, dated as of [&#8226;], 2025, by and between the Company and the purchasers signatory thereto) in full within thirty (30) calendar days after the U.S Food and Drug Administration acceptance of the Company&#8217;s Investigational New Drug for an in-house obesity treatment compound (long-acting peptide or oral small molecule) (the &#8220;<u>FDA Exercise Period</u>&#8221;), the Termination Date shall mean the Trading Day immediately following the expiration of the FDA Exercise Period. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Day</u>&#8221; means a day on which the Common Stock is traded on a Trading Market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Market, The Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Transfer Agent</u>&#8221; means Equiniti Trust Company, LLC, and any successor transfer agent of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 2</u>. <u>Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<strong>&nbsp;</strong>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <strong>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be $ [&#8226;], subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rule or regulation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;"><u>&#8220;Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&#8220;<u>OTCQB</u>&#8221;) or the OTCQX Best Market (&#8220;<u>OTCQX</u>&#8221;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (the &#8220;<u>Pink Market</u>&#8221;) operated by the OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market, the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Mechanics of Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrant), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iii. <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iv. <u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (subject to receipt of the aggregate exercise price for the applicable exercise (other than in the case of a cashless exercise)), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">v. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vi. <u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vii. <u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Holder&#8217;s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 3</u>. <u>Certain Adjustments</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the voting power of the outstanding common and preferred stock of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the voting power of the outstanding common and preferred stock of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the volatility for the remaining exercised period as obtained from the HVT function on Bloomberg (determined utilizing a 252-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five (5) Trading Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Notice to Holder</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">i. <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by e-mail a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">ii. <u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by e-mail to the Holder at its last e-mail address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 4</u>. <u>Transfer of Warrant</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Transferability</u>. Subject to compliance with applicable securities law, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 5</u>. <u>Miscellaneous</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Authorized Shares</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1in; TEXT-INDENT: 0.5in; text-align:justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">g) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">h) <u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holder hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 4B Cedar Brook Drive, Cranbury, New Jersey 08512, Attention: Chief Executive Officer, e-mail address: cspana@palatin.com, or such other e-mail address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">i) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">j) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">k) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">l) <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">m) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">n) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">********************</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>(Signature Page Follows)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><strong>PALATIN TECHNOLOGIES, INC.</strong></p></td> <td></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td> <td style="width:5%;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td> <td style="width:10%;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"></td> <td></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">Name:</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">Title:</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[<em>Signature Page to Series F Common Stock Purchase Warrant of </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>Palatin Technologies, Inc.</em>]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTICE OF EXERCISE</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">To: </p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px"><strong>PALATIN TECHNOLOGIES, Inc.</strong></p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(2) Payment shall take the form of (check applicable box):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; in lawful money of the United States; or</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">[SIGNATURE OF HOLDER]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Investing Entity: ________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Signature of Authorized Signatory of Investing Entity</em>: _________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Authorized Signatory: ___________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Title of Authorized Signatory: ____________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Date: ________________________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ASSIGNMENT FORM</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><em>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Name:</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">(Please Print)</p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Address:</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Phone Number:</p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">E-mail Address: </p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">(Please Print)</p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">______________________________________</p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">______________________________________</p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Dated: _______________ __, ______</p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Holder&#8217;s Signature:<u>&nbsp;</u></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Holder&#8217;s Address:<u>&nbsp;</u></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>3
<FILENAME>ptn_ex44.htm
<DESCRIPTION>FORM OF SERIES G COMMON WARRANT
<TEXT>
<html><head><title>ptn_ex44.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 4.4</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM OF SERIES G COMMON STOCK PURCHASE WARRANT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Warrant Shares: [&#8226;]</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Issue Date: [ ], 2025</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Initial Exercise Date: [ ], 2025</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">THIS SERIES G COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received,&nbsp;[ ]&nbsp;or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date above, and on or prior to 5:00 p.m. (New York City time) on the Termination Date (as defined herein) but not thereafter, to subscribe for and purchase from Palatin Technologies, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to&nbsp;[ ]&nbsp;shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one Warrant Share shall be equal to the Exercise Price, as defined in Section 2(b). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 1</u>. <u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Commission</u>&#8221; means the Securities and Exchange Commission. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Termination Date</u>&#8221; means the earlier of (i) the twenty-four (24) month anniversary of the Initial Exercise Date, and (ii) the 31<sup style="vertical-align:super">st</sup> calendar day following the date the Company receives the U.S Food and Drug Administration acceptance of the Company&#8217;s Investigational New Drug for an in-house obesity treatment compound (long-acting peptide or oral small molecule), provided that, if such date is not a Trading Day, the date shall be the immediately following Trading Day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Day</u>&#8221; means a day on which the Common Stock is traded on a Trading Market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Market, The Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Transfer Agent</u>&#8221; means Equiniti Trust Company, LLC, and any successor transfer agent of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 2</u>. <u>Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<strong>&nbsp;</strong>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <strong>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be $ [&#8226;], subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rule or regulation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;"><u>&#8220;Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&#8220;<u>OTCQB</u>&#8221;) or the OTCQX Best Market (&#8220;<u>OTCQX</u>&#8221;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (the &#8220;<u>Pink Market</u>&#8221;) operated by the OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market, the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Mechanics of Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrant), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iii. <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iv. <u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (subject to receipt of the aggregate exercise price for the applicable exercise (other than in the case of a cashless exercise)), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">v. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vi. <u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vii. <u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Holder&#8217;s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 3</u>. <u>Certain Adjustments</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the voting power of the outstanding common and preferred stock of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the voting power of the outstanding common and preferred stock of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the volatility for the remaining exercised period as obtained from the HVT function on Bloomberg (determined utilizing a 252-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five (5) Trading Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Notice to Holder</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">i. <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by e-mail a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">ii. <u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by e-mail to the Holder at its last e-mail address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 4</u>. <u>Transfer of Warrant</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Transferability</u>. Subject to compliance with applicable securities law, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 5</u>. <u>Miscellaneous</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Authorized Shares</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1in; TEXT-INDENT: 0.5in; text-align:justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">g) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">h) <u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holder hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 4B Cedar Brook Drive, Cranbury, New Jersey 08512, Attention: Chief Executive Officer, e-mail address: cspana@palatin.com, or such other e-mail address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">i) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">j) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">k) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">l) <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">m) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">n) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">********************</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>(Signature Page Follows)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"></td> <td></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Name:</p></td> <td></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Title:</p></td> <td></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[<em>Signature Page to Series G Common Stock Purchase Warrant of </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>Palatin Technologies, Inc.</em>]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTICE OF EXERCISE</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">To: </p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>PALATIN TECHNOLOGIES, Inc.</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(2) Payment shall take the form of (check applicable box):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; in lawful money of the United States; or</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">[SIGNATURE OF HOLDER]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Investing Entity: ________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Signature of Authorized Signatory of Investing Entity</em>: _________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Authorized Signatory: ___________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Title of Authorized Signatory: ____________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Date: ________________________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ASSIGNMENT FORM</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><em>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Please Print)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Address:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Phone Number:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E-mail Address: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Please Print)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">______________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">______________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dated: _______________ __, ______</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holder&#8217;s Signature:<u>&nbsp;</u></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holder&#8217;s Address:<u>&nbsp;</u></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>4
<FILENAME>ptn_ex45.htm
<DESCRIPTION>FORM OF SERIES H COMMON WARRANT
<TEXT>
<html><head><title>ptn_ex45.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 4.5</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM OF SERIES H COMMON STOCK PURCHASE WARRANT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong></strong>&nbsp;</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:left;">Warrant Shares: [&#8226;]</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">Issue Date: [&#8226;], 2025</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">Initial Exercise Date: [&#8226;], 2025</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">THIS SERIES H COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received,&nbsp;[ ]&nbsp;or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date above, and on or prior to 5:00 p.m. (New York City time) on the twenty-four (24) month anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day, the immediately following Trading Day (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Palatin Technologies, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to&nbsp;[ ]&nbsp;shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one Warrant Share shall be equal to the Exercise Price, as defined in Section 2(b). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 1</u>. <u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Commission</u>&#8221; means the Securities and Exchange Commission. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Day</u>&#8221; means a day on which the Common Stock is traded on a Trading Market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Market, The Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Transfer Agent</u>&#8221; means Equiniti Trust Company, LLC, and any successor transfer agent of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 2</u>. <u>Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<strong>&nbsp;</strong>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <strong>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be $ [&#8226;], subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rule or regulation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;"><u>&#8220;Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&#8220;<u>OTCQB</u>&#8221;) or the OTCQX Best Market (&#8220;<u>OTCQX</u>&#8221;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (the &#8220;<u>Pink Market</u>&#8221;) operated by the OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market, the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Mechanics of Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrant), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iii. <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iv. <u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (subject to receipt of the aggregate exercise price for the applicable exercise (other than in the case of a cashless exercise)), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">v. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vi. <u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vii. <u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Holder&#8217;s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 3</u>. <u>Certain Adjustments</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the voting power of the outstanding common and preferred stock of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the voting power of the outstanding common and preferred stock of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the volatility for the remaining exercised period as obtained from the HVT function on Bloomberg (determined utilizing a 252-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five (5) Trading Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Notice to Holder</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">i. <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by e-mail a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">ii. <u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by e-mail to the Holder at its last e-mail address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 4</u>. <u>Transfer of Warrant</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Transferability</u>. Subject to compliance with applicable securities law, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 5</u>. <u>Miscellaneous</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Authorized Shares</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1in; TEXT-INDENT: 0.5in; text-align:justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">g) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">h) <u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holder hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 4B Cedar Brook Drive, Cranbury, New Jersey 08512, Attention: Chief Executive Officer, e-mail address: cspana@palatin.com, or such other e-mail address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">i) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">j) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">k) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">l) <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">m) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">n) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">********************</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>(Signature Page Follows)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:justify;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">Name:</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">Title:</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[<em>Signature Page to Series H Common Stock Purchase Warrant of </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>Palatin Technologies, Inc.</em>]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTICE OF EXERCISE</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">To: </p></td> <td> <p style="MARGIN: 0px; text-align:left;"><strong>PALATIN TECHNOLOGIES, Inc.</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(2) Payment shall take the form of (check applicable box):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; in lawful money of the United States; or</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">[SIGNATURE OF HOLDER]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Investing Entity: ________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Signature of Authorized Signatory of Investing Entity</em>: _________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Authorized Signatory: ___________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Title of Authorized Signatory: ____________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Date: ________________________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ASSIGNMENT FORM</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><em>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Name:</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(Please Print)</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Address:</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">Phone Number:</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">E-mail Address: </p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(Please Print)</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">______________________________________</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">______________________________________</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dated: _______________ __, ______</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Holder&#8217;s Signature:<u>&nbsp;</u></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Holder&#8217;s Address:<u>&nbsp;</u></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>ptn_ex51.htm
<DESCRIPTION>OPINION OF THOMPSON HINE LLP
<TEXT>
<html><head><title>ptn_ex51.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 5.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ptn_ex51img1.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:right;">May 2, 2025</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Palatin Technologies, Inc.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4B Cedar Brook Drive</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cranbury, New Jersey 08512</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ladies and Gentlemen:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">We have acted as counsel to Palatin Technologies, Inc., a Delaware corporation (the &#8220;<strong><em>Company</em></strong>&#8221;), in connection with the preparation and filing with the Securities and Exchange Commission (the &#8220;<strong><em>Commission</em></strong>&#8221;) of this registration statement on Form S-1 (the &#8220;<strong><em>Registration Statement</em></strong>&#8221;) on the date hereof under the Securities Act of 1933, as amended (the &#8220;<strong><em>Securities Act</em></strong>&#8221;), and the related prospectus contained therein (the &#8220;<strong><em>Prospectus</em></strong>&#8221;). We are rendering this opinion in connection with the filing by the Company of the Registration Statement relating to the offer and sale by the Company (the &#8220;<strong><em>Offering</em></strong>&#8221;) of (i) 57,339,449 shares (each, a &#8220;<strong><em>Share</em></strong>&#8221;) of common stock, $0.01 par value per share, of the Company (the &#8220;<strong><em>Common</em></strong> <strong><em>Stock</em></strong>&#8221;), (ii) 57,339,449 pre-funded warrants to purchase up to 57,339,449 shares of Common Stock (the &#8220;<strong><em>Pre-Funded Warrants</em></strong>&#8221;), (iii) 57,339,449 Series F Common Warrants to purchase up to 57,339,449 shares of Common Stock (the &#8220;<strong><em>Series F Common</em></strong> <strong><em>Warrants</em></strong>&#8221;), (iv) 57,339,449 Series G Common Warrants to purchase up to 57,339,449 shares of Common Stock (the &#8220;<strong><em>Series G Common Warrants</em></strong>&#8221;) and (v) 57,339,449 Series H Common Warrants to purchase up to 57,339,449 shares of Common Stock (the &#8220;<strong><em>Series H Common Warrants</em></strong>&#8221; and, together with the Series F Common Warrants and the Series G Common Warrants, the &#8220;<strong><em>Warrants</em></strong>&#8221;). The shares of Common Stock to be issued pursuant to the Pre-Funded Warrants are referred to herein as the &#8220;<strong><em>Pre-Funded Warrant</em></strong> <strong><em>Shares</em></strong>&#8221; and the shares of Common Stock to be issued pursuant to the Warrants are referred to herein as the &#8220;<strong><em>Warrant Shares</em></strong>.&#8221; The Shares, Pre-Funded Warrants, Pre-Funded Warrant Shares, Warrants, and Warrant Shares are being registered and to be issued pursuant to the Registration Statement.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">In rendering this opinion letter, we have examined the Registration Statement, the Prospectus, the form of securities purchase agreement to be entered into by and among the Company and the purchasers identified on the signature pages thereto, substantially in the form filed as Exhibit 10.48 to the Registration Statement (the &#8220;<strong><em>Purchase Agreement</em></strong>&#8221;) and such other documents and reviewed such questions of law as we have deemed advisable in order to render our opinion set forth below. In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, that all parties (other than the Company) had the requisite power and authority (corporate or otherwise) to execute, deliver and perform such agreements or instruments, that all such agreements or instruments have been duly authorized by all requisite action (corporate or otherwise), executed and delivered by such parties, that such agreements or instruments are valid, binding and enforceable obligations of such parties, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, conformed or photostatic copies and the authenticity of the originals of such latter documents. In providing this opinion letter, we have further relied as to certain matters on information obtained from public officials and officers of the Company.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">As a result of and subject to the foregoing, we are of the opinion that (1) the Shares, when issued and delivered pursuant to the terms of the Purchase Agreement against payment of the consideration therefor as provided in the Purchase Agreement, will be validly issued, fully paid and non-assessable, (2) the Pre-Funded Warrants, when issued and delivered pursuant to the terms of the Purchase Agreement against payment of the consideration therefor as provided in the Purchase Agreement, will constitute valid and binding obligations of the Company, (3) the Pre-Funded Warrant Shares, when issued upon exercise of the Pre-Funded Warrants pursuant to the terms of the Pre-Funded Warrants against payment of the exercise price therefor as provided in the Pre-Funded Warrants, will be validly issued, fully paid and non-assessable, (4) the Warrants, when issued and delivered pursuant to the terms of the Purchase Agreement against payment of the consideration therefor as provided in the Purchase Agreement, will constitute valid and binding obligations of the Company, and (5) the Warrant Shares, when issued upon exercise of the Warrants pursuant to the terms of the Warrants against payment of the exercise price therefor as provided in the Warrants, will be validly issued, fully paid and non-assessable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:33%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><img src="ptn_ex51img2.jpg"></p></td> <td style="width:33%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">300 Madison Avenue, 27th</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">New York, New York 10017-6232</p></td> <td style="width:34%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">www.ThompsonHine.com</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">O:&nbsp; 212.344.5680</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">F:&nbsp;&nbsp;212.344.6101</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ptn_ex51img3.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">Our opinion expressed above is limited to the General Corporation Laws of the State of Delaware and laws of the State of New York, in each case as currently in effect, and we express no opinion as to the effect on the matters covered by this letter of the laws of any other jurisdiction.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">This opinion letter is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company, the Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Warrants, the Warrant Shares, the Registration Statement, or the Prospectus.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to being named under the caption &#8220;Legal Matters&#8221; contained in the Registration Statement. In giving this consent, we do not hereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Very truly yours,</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">/s/ Thompson Hine LLP</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Thompson Hine LLP</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.48
<SEQUENCE>6
<FILENAME>ptn_ex1048.htm
<DESCRIPTION>FORM OF SECURITIES PURCHASE AGREEMENT
<TEXT>
<html><head><title>ptn_ex1048.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 10.48</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES PURCHASE AGREEMENT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">This Securities Purchase Agreement (this &#8220;<u>Agreement</u>&#8221;) is dated as of [<u>&nbsp; </u>], 2025, between Palatin Technologies, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#8220;<u>Purchaser</u>&#8221; and collectively the &#8220;<u>Purchasers</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE I.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">DEFINITIONS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Acquiring Person</u>&#8221; shall have the meaning ascribed to such term in Section 4.5.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Action</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(j).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Auditor</u>&#8221; means KPMG LLP, an independent registered public accounting firm.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>BHCA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(mm).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Business Day</u>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally open for use by customers on such day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Closing</u>&#8221; means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Closing Date</u>&#8221; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers&#8217; obligations to pay the Subscription Amount, and (ii) the Company&#8217;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1<sup style="vertical-align:super">st</sup>) Trading Day following the date hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Commission</u>&#8221; means the United States Securities and Exchange Commission.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Common Warrants</u>&#8221; means the Series F Common Warrants, Series G Common Warrants and Series H Common Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Common Warrant Shares</u>&#8221; means the shares of Common Stock issuable upon exercise of the Common Warrants. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Company Counsel</u>&#8221; means Thompson Hine LLP, with offices located at 300 Madison Avenue, 27th Floor, New York, NY 10017-6232.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Disclosure Time</u>&#8221; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agents, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agents.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Disqualification Event</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(qq).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Evaluation Date</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(s).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Exempt Issuance</u>&#8221; means the issuance of: (a) shares of Common Stock or options to employees, consultants, contractors, advisors, officers or directors of the Company pursuant to any stock or option plan or arrangement duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, provided that issuances to consultants under this clause (a) shall be issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a) herein; (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder, warrants to the Placement Agents in connection with the transactions pursuant to this Agreement and any securities upon exercise of warrants to the Placement Agents and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities; and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>FCPA</u>&#8221; means the Foreign Corrupt Practices Act of 1977, as amended.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>FDA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>FDCA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>GAAP</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(h).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Indebtedness</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(aa).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Intellectual Property Rights</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(p).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Issuer Covered Person</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(qq).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Issuer Free Writing Prospectus</u>&#8221; shall have the meaning ascribed to such term in Rule 433 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Legend Removal Date</u>&#8221; shall have the meaning ascribed to such term in Section 4.1(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Liens</u>&#8221; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Lock-Up Agreements</u>&#8221; means the lock-up agreements, each dated as of the date hereof in substantially the form of&nbsp;Exhibit A.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Material Adverse Effect</u>&#8221; shall have the meaning assigned to such term in Section 3.1(b).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Material Permits</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(n).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Money Laundering Laws</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(nn).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>OFAC</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(kk).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Per Share Purchase Price</u>&#8221; equals $[<u>&nbsp; </u>], subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement and prior to the Closing Date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Per Pre-Funded Warrant Purchase Price</u>&#8221; means the Per Share Purchase Price minus $0.0001.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Pharmaceutical Product</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Placement Agency Agreement</u>&#8221; means that certain Placement Agency Agreement by and between the Company and the Placement Agents, dated as of the date hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Placement Agents</u>&#8221; means A.G.P./Alliance Global Partners and Laidlaw &amp; Company (U.K.) Ltd.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Pre-Funded Warrant Shares</u>&#8221; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Pre-Funded Warrants</u>&#8221; means, collectively, the pre-funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.3(a) hereof, in substantially the form of&nbsp;<u>Exhibit B</u>&nbsp;attached hereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Preliminary Prospectus</u>&#8221; means the preliminary prospectus included in the Registration Statement at the time the Registration Statement is declared effective.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Proceeding</u>&#8221; means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Prospectus</u>&#8221; means the final prospectus filed for the Registration Statement, including all information, documents and exhibits filed with or incorporated by reference into such Prospectus.&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Purchaser Party</u>&#8221; shall have the meaning ascribed to such term in Section 4.8.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Registration Statement</u>&#8221; means the effective registration statement on Form S-1, as amended (File No. 333-[<u>&nbsp; </u>]), filed with the Commission, including all information, documents and exhibits filed with or incorporated by reference into such registration statement, which registers the sale of the Shares, Common Warrants, Common Warrant Shares, Pre-Funded Warrants and Pre-Funded Warrant Shares to the Purchasers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Required Approvals</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(e).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Rule 424</u>&#8221; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>SEC Reports</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(h).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Securities</u>&#8221; means the Shares, the Warrants and the Warrant Shares purchased pursuant to this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Series F Common Warrants</u>&#8221; means the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which warrants shall be exercisable commencing on the date of their issuance and have a term of exercise equal to five (5) years following the Initial Exercise Date (as defined in the Series F Common Warrants), substantially in the form of Exhibit C attached hereto.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Series G Common Warrants</u>&#8221; means the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which warrants shall be exercisable commencing on the date of their issuance and have a term of exercise until the earlier of (i) the twenty four (24) month anniversary of the original issuance date or (ii) thirty (30) calendar days after the FDA acceptance of the Company&#8217;s Investigational New Drug (&#8220;IND&#8221;) for any obesity-related compound, substantially in the form of Exhibit D attached hereto.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Series H Common Warrants</u>&#8221; means the Common Stock purchase warrants delivered to the Purchasers upon exercise of the Series G Common Warrants,&nbsp;&nbsp;which warrants shall be exercisable commencing on the date of their issuance and have a term of exercise until the twenty-four (24) month anniversary of the original issuance date, substantially in the form of Exhibit E attached hereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Shares</u>&#8221; means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Short Sales</u>&#8221; means all &#8220;short sales&#8221; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Subscription Amount</u>&#8221; means, as to each Purchaser, the aggregate amount to be paid for Shares (or Pre-Funded Warrants in lieu of Shares) and Common Warrants purchased hereunder as specified below such Purchaser&#8217;s name on the signature page of this Agreement and next to the heading &#8220;Subscription Amount,&#8221; in United States dollars and in immediately available funds.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company as set forth in the SEC Reports, and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Trading Day</u>&#8221; means a day on which the principal Trading Market is open for trading.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Transaction Documents</u>&#8221; means this Agreement, the Warrants, the Lock-Up Agreements, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Transfer Agent</u>&#8221; means American Stock Transfer &amp; Trust Company, the current transfer agent of the Company, with a mailing address of 6201 15th Avenue, Brooklyn, New York 11219, and any successor transfer agent of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Variable Rate Transaction</u>&#8221; shall have the meaning ascribed to such term in Section 4.12(b).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted on a Trading Market but it is quoted on the OTCQB Venture Market (&#8220;<u>OTCQB</u>&#8221;) or the OTCQX Best Market (&#8220;<u>OTCQX</u>&#8221;), the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted on a Trading Market, the OTCQB, or the OTCQX but if prices for the Common Stock are then reported in the Pink Open Market operated by the OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Warrants</u>&#8221; means, collectively, the Common Warrants and Pre-Funded Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Warrant Shares</u>&#8221; means the Common Warrant Shares and Pre-Funded Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE II.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">PURCHASE AND SALE</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">2.1 <u>Closing</u>. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 63pt; text-align:justify;">(a) On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, an aggregate of $[<u>&nbsp;</u>] of Shares and Warrants. Each Purchaser&#8217;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &#8220;Delivery Versus Payment&#8221; (&#8220;<u>DVP</u>&#8221;) settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares and Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the Closing documentation. Unless otherwise directed by the Placement Agents, settlement of the Shares shall occur via DVP<em>&nbsp;</em>(i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&#8217; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agents identified by each Purchaser; upon receipt of such Shares, the Placement Agents shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agents (or its clearing firm) by wire transfer to the Company).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 63pt; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 63pt; text-align:justify;">(b) Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &#8220;<u>Pre-Settlement Period</u>&#8221;), such Purchaser sells to any Person all, or any portion, of the Securities to be issued hereunder to such Purchaser at the Closing (collectively, the &#8220;<u>Pre-Settlement Securities</u>&#8221;), such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement Securities to such Purchaser at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Securities to such Purchaser prior to the Company&#8217;s receipt of the Subscription Amount for such Pre-Settlement Securities hereunder; and provided further that the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise (as defined in the Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the Warrants) for purposes hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">2.2 <u>Deliveries</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">(a) On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) this Agreement duly executed by the Company;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) a legal opinion of Company Counsel, directed to the Placement Agents and the Purchasers, in a form reasonably acceptable to the Placement Agents and Purchasers; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(iii) the Company shall have provided each Purchaser with the Company&#8217;s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(iv) subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) Shares equal to such Purchaser&#8217;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(v) a Series F Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum of such Purchaser&#8217;s Shares plus the Pre-Funded Warrant Shares, with an exercise price equal to $[<u>&nbsp;</u>] subject to adjustment therein; </p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 67.85pt; TEXT-INDENT: 33.75pt; text-align:justify;">(vi) a Series G Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum of such Purchaser&#8217;s Shares plus the Pre-Funded Warrant Shares, with an exercise price equal to $[<u>&nbsp;</u>] subject to adjustment therein;</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 67.85pt; TEXT-INDENT: 35.65pt; text-align:justify;">(vii) if applicable, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to equal to the portion of such Purchaser&#8217;s Subscription Amount applicable to Pre-Funded Warrants divided by the Per Pre-Funded Warrant Purchase Price, with an exercise price equal to $0.0001, subject to adjustment therein; </p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(viii) Lock-Up Agreements, in form and substance reasonably acceptable to the Placements Agents and the Purchasers, executed by each executive officer and director; and</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ix) the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">(b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) this Agreement duly executed by such Purchaser; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) such Purchaser&#8217;s Subscription Amount, which shall be made available for DVP settlement with the Company or its designee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 67.7pt; text-align:justify;">(c) At the time this Agreement is executed, the Placement Agents shall have received from the Auditor a cold comfort letter containing statements and information of the type customarily included in accountants&#8217; comfort letters with respect to the financial statements and certain financial information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus, or any Issuer Free Writing Prospectus, addressed to the Placement Agents and in form and substance reasonably satisfactory to the Placement Agents, dated as of the date of this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 67.7pt; text-align:justify;">(d) On the Closing Date, the Placement Agents shall have received from the Auditor a letter, dated as of the Closing Date, to the effect that the Auditor reaffirms the statements made in the letter furnished pursuant to Section 2.2(c)(i).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 67.7pt; text-align:justify;">(e) Upon the exercise of the Series G Common Warrants issued to the Purchasers in accordance with Section 2.2(a)(vi) hereof, the Company shall deliver or cause to be delivered to any Purchaser that exercises such Series G Common Warrants, a Series H Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum of such Purchaser&#8217;s Shares plus the Pre-Funded Warrant Shares, with an exercise price equal to $[<u>&nbsp;</u>] subject to adjustment therein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">2.3 <u>Closing Conditions</u>. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date); </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(iii) the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(b) The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(iii) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(iv) there shall have been no Material Adverse Effect with respect to the Company; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(v) from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&#8217;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE III.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">REPRESENTATIONS AND WARRANTIES</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">3.1 <u>Representations and Warranties of the Company</u>. Except as set forth in the SEC Reports, the Company hereby makes the following representations and warranties to each Purchaser:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(a) Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(b) Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &#8220;Material Adverse Effect&#8221;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(d) No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(e) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus, (iii) the notice and/or application(s) to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, and (iv)&nbsp;&nbsp;such filings as are required to be made under applicable state securities laws (collectively, the &#8220;<u>Required Approvals</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(f) Issuance of the Securities; Registration. The Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Warrants are duly authorized and, when issued in accordance with this Agreement, will be duly and validly issued and constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms free and clear of all Liens imposed by the Company. The Warrant Shares are duly authorized, and when issued against the payment of any applicable exercise price in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. &nbsp;The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which Registration Statement was declared effective on [<u>&nbsp; </u>], including the Preliminary Prospectus, Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Preliminary Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Preliminary Prospectus, the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(g) Capitalization. The capitalization of the Company is as set forth in the SEC Reports as of the date set forth in such SEC Reports, including the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date indicated in such SEC Reports. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other (i) than pursuant to the exercise of employee stock options under the Company&#8217;s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&#8217;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act, and (ii) securities issued pursuant to that that certain Securities Purchase Agreement entered into between the Company and such purchaser on February 6, 2025 (the &#8220;<u>February 6, 2025 SPA</u>&#8221;). No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &#8220;phantom stock&#8221; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(h) SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &#8220;<u>SEC Reports</u>&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;<u>GAAP</u>&#8221;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(j) Litigation. Except as disclosed in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<u>Action</u>&#8221;) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(k) Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&#8217;s or its Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(l) Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case of clauses (i) through (iii), such as could not, have or reasonably be expected to result in a Material Adverse Effect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(m) Environmental Laws. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;<u>Hazardous Materials</u>&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#8220;<u>Environmental Laws</u>&#8221;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(n) Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&#8220;<u>Material Permits</u>&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(o) Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(p) Intellectual Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the &#8220;Intellectual Property Rights&#8221;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(q) Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(r) Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(s) Sarbanes-Oxley; Internal Accounting Controls. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms. The Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;Evaluation Date&#8221;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(t) Certain Fees. Except for fees payable by the Company to the Placement Agents, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(u) Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the Investment Company Act of 1940, as amended.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(v) Registration Rights. Except for the rights granted to the purchaser pursuant to the February 6, 2025 SPA, no Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(w) Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(x) Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti&#8209;takeover provision under the Company&#8217;s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&#8217;s issuance of the Securities and the Purchasers&#8217; ownership of the Securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(y) Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(z) No Integrated Offering. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of the Warrants or the Warrant Shares under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(aa) Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&#8217;s assets exceeds the amount that will be required to be paid on or in respect of the Company&#8217;s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&#8217;s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. All outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments is set forth in the SEC Reports. For the purposes of this Agreement, &#8220;Indebtedness&#8221; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(bb) Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(cc) Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(dd) Accountants. The Company&#8217;s independent registered public accounting firm is KPMG LLP. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act, and (ii) shall express its opinion with respect to the financial statements to be included in the Company&#8217;s Annual Report for the fiscal year ending June 30, 2025. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ee) Acknowledgment Regarding Purchasers&#8217; Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#8217; purchase of the Securities. The Company further represents to each Purchaser that the Company&#8217;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ff) Acknowledgment Regarding Purchaser&#8217;s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &#8220;derivative&#8221; securities based on securities issued by the Company or to hold the Securities for any specified term, (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &#8220;derivative&#8221; transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&#8217;s publicly-traded securities, (iii) any Purchaser, and counter-parties in &#8220;derivative&#8221; transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &#8220;short&#8221; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&#8217;s length counter-party in any &#8220;derivative&#8221; transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(gg) Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agents pursuant to the Placement Agency Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(hh) FDA. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&#8220;<u>FDA</u>&#8221;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&#8220;<u>FDCA</u>&#8221;) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &#8220;<u>Pharmaceutical Product</u>&#8221;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) Cybersecurity. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&#8217;s or any Subsidiary&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &#8220;<u>IT Systems and Data</u>&#8221;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(jj) Stock Option Plans. Each stock option granted by the Company under the Company&#8217;s stock option plan was granted (i) in accordance with the terms of the Company&#8217;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&#8217;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(kk) Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;OFAC&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ll) U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&#8217;s request.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(mm) Bank Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &#8220;BHCA&#8221;) and to regulation by the Board of Governors of the Federal Reserve System (the &#8220;Federal Reserve&#8221;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(nn) Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;Money Laundering Laws&#8221;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">3.2 <u>Representations and Warranties of the Purchasers</u>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(a) Organization; Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(b) Understandings or Arrangements. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser&#8217;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(c) Purchaser Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be either: (i) an &#8220;accredited investor&#8221; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a &#8220;qualified institutional buyer&#8221; as defined in Rule 144A(a) under the Securities Act. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(d) Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(e) Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the Placement Agents nor any Affiliate of the Placement Agents has provided such Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired. Neither of the Placement Agents nor any Affiliate of the Placement Agents has made or makes any representation as to the Company or the quality of the Securities and the Placement Agents and any Affiliate of the Placement Agents may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the Securities to such Purchaser, neither of the Placement Agents nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(f) Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&#8217;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(g) No Conflicts. The execution, delivery and performance by each Purchaser of the Transaction Documents and the consummation by the Purchasers of the transactions contemplated thereunder will not (a) result in a violation of the organizational documents of a Purchaser or (b) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Purchaser is a party, or (c) result in a violation of any applicable law, rule, regulation, order, judgment or decree (including federal and state securities laws), except in the case of clauses (b) and (c) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of a Purchaser to perform its obligations hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&#8217;s right to rely on the Company&#8217;s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE IV.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">OTHER AGREEMENTS OF THE PARTIES</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.1 <u>Legends</u>. The Shares and, if all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the issuance of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares shall be issued free of all restrictive legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the initial sale by the Company of the Shares, the Warrants or the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again and available for the initial sale by the Company of the Shares, the Warrants or the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Shares, the Warrants or the Warrant Shares in compliance with applicable federal and state securities laws). The Company shall use commercially reasonable efforts to keep a registration statement (including the Registration Statement) registering the issuance of the Warrant Shares effective during the term of the Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.2 <u>Furnishing of Information</u>. Until the earlier of the time that (i) no Purchaser owns Securities, or (ii) the Warrants have expired, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.85pt; text-align:justify;">4.3 <u>Integration</u>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Warrants, Warrant Shares or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.4 <u>Securities Laws Disclosure; Publicity</u>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agents, in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agents, on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law or the rules of any Trading Market, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of the final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.5 <u>Shareholder Rights Plan</u>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#8220;Acquiring Person&#8221; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.6 <u>Non-Public Information</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser without such Purchaser&#8217;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agents, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agents, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.7 <u>Use of Proceeds</u>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and for any purposes set forth in the Prospectus, and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&#8217;s debt (other than payment of trade payables in the ordinary course of the Company&#8217;s business and prior practices or debt outstanding as of the date hereof in accordance with the terms in effect as of the date hereof), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.8 <u>Indemnification of Purchasers</u>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#8220;<u>Purchaser Party</u>&#8221;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#8217; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents, (b) any action instituted against the Purchaser Parties in any capacity (including a Purchaser Party&#8217;s status as an investor), or any of them or their respective Affiliates, by the Company or any stockholder of the Company who is not an Affiliate of such Purchaser Party, arising out of or relating to any of the transactions contemplated by the Transaction Documents, or (c) in connection with any registration statement of the Company providing for the resale by the Purchasers of the Warrant Shares issued and issuable upon exercise of the Warrants, the Company will indemnify each Purchaser Party, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&#8217; fees) and expenses, as incurred, arising out of or relating to (i) any untrue or alleged untrue statement of a material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding such Purchaser Party furnished in writing to the Company by such Purchaser Party expressly for use therein, or (ii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder in connection therewith. For the avoidance of doubt, the indemnification provided herein is intended to, and shall also cover, direct claims brought by the Company against the Purchaser Parties; provided, however, that such indemnification shall not cover any loss, claim, damage or liability to the extent it is finally judicially determined to be attributable to any Purchaser Party&#8217;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in any Transaction Document or any conduct by a Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and, except with respect to direct claims brought by the Company, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel to the applicable Purchaser Party (which may be internal counsel), a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement for any settlement by a Purchaser Party effected without the Company&#8217;s prior written consent, which shall not be unreasonably withheld or delayed. In addition, if any Purchaser Party takes actions to collect amounts due under any Transaction Documents or to enforce the provisions of any Transaction Documents, then the Company shall pay the costs incurred by such Purchaser Party for such collection, enforcement or action, including, but not limited to, attorneys' fees and disbursements. The indemnification and other payment obligations required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation, defense, collection, enforcement or action, as and when bills are received or are incurred; provided, that if any Purchaser Party is finally judicially determined not to be entitled to indemnification or payment under this Section 4.8, such Purchaser Party shall promptly reimburse the Company for any payments that are advanced under this sentence. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.9 <u>Reservation of Common Stock</u>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.10 <u>Listing of Common Stock</u>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&#8217;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.85pt; text-align:justify;">4.11 [Reserved.] </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.85pt; text-align:justify;">4.12 <u>Subsequent Equity Sales</u>. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.85pt; TEXT-INDENT: 33.85pt; text-align:justify;">(a) From the date hereof until forty-five (45) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents other than any sale of shares of Common Stock pursuant to the Company&#8217;s existing &#8220;at the market&#8221; offering under that certain Sales Agreement by and between the Company and A.G.P./Alliance Global Partners dated February 11, 2025 (the &#8220;<u>A.G.P. ATM Facility</u>&#8221;), or (ii) file any registration statement or amendment or supplement thereto, other than (x) the Prospectus, (y) a registration statement on Form S-8 in connection with any employee benefit plan, or (z) a prospectus supplement in connection with the A.G.P. ATM Facility.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.85pt; TEXT-INDENT: 33.85pt; text-align:justify;">(b) From the date hereof until the date four (4) months after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &#8220;<u>Variable Rate Transaction</u>&#8221; means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an &#8220;at-the-market offering&#8221;, whereby the Company may issue securities at a future determined price; <u>provided</u>, <u>however</u>, that, after fifteen (15) days following the Closing Date, the issuance of shares of Common Stock in an &#8220;at the market&#8221; offering under the A.G.P. ATM Facility shall not be deemed a Variable Rate Transaction and the Company may file any related prospectus supplement thereto. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.85pt; TEXT-INDENT: 33.85pt; text-align:justify;">(c) Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.13 <u>Equal Treatment of Purchasers</u>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.14 <u>Certain Transactions and Confidentiality</u>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company&#8217;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed to its legal and other representatives). Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates, or agents, including, without limitation, the Placement Agents, after the issuance of the initial press release as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.15 <u>Capital Changes</u>. Until the one year anniversary of the Closing Date, the Company shall not undertake a reverse or forward stock split or reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority in interest of the Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.16 <u>Exercise Procedures</u>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.17 &nbsp;<u>Lock-Up Agreements</u>.&nbsp; The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements without the prior written consent of the Placement Agents, except to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific performance of the terms of such Lock-Up Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE V.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">MISCELLANEOUS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.1 <u>Termination</u>. This Agreement may be terminated by any Purchaser, as to such Purchaser&#8217;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the fifth (5<sup style="vertical-align:super">th</sup>) Trading Day following the date hereof; provided, however, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.2 <u>Fees and Expenses</u>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.3 <u>Entire Agreement</u>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.4 <u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<sup style="vertical-align:super">nd</sup>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.5 <u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of at least 50.1% in interest of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.6 <u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.7 <u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the &#8220;Purchasers.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.8 <u>Third-Party Beneficiaries</u>. The Placement Agents shall be the third party beneficiary of the representations and warranties of the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.9 <u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.10 <u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.11 <u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such &#8220;.pdf&#8221; signature page were an original thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.12 <u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.13 <u>Rescission and Withdrawal Right</u>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&#8217;s right to acquire such shares pursuant to such Purchaser&#8217;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.14 <u>Replacement of Securities</u>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.15 <u>Remedies</u>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.16 <u>Payment Set Aside</u>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.17 <u>Independent Nature of Purchasers&#8217; Obligations and Rights</u>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through the legal counsel of the Placement Agents. The legal counsel of the Placement Agents does not represent any of the Purchasers and only represents the Placement Agents. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.18 <u>Liquidated Damages</u>. The Company&#8217;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.19 <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.20 <u>Construction</u>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.21<strong> <u>WAIVER OF JURY TRIAL</u>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>(Signature Pages Follow)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Palatin Technologies, Inc. </strong></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><u>Address for Notice:</u></p></td></tr> <tr style="height:15px"> <td style="width:3%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:35%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:2%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">E-Mail:</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Name:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Title:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">With a copy to (which shall not constitute notice):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">[COMPANY SIGNATURE PAGE TO PTN SECURITIES PURCHASE AGREEMENT]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[PURCHASER SIGNATURE PAGES TO PTN SECURITIES PURCHASE AGREEMENT]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Purchaser: ______________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Signature of Authorized Signatory of Purchaser</em>: _________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Authorized Signatory: _______________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Title of Authorized Signatory: ________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E-mail Address of Authorized Signatory: _________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Address for Notice to Purchaser:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Address for Delivery of Securities to Purchaser (if not same as address for notice):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Subscription Amount: $_________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Shares: _________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series F Common Warrant Shares: __________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series G Common Warrant Shares: __________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series H Common Warrant Shares: __________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pre-Funded Warrant Shares: ___________ Beneficial Ownership Blocker&nbsp;&#9744;&nbsp;4.99% or&nbsp;&#9744;&nbsp;9.99%</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">EIN Number: ____________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744; Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur on the first (1<sup style="vertical-align:super">st</sup>) Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit A</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Form of Lock-Up Agreement</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit B</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Form of Pre-Funded Warrant</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit C</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Form of Series F Common Warrant</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">31</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit D</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Form of Series G Common Warrant</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px;margin:0px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">32</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit E</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Form of Series H Common Warrant</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">33</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>7
<FILENAME>ptn_ex232.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<html><head><title>ptn_ex232.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="MARGIN: 0px; text-align:center;">Consent of Independent Registered Public Accounting Firm</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">We consent to the use of our report dated September 30, 2024, with respect to the consolidated financial statements of Palatin Technologies, Inc. and subsidiary, incorporated herein by reference, and to the reference to our firm under the heading "Experts" in the prospectus.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">/s/ KPMG LLP </p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Philadelphia, Pennsylvania </p> <p style="margin:0px">May 2, 2025&nbsp;&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>8
<FILENAME>ptn_ex107.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<html><head><title>ptn_ex107.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 107</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Calculation of Filing Fee Table</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>S-1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Form Type)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Palatin Technologies, Inc.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact Name of Registrant as Specified in its Charter)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;text-align:justify;width:100%" cellpadding="2"> <tr style="height:15px"> <td style="border-top:#000000 1px solid;border-left:#000000 1px solid;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Security </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Type</strong></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Security </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Class Title</strong></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fee </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Calculation</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Rule</strong></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount to be </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Registered</strong></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proposed </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maximum</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Offering</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price Per</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Unit</strong></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proposed </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maximum</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Offering</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price</strong><strong><sup style="vertical-align:super">(1)(2)</sup></strong></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fee </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Rate</strong></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount of </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Registration </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fee</strong><strong><sup style="vertical-align:super">(3)</sup></strong></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Equity</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Common Stock, par value $0.01 per share</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Rule 457(o)</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$12,500,000 <sup style="vertical-align:super">(3)</sup></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$0.00015310</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$1,913.75</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Equity</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Series F Common Warrants to purchase Common Stock</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Rule 457(g)</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$12,500,000 <sup style="vertical-align:super">(4)</sup></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$0.00015310</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$1,913.75</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Equity</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Common stock issuable upon exercise of the Series F Common Warrants</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Rule 457(g)</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><sup style="vertical-align:super">(4)</sup></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Equity</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Series G Common Warrants to purchase Common Stock</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Rule 457(g)</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$12,500,000 <sup style="vertical-align:super">(4)</sup></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$0.00015310</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$1,913.75</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Equity</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Common stock issuable upon exercise of the Series G Common Warrants</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Rule 457(g)</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><sup style="vertical-align:super">(4)</sup></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Equity</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Series H Common Warrants to purchase Common Stock</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Rule 457(g)</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$12,500,000 <sup style="vertical-align:super">(4)</sup></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$0.00015310</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$1,913.75</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Equity</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Common stock issuable upon exercise of the Series H Common Warrants</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Rule 457(g)</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><sup style="vertical-align:super">(4)</sup></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Equity</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Pre-Funded Warrants to purchase Common Stock</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Rule 457(o)</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Equity</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Common Stock issuable upon exercise of the Pre-Funded Warrants<sup style="vertical-align:super">(3)</sup></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Rule 457(o)</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><sup style="vertical-align:super">(3)</sup></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;" colspan="4"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Offering Amounts</strong></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$50,000,000</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$7,655</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;" colspan="4"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Fees Previously Paid</strong></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$3,828</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;" colspan="4"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Fee Offsets</strong></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;" colspan="4"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Net Fee Due</strong></p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td style="border-top:#000000 1px solid;padding-bottom:2px;padding-top:2px;padding-left:2px;border-left:#000000 1px solid;padding-right:2px;padding:2px;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$3,827</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">(1)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">(2)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">(3)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The proposed maximum aggregate offering price of the Common Stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants sold in the offering, and, as such, the proposed maximum aggregate offering price of the Common Stock and pre-funded warrants (including the Common Stock issuable upon exercise of the pre-funded warrants), if any, is $12,500,000.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">(4)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to Rule 457(g) of the Securities Act, no separate registration fee is required for the warrants because the warrants are being registered in the same registration statement as the Common Stock issuable upon exercise of the warrants.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ptn_s1img3.jpg
<TEXT>
begin 644 ptn_s1img3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !- 60# 2(  A$! Q$!_\0
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M:-<^&]?B\4:.NR-I 9E'17/7/^RW?W^M-)PBI1&I*K>G/?H;_P 1MWVSP_\
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MT;7SI^V-_P D#C_["]O_ .@24 2Z7^U5\/\ 5-'US6+;1_$2VNB6T=U<*]O
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MEZ/9:7I^B6=AHL,%OIMO$L=O%;X\M$ X"XXQBM2@ HHHH **** .9\:>'/\
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MX^Q;E*[MWF?O.O3"UYSI_P"S'X[T?3X]-T/X^Z]I5C'DI;65M-#$I)R2%6Z
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*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ptn_s1img1.jpg
<TEXT>
begin 644 ptn_s1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !- 60# 2(  A$! Q$!_\0
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M:-<^&]?B\4:.NR-I 9E'17/7/^RW?W^M-)PBI1&I*K>G/?H;_P 1MWVSP_\
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MT;7SI^V-_P D#C_["]O_ .@24 2Z7^U5\/\ 5-'US6+;1_$2VNB6T=U<*]O
M&=7GCA 3$Q!.Z52<D< ]^#E_\-J?"W_H ^*O_ 6V_P#C]=1^T;_R:1X@_P"O
M>P_]*H*\X\%^+/VI;;P!X:M_#GPW\.7>C1:9;+83S7""2:W$2B-V'VM>2NTG
MY1R>@Z4 >\S_ !2\*6'POL_B-J]\^E:+>6\=Q#]I4><V]=RQA%+9<CL">A/0
M$UY[H/[5WPJUK7(]+DDU72!*XC2\U"!$@))P,LCL5'NP '?%<U\?EEU'XD_!
M72?%D<::5=W^Z_MG/[AI=\ 96Y((^8CDGACSS7MWC#PGX$US1K2S\::7I;Z9
M:31FW6\*Q1QR9PJJ<C&<XV]#G&#0!6\4_$W0?"/C3PKX5U2UO9KWQ-*8;.2V
M1&B0AE7,A+@@?..@;O4GQ$^)FB?#/3=-U#7[34+F'4;Q;&(6,:.RNRD@MO=>
M/E/3)]J\(_:..M:;\6?A&?!NFVUWJMM)+_9MG*0L,CAX=B'YE 7H/O#ZUPOQ
MLUOXY:MH_AJ'XI^"]'T'2TU>)K>?3Y5=WFVL-IQ<2<;=QZ#IUH ^G/'7QJ\(
M^ /&NC^$_$45_%<:LJO'>)&AMH5:0IF1BX90".2%.!S6GXZ^)NA> M4\.:?J
MUGJ$\WB&\^PVIM(T94?<@R^YUP/G'3)Z\5X!^T%X2C\;_M+>"?"<ER;7^T='
MFC28<^7(//9"?4;E7([C->=ZEXZU+7+[X6^"/%$<L?BCPAXF6PO!)R9(A+"(
MWSW/RE2>^T-_%0!]>_$?XM^#?A?9P2^)[^07%SEK>SMH_,GE ZD+D #W8@9K
MF/!?[2'PY\=Z[#H5C>7>D:C<-LMX]3B2(3MV561W7)[ D$]!S7"6]II^M?M]
M:[!XGBBNH['1HWT>*Z4,N\1P-\@/!(WW#>Q!/:KG[7MCH\'PUTK7BL=OXAMM
M4B73[F/"SGY6+*".=HP&]BJ^M 'KNM?$_0="^*N@_#N[LM0DU;786FMIHHT,
M"JN_.]BX8']V>BGM7?U\P^.FF?\ ;0^$KW (F.EOY@(P0VV?/'UKZ3NVF6RG
M:W7=,(V,8QG+8X_6@#QWQO\ M(?#CP#KL^A7]Y>:KJ5LVR>'385D$#?W69W1
M=P[@$D=#S73_  W^+G@WXH6,MQX6O)#<VX'GV5TGESP@]&*Y(([94D9XS7DG
M[']GH]Q\/=:U^2..?Q)/JTJ7MS(H:X"[$*J2>0"2Q]R6].&:E9Z;HW[?7AJ/
MPY'';-?Z3,^L0VR@*6,4Y4N!T)V0D_13WH ]!^(/[0GP]^'6LG1M9NKR]U:-
M5:6RTZ%97B!Y&\LRJ#CG&[."#CD5<^&_QP\!?$N[?3]"NKNWU../S38WT0BE
M*#@LN&96QWPQ(KR[]F.'3[B\^(OB'4X+>[\8QZS,9V<!KA$.3M'4J&DWCCJ1
MWP*K>"_B3IFJ_M$Z1'KWP'D\*^*-:5U34[Z>1)@BQR9=8W@3<2 4+#!(X).,
M4 >R6OQA\.7?B'QGH$=EJ0NO!]LUS?.T4>R554L1$=^2<#^(+7F7_#:GPM_Z
M 'BK_P !;;_X_7/Z#_R6S]HS_L$3?^BFKG?@OXB_:*T[X4Z;:_#OP+H>K^'5
MEF,%U>3(LKL96+@@W,?1LC[H_'K0!]&:'\9?!NM?"N;XD3376D>'X)'B<WT:
MB7<K!<!8V?))(  .:Y#P]^U5\+M>\0Q:.S:KI7GR"**ZO[=%@9B<#)1V*@GN
MP '?%/\ B1H]YXX_9XMM)^)VKZ-X(\274J2 W%TD=JERCL5C!,C;@T>> S$9
MS@XQ7F/C2]\?:#X-LM-^-GPHTCQ-X+TEHE&HZ1=&V>'_ )9JV8W!&=P&-J*Q
M(''8 ^RJS]0O(]/TNZU"92T5K$\SA>6(523CWXJ'1-0L=6\.:;JFER%K"\MH
MKBW?^]$Z!D//L13/%/\ R)FN?]>$_P#Z+:@#S;_A?W@__A37_"TO[/UO^Q?M
M?V/R/)B^T[]VW.WS=N,_[7X5T(^)_AN3X02?%"T^T7.AK:F[9(E4S@ X9-I8
M+O5L@C=C(/-?(O\ SCR;_L/?^U:=?W6H?"'PAXL^&NKSRS>&?%FBC4M#N'Y$
M<[(I:,\=3@J?=4.!OH ^O+'XC>&I_AA!\1[JZDTOP_/;"Z\R^PKQJ3@ A2V6
M)X !))( KS:S_:Z^$L^LC3Y)-9MK<MM_M":S7R/KA7,@'_ *\H\=-O\ V3O@
MY8WCF/1[F^MUOCNVJ5P^-Q],%S^&>U?4OB+PGX#OO PT/Q%I>E)X9@";8I0L
M,$(!&PJP(V=AD$9SCO0!TMI=0ZA:07EG<)/:S1K+%+$P99$89# C@@@@@UIU
MEZ/9:7I^B6=AHL,%OIMO$L=O%;X\M$ X"XXQBM2@ HHHH **** .9\:>'/\
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MX^Q;E*[MWF?O.O3"UYSI_P"S'X[T?3X]-T/X^Z]I5C'DI;65M-#$I)R2%6Z
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*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ptn_s1aimg4.jpg
<TEXT>
begin 644 ptn_s1aimg4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %. G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[*KSW7/%V
MN2^,7\(^#]/M;K4H+=;J\N;Z1EM[5&)"*0HW,S8)P.@YKT*O(;G4H_ OQ>U[
M6-<AN(]%\06UL8=0CA:5(9HE*-&^T$KD8(.,4XJ]]+E15SL[/7;S3M EU#QL
MEAHDD$A1YEN08)!V=2V",_W3SQ5NR\3>'=1TB?6K'6[.ZT^!6:6YBF5DC &3
MN(Z8'K7G'BK7K'6-7\)>++C3;VX\*:=?3K</-9OM#F/$5QY9&XQAL@-C@\UC
MW*QZRWQ+\2>';&6/0;O0#;K((&B6\N520LZ(0"<*0N[')K3V::N]/^'V+Y;[
MGK*^-O"$ES<6\?B;3'EMH_.F4729C3^\>>G-3VWBCPY>:))KMKK5G/I<63)=
MI,IC3'!R>U>77WA71Q=_".%=#A\J-CYBBWX'^C;OGX_O@'GO5#Q-IYM]$^,]
MI:6+1P2_9G2**,A79H$W%0!R2>N*?)%VL_ZO87+%GK:^./!\C7BQ^)],8V2[
MKC%TG[H>IYJW:^(M#O=&.M6FK6D^F;2QNTF4Q #KELX%>::IX7T=?B7\.(XM
M#MQ;P6=T,) -B;8E*9XQP>1GO7*:YH^I-HWC*WTRUF@L;7Q;!=SQP6WF#[.$
M1I&6+I( Q#%>^#0H1=K/^KV!13/;]-\5>'=7M;B]TO6;.\M[8$S20S!A$ ,Y
M;TXIMKXN\,WWVK['KUA.+2-9K@I<*1$A&0S'/ KS#2;:PU&Y\2^(+/Q9-KUX
M="FM'6+3/LD>WEER0HW..0!U )J"\T#[/^SIX8CT_1V>WA6PN]1M((?WD\(9
M7E!7JQS\Q'?!J>6-[7#E1Z+=>.-)NM FU+PUK&CZCY$\44C27H2--[A>6&<'
MG@=SQ5_4O%WA?1K]+'5O$%A8W;XQ#/.JMSTX)XS7FWC+6M!\3> -0D\,Z?(\
M<=W8"2ZCL6B67_2%^0$J"VT=>,#-9OQ%UK4IM4\6Z'/)'I47V():PQ:4;J?5
MMT1R=^,  _+QRO6DDGIL-1N>EWWB*_A^*.A>'8&B-A>V%S<R';EBR% N#GI\
MQJ/QYXDUK08=#MM M[*:]U;4$L5:^+^5'E&;<=G/\-<KH,-Q_P )S\.))(I?
ME\-2J[,I^4[8>"?6M+XK:?/JDW@NT@N+NT+Z[&#<6?$D(\J3Y@2"!]2*+)22
M%9<R1:T'QS>IK&M:%XUAL--O=*ABNGNK>8FVDAD)"ME^5.X$8-=-'XN\,36-
MYJ$?B"P>TLG\NYG%PNR%O[K'. :\Y\>^"]/T#X3^+Y+-K[4]1U.%/M-W=R&:
M>?#*%7('  S@  4_QYI=II)\%WG]D[O#.EWPDOK>VM]ZQCRBL4C(HRRJW7@X
MSFG:,M4.T7L>D:3XBT+7;.2\T?6+34+9#AI()E=4^N.GXUR.J_$73[CQ1X7T
MWPUK.G:C'?:FUI?+#(LK(HA=QC!X^91S7"ZQ;R>+;SQQK/@6QG%C<^'A9&:.
M%H%OKD.6^0$ L1'E<X[XI&U+PSK7BKX:_P#"+Z+-$]A=>7/*+%H1:K]G<>2[
M%1SD=.>GO34(K7^MAJ*/;!K>DFUOKM=0MS!I[.EU)Y@VP,HRP8]L#DU!J7BK
MPWI-A;ZAJVN65E:W0!@EFF55E!&05SUX->.:EKL.@Z)\3_#-_8WYU;4;F[N+
M.WAM'D^TQ2P@*ZL!MP,'.3QBK5O=V/AWQEH&M>+;20Z5-X9M[2TN7MFF2"88
M,D9 !VLPQVYQBIY2>0[S5/B;X1TOQ%I.CW.K6Y_M*%ITG$JF-% !4D_[6>,>
MAKL;BZM;6T>\N;B.&"-=[RR,%55]23T%>2:_J6DZ?XM\!^)KC2Y]-T0P7<.'
MLB# TBKY:NB@E<X..*[?QUJ-YI_P^U74--TM-6N(X-R6LL1D5QD9)3JP YQW
MQ2DEHEU!QVL:.D^*?#NN-,-'UJSU P#,H@F#%!ZD#M[U%;^-O"5UJ-MI]KXD
MTZ:\NEW0P)<*7D'L,UY'X5NIM1^,4-^NL-K,1T*>)KJ+3C9PJV]#Y8X^?'OR
M*I6^@V]K^S_X<N;?25BOQJMI<-(D.)0YO "Y.,YV\?2CEBG:_;\1\B/9=<\7
M>']#D:QO=<L;349(6>"WGF57<@''!/K3? >L7GB#X?:)K>H^7]KO+999?+7:
MNX^@[5Y?<W6DZ/XK^(%CXJT>>\O]9D5[!?L37'VV#R0J1QD CY6!R,C!YKT#
MX4Q20_"3PU#-$T3I9(&1Q@KUX-.45&/W"<;(YG3/&7Q)UBSU+6M+T+1;S3[.
M\N+=;(32QW4JQ.5.&(*;CCBNRTKQMX?U+P79^+)+R.PTVYC#%KMA'Y;9P4;/
M\0((Q[5YQX'\>:+X7T#6=*NEN[C64U:]>/3K>TE>64M*2H&%QSZYQ6/?>&=>
M\.^$OA]-J4TFFPV5Y=76HRQVHNULI9MS1EH^00I8KN_A)S1))NUK=A\J;ML>
MVV_BCPW=VEI>6NN64UO>3_9K>1)E*RR_W ?[W'3K5R35=-CU!M.DO84O%@-R
MT+. PB!P7([+GC->*KX7AUGPAXMU30_$$VMZE+-;ZA!-]A^RQ)=6XW*8U  8
ML!M8BH+BUUCQU\._&OC33[&YAO=9BAM+.V:,B46L)4R*%/=F,O'?@4[1[AR+
MN>R:5XJ\.ZY/-#HVN66H20C,B6\ZN5'K@=O>L/P9XR6^^&]KXF\47MI9;Y)E
MEF8B*,!9G1>I]%%<;X/@TO5_'&D:I;^+I=3N=.M9HTM(]'%F(XV4 I*P48P<
M84]Q6!IMN;'P3\.]7UG39[C0M.U*^DOXQ TGDLTD@BE= "2JMWQQD&BT=@Y%
ML>VV?BKPWJ.C3ZQ8ZY97&G0 F:XBF5DCQUW'M^-.L_%GAK4M5DTG3]>L;N_C
M7<UO#.K.!ZX!KQ+7FM=8B^)'BCP_:20Z!/X?6U:?R6A2\N5+$NJD G:I"EL5
M<L;K0]>U;X=:?X3T>:VO](E6XO3]C:#[' (2'5V( .\D8&3GK5^S5K_UM<.5
M'J__  FGA%;^&R;Q%IPNII&BCA-RNYG5BI7&>H((JYIWB7P]K%[=6.DZU97U
MS:G$\4$RNT?;D UX5>>';.3X'^-IGT<-=W&LW,A8P?O7Q=@*0<9X'3';-=Q>
MZ1#IWQ?\)#1[!+)#HU[ 6ABVJ /+**V!V/(S[U/+'H^_X XH[M?%GAEM<_L-
M=>L#J>=OV43KYF[TQGK[=:BU#QEX5TF>2'5/$6GV4L<@C=)KA496(R 03Z<U
MX-X<TE;C0-,\*>(/%EUIVJ6]\LDNG+HX,PN%FW;Q,%RP8\[\]#7>Z3H5C??$
M#XFW-_I,=P\BV\*230[MR&W.54D=,]<5+C%7U$XI'2^(OB)X9\-Z_H^DZGJ$
M4;:F&99?,&R) I8.WLV, CO6SXFUIM&\$ZMX@LT6Y:SLI+J)6/RR;4+#IV->
M,Z=<IH_@[X0ZYK4,RV-BCQW4S0-(8=UNRIN !(&<#I7JGQ /VGX4>)'MT:02
M:5.44*<MF,XXZ_A0TDXH&DFD<YI?C;Q99ZKX<@\6:?I1LO$0"6T^F22;H93'
MY@5U?J",\@\&NTM?%7AJ^U1-+M=<LI[Y_,VV\<RLYV$A^.O!!!^E<IX.\ V-
MM;Z#KVH:GJNKW]K9)]E&H3ATM-\8#;%"@ XXR<G%<YX7\/W4GPC\:C1K'R-:
MOKW5%BEV;)78R.JX8\].!5-18VHL],LO&/A74]7?2M.\0:?=Z@F=UO%<*S\=
M> ><5!J'C[P;HUZUCJWB;3K.Y7 :&6X4,I/8CL?:O)/MF@Z]I'@CP[X3T>:V
MUO3;ZTEF3["\+:<D?^O,CE0!D9'4[B:R8YK6:?7;77+J73/#W_"1RWES*-(D
MF*,DP(_TL$H%)49.,J,BA0CUN/D1[W>^+/#&GRK!?:]8VLK^7M26958[_N8!
M]>U(OC#PO)K7]B+X@L&U(L4^S"==Y;^[C/7VZUR&G:997OQWUW4IK-+C9H]H
MMO.\>Y0&9R=I/'.!TKS;7M9U+688(KJ06%[!X@A)T*UTDAK9%N0!*\^.X^;<
M.#NQZU*2;L)13/=M0\9>%M'GEM]5\0Z?92PLJ21SW"HRLPRH()[CFI8_%?AN
M;61HD.N64FILN];5)U,A7&<@9].:\^MM#L;[XF?$JZOM*CN':SM88Y)8=V5-
MN=RJ2/7&<5S.FZ';V/PJ^%,]GI8@NTU>RDD=8<2 L'WECC//?/M5^SC;?M^*
MN3RH]H7Q/X?;6CH"ZU9G5!UM!,OF=,XV^N.U;U>'V5]#H_Q)CT_PS,=7@U#5
MI);_ $RZT]EFTYVSON$F*C"Y'0YX/!KW#TK&4;6$U86BBB@D**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,J^
MU73],C1]0NHK<.<*9&VY-4?^$N\-_P#06MO^_@KC?BT,6>F?]='_ /0:\^71
MUD6WCCE82S0?:7=E_=HG)/3DD 5YM7%RIS<(J]CZ+!991KT8U:DFKW_ ]S_X
M2[PS_P!!:V_[^"E_X2[PW_T%;;_OX*\/_P"$8O%XDO+=#NP =QR-P4'IW+"C
M_A&[[R@PN+<R8SY?S9SMW8SC'0&L_KM7^4Z/[*P_\[_KY'M__"8>'/\ H*6O
M_?P4O_"8>&_^@K;?]_!7AC>';A9FC%[:O(&$>$8MAVS\IQTQM-21>&[BZACD
MM)(S\CL78D*V&(  (X/!J?KM;^0/[*P]K\[/<!XL\.XS_;%K_P!_13/^$N\/
M9_Y#%K_W]%>(QZ/9M=ZA'->&**S6,^8=H^^,Y.?3T')IBZ#)(Q2.ZMV?Y<+A
MAEBF\+TX^7G/2G]<K?RH%E5#6\W]Q[I_PEWA_P#Z"UM_W\%)_P )=X=_Z#%K
M_P!_!7BDWAMHX;=H[J.1W?RY!M("MO"#''/)YJE+H[6]O<37%U&LD,:,8E1C
MG<0 ,].XI/%UEO%%1RBA+:;^[SL>\_\ "7>&_P#H,6W_ '\%-_X2_P -_P#0
M7M?^_@KYUQ[48K+^T9_RH[?]7:?\[_ ^B_\ A,/#G_08MO\ OX*/^$P\-_\
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MNG_._P #Z,_X3#PW_P!!BU_[^"C_ (3#PW_T&+7_ +^"OG/%&*7]I3_E1/\
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M*_X4;;K_ )_I/^^5_P */J5+S_ K^V,5_=^YGD/_  @/BK_H'K_W\7_&C_A
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MTJ":>!+X3;][Q*"P9, KG/')Z=JQ+;5O@S9Z@M[;:QI4<R[-I%TY"[<;2!G
M^ZOUQS4DNN?!N>[O;J?7-+FEO=_F^9=NRY;&XJI.$)VC)7!XI>PJ_P K^YA9
MF]%\1_#]Y;K-8R32*8XI6:2)D55DD\L<_P![.>!Z=:++QSX3U[7M-T9?,>_F
M7[7;1W%L5*#:2K\_=)7)!]/K7/2:Y\)9IHIKGQ)8W<D48B1KB_DE*J&##&XG
MG(!)ZG J[:^+/A38ZA%J%GXDTZWGBA6 >7=N%9%&%#+G#8'0D$BCV%7^5_<P
MLRW#\056ZB34M)-C!<R2"UF$WF^:L<OEOE0N5;D$#D'/6K7_  L+PT((IGDN
MTBDB$V\V[;4!#% Q'1F"-@=3BN?AUCX,V\\EQ%KVF^:[^9O:]=C&=V_Y,GY!
MNYPN!FHH]0^"<80+K6EX52I#7CD/G=\S9/S-\S88Y(R<&CV%7^5_<QZF[??$
MKP_I\\(N8KR&V,;R37$L#(L&$#A#GJY#+\O7D5LZ'XLT?Q'+Y>DM<3#R$N&D
M:!E158D*"3_%\IX]JXV\UCX,WUY)>7>M:7+-)'Y;'[6X&-H7( . V% W=>!S
M6I8>-_ACII=K7Q9IX>1$1Y)+MI'<)D+EF))QDT>PJ_RO[F&IWG\54M61Y-/<
M(I8C#;1_$ <D?I7/_P#"SOA__P!#?IG_ '^I4^(G@6:"6:/Q3IK1P@-(PFX0
M$X!/XT.A5:MRO[BXMJ2EV-E)$EC62-MR,,@CN*=7(?\ "<_#LR,\/C2PMRQR
M52<;2?7!%._X3KP)_P!#[8_]_%_PK+V%;^1_<='/'N=;Q1Q7(?\ ">>!?^A\
ML?\ OXO^%'_">>!?^A\L?^_B_P"%/V%7^5_<5>/?\SKZY#QUH>L>)=,M=&TU
MHH;>21I+F:5V7;M4[  IR?G(/_ >:=_PG7@3_H?;'_OXO^%'_"=>!/\ H?;'
M_OXO^%.-*M%W4']Q-X]_S.<N+'XF30S.LCI*]O;X1+M559%P)$7'\+8)+<,,
M\9IE]X=\=:C-='4+ZZD1+Z&XAM[:X2.(QI*K85L[@P7(Y !/>NGB\<>!YIHX
M8O'5D\DC!%42+EB3@#I2/XX\"QR-')XZLE="58&1<@C@CI6MJRVA^ 7CW_,S
M_$VB^))/%\>M>'8%>06IA8W,RB,?*V-G\2/N(R1D$=>E<_'X>^)14WK7)2^\
MG[/Y_FH9C#Y^_:#G&[;W)_&NN_X3SP'_ -#]9?\ ?Q?\*7_A.O ?_0^6/_?Q
M?\*$JR5N1_<%X]_S,W7?#OB:_@\/75E>2/J>FVUQNFG=4_?-& C,JY4G.>F0
M*F\.Z;XPC\117&L7ETNE1QRM';R7*R/N++M$A4?-QO/'M5W_ (3OP'_T/UE_
MW\7_  H_X3OP'_T/UE_W\7_"IY*UK<C^X+Q[_F<Q?>"M<?3-5EBAC>^FU:6\
MME39RN24\XL</'S]W@KU'(JWHWAGQ!;^+HK^XL8[5EU*6[GO8YP1/"T(40A<
M[B-_/S=,5M_\)UX%_P"A^L?^_B_X4?\ "=^!?^A^L?\ OXO^%5R5K6Y']P>[
MW_,XO_A"/%=IK5]J4$<<PN[F23:TJ?NE^U+(IP?OY0'&<E2,#&:K:=IOC3Q%
M##?2W&JQ:C93S2JUR1"(6:!E01YZ@OC<,8%>@R>-/!4*QM-XXLT$J^9&2Z_,
MO3(X]J9_PGG@4]?'UB?^VB_X4[5OY']P>[W_ #.>TW0?'&G7ZR++.RS:L;JZ
M5KQ?+DB9$S_M#:0WRC@\=JM:IH7BJ'Q+K=]I$ET;6_GMY"(KQ48QK&594W<(
M=VTY[C-:W_"=> _^A\L?^_B_X4?\)UX#_P"A\L?^_B_X5/+6O?D?W!>/?\RE
M>:+X@N?^$7N-6MH]:^QV[IJ%LLHC5YF50LHS@';@_GD5ES:7\2C%=F.\E#Y!
M""Y3;*1*2HCZ&-/+PI[YY&:Z+_A._ ?_ $/UE_W\7_"D_P"$Z\!_]#Y8_P#?
MQ?\ "A1K+[#^X+Q[_F<U=>'?'5^9VU*^NI/+OX+B*"WG2.(QI*#A&SNW!.,,
M #BGZ/X=\<Z;?:=:B_O(M,AN)9)0LT<S2;IBP+;B#L*'&!D@YXKH?^$\\!_]
M#[9?]_%_PJ1?&G@EK>2X7QQ9F&-E5W#KA2V< \=\'\J=JUK<GX!>/?\ ,PM5
M\,>(+KQI?7^GVB6[RWEM<6^IM,/W4:1X>/:#N.X\8QCG--TW3?B)%#9?;]0N
MYV\UVN%\V)-K; $*D$[HMV25.#R.*W?^$Z\"?]#[8_\ ?Q?\*/\ A.O G_0^
MV/\ W\7_  I<M:UN1_<%X]_S.8&B_$R328XWUJ\6\_?-*1+$B[_*_=[""24+
M\X.,>E0S>&_B%_;T5_'=2R30B2&&Z:Y3*QM)$W[P8^9>).!STKK/^$[\"_\
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M]#Y8_P#?Q?\ "C_A// O_0^6/_?Q?\*R]A6_D?W%7CW_ #.OXHXKD/\ A//
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M+*&&*:.1RTLGE.LGR!MJJ6*DG&[@8(KI/^%G?#__ *'#3/\ O]1_PL[X?_\
M0X:9_P!_J?L:O\K^YARG'7GPG\1S02O:^-);2\F@2%Y4>8[%69Y!&I+$[-K;
M<G+?*.:LS_"W6;AA)<>+I[IA<1W)6XDE*LR2!ESAACY=R\8SFNH_X6=\/_\
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M:I<11RPP(P,:.1R'(P>#CU![5JW7PZT^X$EU!>/HD,,<K2V]V&FD&V4QJP
M;:V,YQQ4Y^"/Q29$1K*,K&=R*;Y<(?4<\&G?\*4^*WGF?[,OG$;3)_:"[B/3
M.<XI.M#3WU^ <R[F?_PJ_9927D_B*VA@^SB[B;R68R1-@(^!DX+;@?3%6/\
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M'XJ(P9+-%8,6!6_4$$]3UZ^]'_"D_BIDM]D7)[_;U],>OIQ0JT5_R\7X!?\
MO&=IO@?2=3\,6&II<7<+/;S/.0N7,R1LZHB$ ,A"_>!/?.*E3X6[KTV@U]9)
M4BB>00VKOL+L%'/ *_-DL.@!JV/@C\4E$86RC41YV 7RC9GKCGC\*LQ?!_XO
M06LUK%$%AG01R)]O7E0<@=>!GTINM#I47X!S>9P?B3PT_AX:>QNA=)>0F02*
MNU<@X*CG)QZD#VK KU!_@9\3I HDTZ%PHVKNO4.T>@YX%,_X41\2O^@5;?\
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M25E12"I )4=02,]JMWOQDN8[:Z2S\'W+WT$$KF&6; WH')Z+DQ_(1O'<@8H
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MP:*^/O\ A?/Q)_Z"5I_X"K1_POGXD_\ 02M/_ 5:/[-K>7WA[*1]@T5\??\
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MK9Z[X6:\O98FG$F?)9HSO*%@@9%*A1O^;C<,9KU:ZN1;PM<3[8HHU+.[. %
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M032(NYQLF#;0CX0G@^H[5?C^,WA%SII6/47CU.9XK9TMP^\(0'<JI+*H)'4
MGJ!BI=+\9>!;ZUU:XM=-C5['RY;Q4LE^>5_EPIP-[;FVY..OH:IMX_\  -HU
MU/>Z$MG!;2"2.;[$A+2A1E>/NR#I^'6@#-U[XV+HOB.32?[#^U(&RDPD9,I)
M&#;,5*Y!DEW1X[8SS6C;_'#PC/+;VGV74S=S3M;*JVC%"Z\,0>ZAN/7OBK5[
M\0/"LV;Q=#FU"5EB8A[11-(.&C*[^H4MG)P <XYJ[+XA\%_V5/K"Z1 T5O=+
M]H+V2ATF*DMT!S(,8/OWH YG2?CQH-[9Q7U]I\]M9FW1I)8_GV7#,R^7C@X)
M7:I.,DCC!!JUJ?Q<70_%FM6>J:/*-'TKRTDN;<,\J2.L9177&T;C)M #9RI)
MXI=4\4>!KJ"*U7PRQS/')<*]L+?R'B+/&)-O)(,>0O(XK0U7XB>#[6RW7FEW
M$\6IK++'&;6,_;O+7.<%N<A< L.W:@"G+\;/#OVFVMK/2=4N);BX6W =$BVD
M[<DAFR-N]>"!G/&:I3_'CP[:36/VBQNGMIK<O)-$F3YN(RL:)G)XE&2<#TS5
MZ#Q!\/=):]:3P\('NIC-=#[&LFU_X%?/0G9PJY ([5N:3J7@[7M4?3H?#L<=
MT;<F1;JPC3Y%;:8SGK@@<#('% '-^)OC!_PC^L-90Z"UU%<:7%=V+O(8WFN9
M,F.!UQ\F55CGMM/%9UQ\;I+?P5<^)WTNPC3SA;6]K+>E)6D !D9\K\J8W%>Y
MP/6O76TW3G96?3[9RH"J6A4D  @ <=@2!]33/[&TC,I_LFSS,H23_1T^=1T!
MXY [4 >::1\7/MEMXLN[S2XX+?1(VD@9)&)N?WKQ(,$<[F0<KD<XZBGZ7\;-
M!O+6!+G2]0%\(5:[2WCW16TID\L1%G*D$MP,@=<G%>EC3=-4Y73K4'VA7^]N
M]/[W/UYK&D\"^$YO%$OB:71H9-2FC,<KMDI(",$LGW2<=R*8'+_\+H\,S20P
MVMK?[Y9D@5Y81L+DKN088G< X/I[UJ^&_B!IWC#5I['3M.NX(X+9;DS3M&,Y
M=D*%0Q(8%#G-=1_8NC[57^R;+:N-H\A,#  &./0 ?@*1=-TVR,;6>GVULRJ8
MU,,*H0N<[>!TSSCUIH#DOB%X[L_ /AU-1GMFO+JXD\JVMPVW>V,DD]@!UKQ5
MOVC/%!8[=!TL#L"TAQ^M>K?%CP%=^.O#EM#ILT<6HV$IFA24X24$892>QZ8-
M> 'X,?$D$C_A'<^XN(\?SKUL'##RA>H]?,Z(*-M3J/\ AHOQ5_T ]+_.3_&C
M_AHOQ5_T M+_ #D_QKE_^%,_$G_H7?\ R8C_ ,:/^%,_$G_H7?\ R8C_ ,:[
MO9X7R^\NT#J/^&B_%7_0"TO\Y/\ &IK7]HW7UN4-[X=L)+?/SB%W5\>V>,UR
M/_"F?B3_ -"[_P"3$?\ C4UM\$OB-<7*0R:/':HQYEEN%VH/7@DGZ5BZ>'MN
MOO"U,^L-%OH]=T*QUK3KA'M;R)9HRT9!P1G!YZ]JV/(NO^>T7_?!_P :P_"N
MGV_A?PIIGA^WCFE2RA6+S"H&\]VZ]R2:WOM;?\^LOZ?XUX$OB=MCE8GV>[_Y
M[1?]\'_&C[/=_P#/:+_O@_XT[[4W_/M+^G^-'VIO^?:7]/\ &IU$-^SW?_/:
M+_O@_P"-'V>[_P">T7_?!_QIWVIO^?:7]/\ &C[4W_/M+^G^-&H#?L]W_P ]
MHO\ O@_XT?9[O_GM%_WP?\:=]J;_ )]I?T_QH^U-_P ^TOZ?XT:@5VLKEF+>
M?'S_ +!_QH^PW/\ SWC_ .^#_C4AU!02/L\V1[#_ !I/[07_ )]YOR'^-/48
MS[#<_P#/>/\ [X/^-'V&Y_Y[Q_\ ?!_QJ3^TE_Y]IOR'^-']I+_S[3?D/\:+
MR C^PW/_ #WC_P"^#_C1]AN?^>\?_?!_QJ3^TE_Y]IOR'^-']I+_ ,^TWY#_
M !HO("/[#<_\]X_^^#_C3TM+I"<31G_@!_QI?[27_GVF_(?XTY;\-]VVF_(?
MXT:B#[/=_P#/:+_O@_XT?9[O_GM%_P!\'_&G?:F_Y]I?T_QH^U-_S[2_I_C2
MU ;]GN_^>T7_ 'P?\:/L]W_SVB_[X/\ C3OM3?\ /M+^G^-'VIO^?:7]/\:-
M0&_9[O\ Y[1?]\'_ !H^SW?_ #VB_P"^#_C3OM3?\^TOZ?XT?:F_Y]I?T_QH
MU 8;>[((\Z+_ +X/^-1?8;G_ )[Q_P#?!_QJ<WA S]FE_3_&F?VDO_/M-^0_
MQIZ@1_8;G_GO'_WP?\:/L-S_ ,]X_P#O@_XU)_:2_P#/M-^0_P :/[27_GVF
M_(?XT7D,C^PW/_/>/_O@_P"-'V&Y_P">\?\ WP?\:D_M)?\ GVF_(?XT?VDO
M_/M-^0_QHO("/[#<_P#/>/\ [X/^-1%9H9XUFVLCM@.O&#Z$58_M!?\ GWF_
M(?XU!)/)<S1CRS'$C!LMU8]OI35P(O$%O!>^'=0L[JZ6T@GMI(Y)WP!$I&"Q
MSQQ7GK^%?#]G+<:K8^,K*T*DM(TIC>%9DGCE+L-XY 5$89'4$UW7BO38]8\(
MZKI,UVEG'>6DD+3N,K$&&-QR1P*\RC^$=G=B2XT?Q1;2^>DDS*L0ECDD>=9%
MDPK=,1[#ZX]J0C9U+PGI-YI7AME\:+:V]I=27"312JD5Z[L78+M8 8.< $X&
M:B7X:V5_+8KI'BUU@LIQ<2QP*)"[;=K9;=D;BIR._/I4M[\)Q>:380OJPBO+
M6YO;P310%5CEN0<^6H;Y0I/ YK//PEFBN#;CQI) \IED@@3=&0YWD. '&=I<
M'\* -&+X8PZ=I;B?Q$UO%'&=[I%Y,<: <GEOE'&3SC.3Q6;I_ANUT[XJ:;>V
MFL:;-I,%E(\4+7V)8$<,Q9(PW(^8?-TQD^E5/#/@W59/ OBCP[XFU^WL;R^O
MAYUTMZ+LN">$=6.$#<#;P2":6W^']UIJP0:5XLT>Z?2[A+RY::W'FPNEMY'.
MUCB, ;MA S@C- '8/IGA>]TU='T7Q%"MU=R1WUL7OC>ES&V0P1W.Y,C! P/Q
M%5KKX:1WU_-?76M/YERR27,<5NJ1RR)M\ML9XVD-C_>]JRO"?@VST2YT+5+'
MQ1IRQ6<9ANGM&*C4&D+.JN&<JN6DW@ 9R>..*])EU32[>/S)]3M(D\PP[GG5
M1Y@ZIDG[WMUH YF3P5=/X/U#PRNN*EO.OEV\PM%WPIO+$-S\YY(SQZ]:R8?A
M>D9MO/UA;R:V:-X[JXM=\^5A,1!;?TP<KQP?6O1FDC0HKR*I=MJ9.-QZX'J:
M?M;^Z:8'GDWPSAN+*XL[C7)[B"1#'''-'N6-2OW2,_,-^Y^?7':H;OX7276I
M"]_X22X ^R2VOV?8PA&\L<A0XP/FZ9_A%>A275K"YCFNH8G"F0J\@4A1U;![
M>]1-J%BLZ0&]@$SL56/S5W,P&2 ,Y) [4 <O?>#)[]-.MY-6C6WM].ET^4BT
M DEWJ%W!@V%QM!VX(Z^M4H_ ^MMK'VN]UVSN(3<Q74L0T\J)3&@5%P'^7&-V
M><G&1P*[NWN;:[A\ZTN8KB+)7?$X=<CJ,BI: .2TKP7;V>@2:/?WUS=6YN#/
M$D,\T @&,!$(D+[>^"Q&3T%1:Y\/=.UO4K>];5-1MC#;-:>4LV]&0H5&0V3G
MG)YYQS7944 >?#P/K<FJFXO-<LIXGNHKF:,:>5$WEH%5,!_EP5#9!.3C(P!7
M0>&-!DT'3IK5M2>[1YC)&I#!(%/1$#,QQWY/?C%=#10 4444 %%%% !4T/W3
M4-30_=-)@-N'5-NY@,^M9]U;Z9>@"\M[>Y"\#S4#8Y![^Z@_@*TINU<-XS\?
MV?@O4-*M+K39[PZAO(\F10RA613A3RYRXX'. 3VH0&]_8WAT7@O1I5C]I QY
MWD+NQG/7'KS57_A&/"@OX+P:/9"6W0QQ 1#:@/4@8QGCKZ5AK\09+@Z!]A\.
MR3IKEE)>PE[R.,Q*B;F\P'HO*C=TRPK/A^+$<T-BS>&;B"2^TV;4XEGNHT7R
MHS\Q+= "OS ^G84@.W&DZ J72+IMF$NU"7"B(8F X 88YJ(:!X7&[&BZ<-T7
MD-_HZ\Q_W>G2N7OOB9;V&GV-Y-X?O=TNF+J]W#YB!K.W9@N3D_.V3]T>AIVI
M?%OP;I^G1727<MPUQN^S1>0T9N-K;6VE@!P<_7!Q5 =.N@^&4$@71[ "5=DG
M[A?G7&,'CICBG6^CZ%:V4UE'9P-;S3O<R1NNX-(QR6Y_SBN=OOB1H>C^)=2T
M?68YK 67EA)74LUT6&<Q1J"S*.A;L014%W\7/ ]OIWVJ'4GN'97,,/DM&TK*
MN_:-P&"5Y&>HH ZJ31_#LMR+F72K%YP"!(T*EL'KSCO40\/^%A,9AHNG>82S
M;OLZYRWWCT[]ZY2[^+&AZ?#H5W?6-S;V>K3W4!N&9=MKY!VEG]F. ,>HS5>S
M^-'A>Y\/0:E+!=6MY*XC_L^5?G1C(5"LX^0-M!?;G.T&@#MO[#\-AXG_ +'L
M-T*E(SY"Y13U X[U/#I^C6^H/J%O9VL5VZE6G2,!V!.2,_6N;M_BCX%O%G:Q
MUP7:VXD:8PP2/Y:)]YVP.%Y'S=#FH)/BSX)M]6O+&\U/[,EM+';B9U.V65MV
M5 QGY=G)Z<B@#M_.B_YZ"CSHO^>@KS;6_C-H.@ZKJ^F76EWCW6FWD-J$0K_I
M"N 6E3G[J9^;//3U%6)_BKI]KIFE:C<:+=)%J\P6S42QEG@/_+=AGY1G:,'G
MYA[T >@^=%_ST%'G1?\ /05YE9_&31[KX;W?C9]+GA@M[A;5;=IH\S.RJV%<
MD+D!N<]P16PWQ4\$M-+"NL-))$B.XCMY' W+O !"D$[<DXZ $]J .U\Z+_GH
M*BGFBPOSCK7'2?%CP.H5X]6\V'+;Y!#(!M4.2R_+\XRC#CTK9T7Q1I?BA;U]
M+%R4L;C[-(\T#1AFV*_RD_>&&%" T?-C_OBCS8_[XKF?'/C;2_ GA\:IJ$;W
M$LK^5;VT9PTSXSU[ #J:\C_X:2F_Z$Z/_P #3_\ $5V4Z-6JN:$;HT4)/8^@
MO-C_ +XH\V/^^*^??^&DIO\ H3H__ T__$4?\-)3?]"='_X&G_XBM?JE?^4?
MLY'T%YL?]\4>;'_?%?/O_#24W_0G1_\ @:?_ (BI(?VDAYZ"Y\(;8<_.T=WN
M8#U *C-+ZK5_E#V<CW\31[A\XJWYT7_/05FZ5=#6=)M-6TZ2":TNXUFB?+#*
MD9':M3RKS^[!_P!]'_"N!LS8WSHO^>@H\Z+_ )Z"G>5>?W8/^^C_ (4>5>?W
M8/\ OH_X5-Q#?.B_YZ"CSHO^>@IWE7G]V#_OH_X4>5>?W8/^^C_A1<!OG1?\
M]!1YT7_/04[RKS^[!_WT?\*/*O/[L'_?1_PHN!3>:/S&^<=:;YL?]\58:TO&
M8M^XY/\ >/\ A2?8[S_IC_WT?\*KF0R#S8_[XH\V/^^*G^R7G_3'_OH_X4?9
M+S_IC_WT?\*?,AD'FQ_WQ1YL?]\5/]DO/^F/_?1_PH^R7G_3'_OH_P"%',@(
M/-C_ +XJ:":++?.*7[)>?],?^^C_ (4^.WO$)^6$Y_VC_A2N@'>=%_ST%'G1
M?\]!3O*O/[L'_?1_PH\J\_NP?]]'_"IN2-\Z+_GH*/.B_P">@IWE7G]V#_OH
M_P"%'E7G]V#_ +Z/^%%P&^=%_P ]!1YT7_/04[RKS^[!_P!]'_"CRKS^[!_W
MT?\ "BX#'FBV-^\'2JGFQ_WQ5TQ7A4C;!S_M'_"H?LMY_P!,?^^C_A5)E$'F
MQ_WQ1YL?]\5/]DO/^F/_ 'T?\*/LEY_TQ_[Z/^%/F0$'FQ_WQ1YL?]\5/]DO
M/^F/_?1_PH^R7G_3'_OH_P"%',@(/-C_ +XI5ECWK\XZU-]DO/\ IC_WT?\
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MA1O/S3_XJI(/A'\1I[A(?^$7N8=YQYDKH$7W)W=*^R=R_P!Y?^^A1N7^\O\
MWT*CZ[6[(?UJ'<R_!^GQ>%O!VE>'_P!].UE L32"/AVZL1[9)KH/MR_\^\__
M 'Q50.FX?.O_ 'T*M>='_P ]%_,5Y<HMN[ZG.Z\.X[[<O_/O/_WQ1]N7_GWG
M_P"^*;YL?_/0?F*7S8_^>@_,5/(P]M#N+]N7_GWG_P"^*/MR_P#/O/\ ]\4G
MFQ_\]!^8I/.C_P">B_F*.1A[:'<=]N7_ )]Y_P#OBC[<O_/O/_WQ2>9'_P ]
M%_[Z%'F1_P#/1?\ OH4<C+]I#N-.HQ@D>3/G_<I?[0C_ .>,_P#WQ55W3S&^
M=>O]X4FY/[Z_]]"J]F+VU/N6_P"T(_\ GC/_ -\4?VA'_P \9_\ OBJFY/[Z
M_P#?0HW)_?7_ +Z%'LP]M3[EO^T(_P#GC/\ ]\4G]HQ?\\9_^^*J[D_OK_WT
M*-R?WU_[Z%/V9'MJ?<M?VC%_SQG_ .^*5=0C;[MO.?\ @%5-R?WU_P"^A4L,
MD>3^\7_OH4O9C]M#N6/MR_\ /O/_ -\4?;E_Y]Y_^^*;YL?_ #T'YBE\V/\
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M?N8NO]P4W[/;?\\8O^^!7RQ_:>I?]!"Y_P"_K?XT?VGJ7_00N?\ OZW^-/\
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M,&5AD$="*6J.DV_]GZ'86$DZR/;6\<+/N^\54 G]*N>9'_?7\Z8#J*;YD?\
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M_6-)NM*U!5FM+N)H9H]^-Z,,$9'/2L"]\!^#;^)89]*B2-8XX52"0Q!53?M
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M'UI@.HIOF1_WU_.CS(_[Z_G0 ZIH?NFJ_F1_WU_.K$+*RG:P//:DP$G53MR
M?K7/>)_$&G^%="DUB^M9)XEDCA$<(7<S.P5>6( Y/4D5T4W:N<\46^@7.@2)
MXGACGTU98Y&CD4L'=7!0;1RQW8^7G-" Y=_BUX77PO)XB6WOFLX[A+=OW*JP
M9HO-R<G  7WY/ SD4RY^,'A2UT:75I+.[-JEZ+%=HB+LQ!(;;ORH.#C=@GC
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M21R7CDYNQ_W[%*S)+/\ 9UC_ ,^L?Y4?V=8_\^L?Y5%_I?\ S^?^0Q1_I?\
MS^?^0Q2L!+_9UC_SZQ_E1_9UC_SZQ_E47^E_\_G_ )#%'^E_\_G_ )#%%@)?
M[.L?^?6/\J/[.L?^?6/\JB_TO_G\_P#(8H_TO_G\_P#(8HL!+_9UC_SZQ_E1
M_9MC_P ^L?Y5"WVP*3]K_P#(8J#SKW_GZ'_?L4[,"W_9UC_SZQ_E1_9UC_SZ
MQ_E53SKW_GZ'_?L4>=>_\_0_[]BCE91;_LZQ_P"?6/\ *C^SK'_GUC_*JGG7
MO_/T/^_8H\Z]_P"?H?\ ?L4<K M_V=8_\^L?Y54N+6.WEBDA4(&D",G4'/?V
MH\Z]_P"?H?\ ?L4U59YTDED,K*?ER,!?H*:3 77-1L]#T.]UF\B9K>R@>>01
MJ"Q51DX'K7#GXN>%C'=>78ZA)-;R21& 0H'<JZ)E<MC#,X .>QZ8KM?$:Z6W
MAS4%UM=^F&W<72\_-'CD<<\^U>?S:;\-YF5=5T*XTB7[-(S&\9H'CB:0RDDA
M_P"^FX8R1[4B37N_B7X<L;/3[BYM;N*2]NI[0PM$H:VD@!\WS#G: N.N3G(Q
M3[7XF>#9@#<WZ6($AC N0 6(+ \+G ^4G)P,55^S_#6ZT^TTPM ]KF3[/^^=
MC,TRGS&R#N8D9R6[U3M]'^%-RM[<06\#6Z6IFGN?-?RQ&[.C#.>N=X(QQF@#
MIH_&7AV]T?5M2T:X&L1Z266Y2T495@,D9;"]!G.<5D:?\4O"NJ7D%C8PW4M_
M<9\NS,:K,1Y GR5)X&T@9/?\ZY_1=#^'NC^#=4\.WWBHZII%_(MP\<LYB\M6
M.0 8\'DCGGG'/%;$UG\*;QKK39KZVGG\PK-MNY#*7>'RS\X.[)C7'![&@#1\
M,_$+0_%6HPV.GV5Q"\MHMV#<^7&=ISP%W;FZ'E05Z<\UV6Q/[B_E7G=K=_#'
M2;S2]1CUJW,]M;M#8O<7DDOE1GY6"AB<?=P>_'M787GB70M/O$M=0U."UDDV
M"/S' $A?[N/RI@:FQ/[B_E1L3^XOY5ST?C?PS+)-&NI*'M^9P1_JAM+9/KP#
M]W-$?C?PK++(D.L02"'!DD!PB IO!R>N5],T =#L3^XOY4;$_N+^59=EXF\/
MZE?QZ?8ZQ:W-W+%YR0H^69/7%5+KQAHFGZ/+JVH7'V6U6>2"(MRUP4)!* =<
MD'\J -_8G]Q?RHV)_<7\JPF\9>%DO19MK4'VC=*IC 8E3& S@X'& 0>>O:IO
M^$DTKR])F@F:ZM]6D\NVG@7?&3M+<MV^Z?QH U]B?W%_*C8G]Q?RKD8_B+X=
MN+3[78R3W\*B!IGM4600"8D)OPW!R.1U&1Q6IH?B/3_$2W<FFL\D-K,8#(VW
M#L."5P2<9!Z@4 ;6Q/[B_E1L3^XOY4ZB@!NQ/[B_E1L3^XOY4ZB@!NQ/[B_E
M1L3^XOY4ZB@!NQ/[B_E5B  *< #Z5#4T/W328"3D#;DXK(UC2K76].:QN9I(
MAO66.6%@'B=3E6&<CCW!%:UPJMMW*#]:Y3QQXC'A#PG+K<=G#<NL\,"I*Q5<
MR2!,DJ">,YX!-(#&E^%7A^:RL[1]0OQ':S+/A)442,K%AD!< 98\#&.U68OA
MQH\4HD_M6_D;8\)+M&<PLH7RQ\G   PPPW'6N>E^*E]'X1O]:_X1,I<Z?<)#
M<VCS?-"A@$I=@!N')"CCN"<<U!;_ !DM[W3[B_M]'BMX;:[6*<7/F[K6#+#S
MI J'C<A "YQWQ3 Z>W^&7AB%09]]Y+N#&298\DC/8* /P Z5H>&_!>E^&-5U
M'4K*]N[B:_CBB<7,@8(L>=H7 'J:Y.;XLV\NE^,;W1]'M]0/A^2".V07(!O/
M,;9D\?NQN! ZYX]:JZ?\8H=9U8V.E:%#Y4TT$%I=75QY<;LR2&7?\IVA6B9!
MUW,* /7=R_WA^=&Y?[P_.O-/"_Q,AUV_\31:EI,.G6NA1R3-.LI82(CNA(RH
MR/D)RN1SCK5+2?C7X?N[&U.H:3>07TAF:>"VB\T6L<8W;W)VD H0>E,#UC<O
M]X?G1N7^\/SKS<_%_P *_(!8Z@KD-NWP+MA.<*'(8]3C&W/6GZ3\4-&UC7=+
MT6STN[:XOG$;R$1HD),/FAL%MQ4CH<<X/6@#T7<O]X?G1N7^\/SI/+C_ +B_
ME1Y<?]Q?RH 7<O\ >'YT;E_O#\Z3RX_[B_E1Y<?]Q?RH 7<O]X?G1N7^\/SI
M/+C_ +B_E1Y<?]Q?RH 7<O\ >'YT;E_O#\Z3RX_[B_E1Y<?]Q?RH ;(R^4WS
M#\ZJ&2('!E0'_>%<5\6-4OM)\-VZZ<Q@^TS>7)(@P0N,XSVS7@QNKIB6:XE)
M/4ES7J87!.O#GYK'S>89K'!U/9J',UYVW/JWS8?^>R?]]"CS8?\ GLG_ 'T*
M^4?M-Q_SWD_[Z-'VFX_Y[R?]]&NW^S/[_P"!YO\ K#_<_$^K]\>,^8N/]X4;
MT_OK^8KP3X;ZQJ,7B^SL [7%M=$I)$_S #&=W/3%?1'V6W_Y]H_^^!7D8FD\
M//E;N?1Y?C8XRDZBC:SL4BZ8^^OYBK@DCVC]XG_?0J?[):_\^T7_ 'P*/LEK
M_P ^T7_? KDYCTR'S(_^>B?]]"CS(_\ GHG_ 'T*F^R6O_/M%_WP*/LEK_S[
M1?\ ? HN!#YD?_/1/^^A1YD?_/1/^^A4WV2U_P"?:+_O@4?9+7_GVB_[X%%P
M(?,C_P">B?\ ?0H\R/\ YZ)_WT*F^R6O_/M%_P!\"C[):_\ /M%_WP*+@9SR
M1^8_[Q>O]X4W>G]]?S%:?V2U_P"?:+_O@4?9+7_GVB_[X%/F'<S-Z?WU_,4;
MT_OK^8K3^R6O_/M%_P!\"C[):_\ /M%_WP*.8+F9O3^^OYBC>G]]?S%:?V2U
M_P"?:+_O@4?9+7_GVB_[X%',%S,WI_?7\Q4T$D>3^\7_ +Z%6_LMM_S[1?\
M? H^RVW_ #[1?]\"CF&1^9'_ ,]$_P"^A1YD?_/1/^^A4WV2U_Y]HO\ O@4?
M9+7_ )]HO^^!2N20^9'_ ,]$_P"^A1YD?_/1/^^A4WV2U_Y]HO\ O@4?9+7_
M )]HO^^!1<"'S(_^>B?]]"CS(_\ GHG_ 'T*F^R6O_/M%_WP*/LEK_S[1?\
M? HN!7:2/8W[Q.G]X54WI_?7\Q6G]DMO^?>+_O@4GV2U_P"?>+_O@4<PS-WI
M_?7\Q1O3^^OYBM/[):_\^T7_ 'P*/LEK_P ^T7_? I\P7,S>G]]?S%&]/[Z_
MF*T_LEK_ ,^T7_? H^R6O_/M%_WP*.8+F9O3^^OYBGHR[E.X=?6KWV6V_P"?
M:+_O@51N+6&"6"2&-4+2!&4#A@?;VI\PRQJ-K::A8S6-XBRVUQ&T<B$_>4\$
M5SQ\%^'G\IKA;F[DC78);BZ>1R.>"2>>IKIYHX@1\B@?2J[M:Q@-(\* ]"S
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MVNE:-I=HUU;6FC2>;:QQ73*-W/WO[WWCP?4UT(CC(!"J0>X%-8VT;*LC1HS
MD!B 2!U_*@#G&\"^&Q]E^S1SV1MC"4^RW#1;O*W;-V/O8WMUJ_HGAO1/#TEW
M)I,'DM=OODS(6[D@#/09)X]ZU4^SR+NC,<B^JD$?I2[(MVW:N[KCO0 [<O\
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MEMHI+4RB/=';"1KQD02*0 "2 .03TQGBJDOB7X>K8W7]H1V$%M$@DGCDM R
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MPH^T7W_0-_\ (R_X4 #/<AV47<F ?1?\*3S+K_GZD_)?\*K/->^8W_$O[_\
M/44GG7G_ $#_ /R**JR&6O,NO^?J3\E_PH\RZ_Y^I/R7_"JOG7G_ $#_ /R*
M*/.O/^@?_P"1119 6O,NO^?J3\E_PH\RZ_Y^I/R7_"JOG7G_ $#_ /R**/.O
M/^@?_P"1119 6O,NO^?J3\E_PJ2(W#D[KN3\E_PJAYUY_P ^'_D45+#/>Y.-
M/S_VV%)I 7MLW_/Y+^2_X4;9O^?R7\E_PJ#[1??] W_R,O\ A1]HOO\ H&_^
M1E_PI")]LW_/Y+^2_P"%&V;_ )_)?R7_  J#[1??] W_ ,C+_A1]HOO^@;_Y
M&7_"@"?;-_S^2_DO^%&V;_G\E_)?\*@^T7W_ $#?_(R_X4?:+[_H&_\ D9?\
M* )F68*3]LE_)?\ "H/,NO\ GZD_)?\ "D:XOMA_XEW;_GLO^%5?.O/^?#_R
M**:2*+?F77_/U)^2_P"%'F77_/U)^2_X54\Z\_Y\/_(HH\Z\_P"?#_R**=D!
M;\RZ_P"?J3\E_P */,NO^?J3\E_PJIYUY_SX?^111YUY_P ^'_D4460%OS+K
M_GZD_)?\*:J[IUDDD:1QP"QZ?056\Z\_Y\/_ "**<L]YO'^@=_\ GJ*- )_$
M%C-J?A[4--MY%CFNK:2%';HK,N 3BN*D^'<EW'>6VI"QO;5)X3IT<T>\00B4
M2R@Y'4G<HQ_#@&N\DN+_ (SIN/\ MLM1?:+[_H'?^1E_PJ"3BO%'A7Q9JFOI
M>:+K4>GVUO"PM1O8"W<Q.G$8&T\L#NSD <"JEGX/\;6L#W0\21-JIBC_ 'TC
M%O,D50N'.WE3@CU_&O0/M%]_T#O_ ",O^%'VB^_Z!W_D9?\ "F!Q%EX3\;+K
MUTVH>,+F;2GFC:)(IBDBQJI!' X.<9YP:2;1?B%J'@JTACUQ+'6OMOFRRR.R
M[85.%4;>I( )!XRQKN/M%]_T#O\ R,O^%'VB^_Z!W_D9?\* .&;PCXNN+B">
MYUMFF03QR.;Z1HY [HR.(MNU2 I7;VSD&EE\(^,;B:"XO/$0GD@E4@1SO#OC
M60;02HR<H,L.A8_C7<?:+[_H'?\ D9?\*/M%]_T#O_(R_P"% 'GJ>$_B-#/=
M_P#%5++ WV?[/$LK0I$$*[P0%S@X;H1NSSBKFN>&_'E_K^KW%CX@BATFZCC2
M&S%Q)&1C&[Y@#L)YY7K7;?:+[_H'?^1E_P */M%]_P! [_R,O^% 'GDWA'XA
MQZ/#I^F^*(HOL[6ZPL9'!5%&9 <#YOF& #QMJ]_PC/C2.XC=O$$EY;O*9)H7
MNWCY._[K!3\@!3Y.AQ7:_:+[_H'?^1E_PH^T7W_0._\ (R_X4 >7^(O#OQ"L
M/#\C:1K=_>7,KI&\-E/L:.,%<&,$ +P&SC^]7<V>G7%YK)N=4M3]F@T]+2*.
MX82F1G&9BWKT53ZX-:_VB^_Z!W_D9?\ "C[1??\ 0._\C+_A0!Y.OP_\=>'_
M  S96/A?7(+)+*SEW069,?FSEI&R%QARP:-06(V[<C-6M.\'?$Q6L[R]\3(S
M83S[=KEQ)LWEC'YP7=QG/O\ =Z<UZ=]HOO\ H'?^1E_PH^T7W_0._P#(R_X4
M@/.]!\&^/+?Q<VM>(/$EM=11"Z6TC1I', E50N-W8%<X)^E8=K\-_B9#<R-)
MXTC6&\=GO8UF9S.3$L>YF9>0=I^7 P#P>*]@^T7W_0._\C+_ (4?:+[_ *!W
M_D9?\* /+;7P#\2-/M4L]-\:064)CD#!%9MCB,"$J,=-V=^>H"TMQX5^*5CX
M5N9H?%US?:Y''!':(LVZ/=YC"4R @!AM8$'J-E>H_:+[_H'?^1E_PH^T7W_0
M._\ (R_X4 >8^)/"7C[7->O--L]<EAT(:;%;^9<S$K<2&-U?Y .I;8Q8XQCC
MK34\%_%1KJ^,GC9(+=IC+:Q0328C 0A5.03MW;25Z<&O4/M%]_T#O_(R_P"%
M'VB^_P"@=_Y&7_"@#S*;P7\5,QI;_$!E!N4GF!D)8C+Y525^5<%/EQ@[370^
M!?"_B30]7UW5/$FKIJ4^H>2JR+(S'"&3G! "##CY1D#!KK/M%]_T#O\ R,O^
M%6[629XW\ZW\D@\#>&S0P)YNU>9>(/!/BJ^\9WVLZ'K=G9QWZ6\;2SQ>9+;I
M$&S$BE2I5F8-G*D$9YKTV;M7'^/X?$D_@^2'PHTXU-[F!08)1$XC\Q?,^<@[
M1MSDX)I >?VOPI\6QVR1S:Y:B0S/+)FYGECP;81 ;6ZL7R^[(P2< U)_PJ/7
M(=&CM;/4;2%E6"W^S"XG$"PI;["!C!SYQ\WH,D $U6UA?BY;^&+_ $>WN-3N
M]9BOH6CU"WC4120" ;@IX/,G7CW/&16I<Q>/M4MM>T^$^(+*Y?4K06-VSI$L
M,3(HG8%>&12)#@CDE:8%?_A5'B22:Z:^\437TDD\?^D27LR^;;(ORQ-&H 4[
M@N2&.1NZ9JO#\'M>C8+-K:3137%N]ZT5W-#-=QQVZQA2^"1M<,X'?/)%=!<:
M?XVM]/\ &%YIMUJ;/)<Q0Z;!<3+)((5*^=+%G@,X+[0?[H]:S[6_^*FGZ?J9
MATZYO+2))9=/6\C62\ES*JQI(=P (7<QZG&.] #)/A?XF!L&M_$0$R.]Q<3M
M<3;DG,_F!T&<'Y (\-P!G&<UE-\*_&>EZ;-)::_YTEO;;(DM))%><,J!X2I(
M54+>8VX?-E\\8K4D;XL:EX&N9UCGTO7Y=5@FCA0KMB@$:ET&<_(7# ]^35;1
M?^%K3:O%=^)HM7M]-N[PW+VUB\9DM=T:&.'/>)6W!O4^U %7PSX%^(&G^(M)
MOI#Y%I!&EQ<VD]X[1"=II3M4[B66.*3&#U8+V%:OC/X4:SXH\;WWB"VUNVLX
MKRW^P2QE6+26HB_U1/;,V"<?PY[FLV^'Q6O%M&TO^VX%M=5O))C<;$DFMO,C
M,( '#?+YF%.!USVK5\::]\0O#_B35?$ECI[S>&[.T:WC@9PP:39O%P8P,E0^
M$SNZ=N] &?:_![7+> VG]O?N4:WBC,=W+&BVL:KF 1* %RR#YMQR">F:Z+3_
M (?ZA8:CX/NA=0N^DP!=2G>1V:]<1[1\I')4_=9FX&1@YK!TSQA\5M5TFTO-
M-T>TOHYX%87"VK1QL3D,PW.#E6XVXY'S9K1CUCXM?:HUDT)5,T@AD=8MRJ L
M@\Q07P@R$8@]<X% &=J?PE\175U<ZG8^)!:ZC<2WUPY6>41B2>1 NP<B,B%2
MA8#.6[U'>?"7Q/--Y=GKT4-DMJT$*3W<\SQ[H2C(3@!EW,SY(ST&!BO4O"\V
ML3^$=+F\0*RZLUNINPT0B(EQ\WR@D#GT-;%,#P^/X+ZI:7HO+.\M(GM+J6ZM
M3!-*CONGC;YCT!\J,1XY')KH/'G@+Q%XZLM%^U:C:V,UG;S?:(4W-%-+*%5D
MY!.S9YBYX;YABO4** /%;CX1>)+BTN8F\1$2S332-)]NFV2+Y;K;J$ &P)O&
M0"<[!S5BS^%OB?\ MQ+K5O$$%Y;"XA:4M+*SW,:3^;\RGY0V$C08[ ^M>Q44
M <5\1O%%UX9T".2Q1?M-S(8T=AD)QDG%>+GQ]XO9BW]MSC/88Q7T#XH\.6'B
M;1FL+[<NT[XY$^\C>HKS4_!I,\:Z<>\/_P!>O7P57#PIVJ+7TN?*YGA\75K<
MU%OEMT=CA_\ A/?%W_0<G_2C_A/?%W_0<G_2NX_X4VO_ $'O_(/_ ->C_A3:
M_P#0>_\ (/\ ]>N[VV%\ON_X!XOU7']Y?></_P )[XN_Z#D_Z4?\)[XN_P"@
MY/\ I7<?\*;7_H._^0?_ *]'_"FU_P"@[_Y!_P#KT_;87R^[_@"^JX[O+[SA
M_P#A/?%W_0<G_2G?\)_XP_Z#T_Z5VW_"FE_Z#O\ Y!_^O3O^%*J1_P AK_R#
M_P#7I>VPOE]W_ *^JYAWE]YQ'_"P/&'_ $')_P Q1_PL#QA_T')_S%=Q_P *
M3_ZC7_D'_P"O1_PI/_J-?^0?_KT>VP?E]W_ ']6S#O+[SA_^%@>,/^@Y/^8H
M_P"%@>,/^@Y/^8KN/^%)_P#4<_\ (/\ ]>C_ (4G_P!1S_R#_P#7I^UP?E]W
M_ *^JYAWE]__  3A_P#A8'C#_H.3_F*/^%@>,/\ H.3_ )BNX_X4G_U&O_(/
M_P!>C_A2?_4:_P#(/_UZ/;8/R^[_ ( ?5LP[R^\X7_A/O%Y.?[<G_2D_X3WQ
M=_T&Y_TKN3\&55BO]N]/^F/_ ->D_P"%-+_T'O\ R#_]>E[;"^7W?\ GZMF'
M>7WG#_\ ">^+O^@Y/^E'_">^+O\ H.3_ *5W'_"FU_Z#W_D'_P"O1_PIM?\
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M6;_OX:C\R\_O0_\ ?)H\R\_O0_\ ?)HU D^PQ_\ /6;_ +^&C[#'_P ]9O\
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M3<DEHJ+^SV_Y^#_WS1_9[?\ /P?^^:+@2T5%_9[?\_!_[YH_L]O^?@_]\T7
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M",AB/2LW3?''@W5=.%_;ZU;Q0F)I\3R>6WE*VTO@GA<BF!KOX?T.10KZ3:$
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M_P#6I:*+ )]JN?\ GT7_ +^__6H^U7/_ #Z+_P!_?_K4M%%@&&ZN0"?LJ_\
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MAW1;XF2_L_,<A5RKLO"Y4=".SL/H2*R;'P?X9<?:O[/\TWLC/^\8X3/\*@'
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''[II,#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ptn_ex51img3.jpg
<TEXT>
begin 644 ptn_ex51img3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  Y G # 2(  A$! Q$!_\0
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M;\#W']L?%#Q_J6HXEO\ 3+^/3;56Y,%L(E<;1VW,S$GO@>E4_BA;_P!E^,O
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MN1_X6'X1_P"@Q_Y!D_\ B:/^%A^$?^@Q_P"09/\ XFCFCW0>RJ=F==17(_\
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8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ptn_ex51img2.jpg
<TEXT>
begin 644 ptn_ex51img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  ; '<# 2(  A$! Q$!_\0
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MPOW?, X?'3Y@>.*LS>']#N+M[JXTNWFG>>*Y+R)N/FQ#$;C/0KV(Z4 >6_\
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(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ptn_ex51img1.jpg
<TEXT>
begin 644 ptn_ex51img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  \ FP# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(K:UU:71[.RNM0OX(!<RPVBJ3$C$A2Q9E&6*M@9R=IJ__;-A_P _4'_?Q?\
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M#F$W<LFY,L03M<'!'M1[O9?<'/+N_O-B/X>_"^2&2:+3[&2*)@KR+=$JA.,
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MG**4+ GN1@<FO3Z?*NR^X/:2[O[S@O\ A4WP_P#^A?A_[^/_ (TO_"I_ /\
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MGGGKUHY8]E]P>VJ=W]Y83X7_  Y:1XUT.U9T^^HE8E?J,\4A^%WP[6586T&
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M5=%M69F* "9B2PZC[W4>E<5%X#\36-Q9-)I/V^.QM89/*\Q3)M2_DG2WBF+
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
